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ABSTRACT (ENGLISH) 
Ubiquitin signaling is a key regulatory mechanism for many important cellular processes such 
as transcription, differentiation and cell division. Cell division requires duplication of all 
genetic material during S-phase followed by its precise partitioning between two daughter cells 
during mitosis. Misregulation of the complex mitotic machinery may lead to aneuploidy and 
genomic instability, known drivers of tumorigenesis. Indeed, systematic genetic analysis of 
many cancer tissues over the last decades, indicates the presence of severe chromosome 
abnormalities in thousands of cancer tissue samples. In this work, I investigated the function 
of two components of ubiquitin signaling, the deubiquitinating enzyme UCHL3 and the E3 
ubiquitin ligase TRIM15. The hypothesized role of E3 ligase TRIM15 in the cell cycle 
regulation could not be confirmed by our experiments, but I observed an effect on cell adhesion 
and motility instead. UCHL3 was identified using high-content visual siRNA screen, as a 
critical factor controlling genome segregation and integrity. Interestingly, it has been 
previously reported that UCHL3 levels are altered in various cancer types, especially colon 
cancer. My data demonstrate that UCHL3 drives proper alignment of chromosomes at the 
metaphase plate by facilitating congression of polar chromosomes and by regulating 
recruitment of key kinetochore components necessary for formation of stable microtubule 
attachments. Depletion of UCHL3 leads to chromosome misalignment as well as defective 
kinetochore-microtubule attachments often leading to severe segregation errors such as lagging 
chromosomes. Using an unbiased proteomic approach, we identified a potential interactor and 
mediator of these phenotypes, the Aurora B kinase. I confirmed that UCHL3 interacts with 
Aurora B and I show that UCHL3 removes the non-proteolytic ubiquitin modifications of 
Aurora B. Since aneuploidy and the resulting genomic instability are hallmarks of many 
cancers, and cell adhesion plays an important role in tumor invasion and metastasis, our results 
suggest that both proteins could play a role in carcinogenesis. 
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ABSTRAKT (CZECH) 
Ubikvitinace patří k důležitým regulačním mechanismům buňky, které kontrolují různé 
biologické procesy mezi které patří diferenciace, transkripce a buněčné dělení. Buněčné dělení 
vyžaduje duplikaci celého genomu v průběhu S- fáze buněčného cyklu, která je následována 
rovnoměrným rozdělením genetické informace mezi dvě dceřiné buňky v průběhu mitózy. 
Nesprávná regulace buněčného dělení může vést k aneuploidii, tedy k abnormálnímu počtu 
chromozomů v buňce. Aneuploidie jsou známou příčinnou vzniku rakoviny. Systematická 
analýza genomu tisíců vzorků z rakovinných buněk ukázala, že většina nádorů má abnormální 
počet chromozomů. V mé dizertační práci jsem se zabývala studiem dvou proteinů, které jsou 
součástí ubikvitin- proteazomového systému, konkrétně deubikvitináza UCHL3 a ubikvitin 
ligáza Trim15. UCHL3 jsme identifikovali pomocí „high- throughput“ testování, které bylo 
cíleno na rozpoznání dosud neznámých faktorů regulujících buněčné dělení. Předchozí studie 
ukazují, že zvýšenou expresi UCHL3 můžeme najít v buňkách některých nádorů a to především 
ve vzorcích rakoviny tlustého střeva. Můj výzkum ukázal, že UCHL3 reguluje správné 
seskupení chromozomů v metafázi a jejich následné rozdělení do dvou dceřiných buněk. Ztráta 
(delece) UCHL3 vede k nesprávnému uchycení chromozomů k dělícímu vřeténku a k 
následnému chybnému rozdělení chromozomů jehož častým důsledkem je aneuploidie. S 
využitím proteomiky se nám podařilo určit potenciální substrát UCHL3, kterým je kináza 
Aurora B jež je pro správný průběh mitózy nezbytná. Výsledky proteomické studie se mi 
podařilo ověřit a ukázat tak, že UCHL3 se váže na Auroru B a že ji deubikvitinuje v počáteční 
fázi mitózy. V rámci své doktorské práce jsem se zabývala také studiem ubikvitin ligázy 
Trim15 a jejím vlivem na regulaci buněčného cyklu, adhezi a motilitu buněk. Aneuploidie a 
genetická nestabilita jsou průvodními jevy většiny druhů rakovin a adhezivita buněk hraje 
důležitou roli v invazivitě nádorového onemocnění a jeho schopnosti metastazovat. Výsledky 
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SUMMARY (FRENCH) 
J'ai effectué mon doctorat dans le cadre d’un programme de doctorat en co-tutelle entre 
l’Université de Strasbourg (France) et l’Université Charles de Prague (République tchèque). 
J’ai passé une partie de ma thèse à l’Institut de Génétique Moléculaire, AS CR (IMG) à Prague, 
sous la supervision de Kallayanee Chawengsaksophak, PhD et du Professeur associé Radislav 
Sedlacek, PhD. Le reste du temps, j’ai travaillé à l'Institut de Génétique et de Biologie 
Moléculaire et Cellulaire (IGBMC) à Strasbourg sous la supervision d’Izabela Sumara, PhD. 
Au cours de ma thèse, je me suis intéressée à comprendre le rôle de la signalisation de 
l'ubiquitine dans la régulation du cycle cellulaire tout en étudiant le rôle d'une ligase E3-
ubiquitine, Trim15 et le rôle d'une enzyme de dé-ubiquitination (DUB), UCHL3. 
Introduction 
La signalisation par l’ubiquitine (Ub) est un mécanisme de régulation clé impliqué dans divers 
processus biologiques. L'ubiquitination est une fixation covalente d'un fragment d'ubiquitine 
de 8 kDa à son substrat. Les modifications uniques par Ub ont généralement un rôle de 
signalisation, les substrats polyubiquinés sont souvent ciblés pour la dégradation des protéines. 
On sait également qu'il existe des chaînes Ub ramifiées et des chaînes mixtes avec d'autres 
molécules de type ubiquitine1. L'ubiquitination peut être inversée par les enzymes dé-
ubiquitinantes (DUB) qui peuvent couper les chaînes d'ubiquitine des substrats et les 
transformer en monomères. 
Les protéines à motif tripartite (TRIM) représentent une grande sous-famille des ligases 
d’ubiquitine RING-E3 comprenant plus de  70 de gènes chez l'homme2. Leurs rôles dans la 
catalyse de l'ubiquitination et l'assurance de la spécificité du transfert de l'ubiquitine à partir 
d'enzymes de conjugaison E2 sur diverses cibles impliquent les protéines TRIM dans la 
régulation de nombreuses activités cellulaires. Les protéines TRIM jouent également un rôle 
important dans d'autres fonctions cellulaires, telles que la prolifération cellulaire3,4, la 
réparation de l'ADN5, la pluripotence6 et l'apoptose7. Cette large implication dans divers 
processus cellulaire est soulignée par l'association de nombreux gènes TRIM dans de 
nombreuses pathologies, comme les infections virales8,9, les maladies cardiovasculaires10, les 
troubles neuropsychiatriques11, les maladies génétiques12 et le cancer, soit comme oncogènes13, 
soit comme suppresseurs de tumeurs14. Parmi de nombreux processus biologiques, qui sont 
régulés par la signalisation de l'ubiquitine, je me suis concentrée sur l'étude du rôle de 
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l'ubiquitination dans la division cellulaire, essentielle au maintien de l'intégrité du génome. La 
division cellulaire nécessite la duplication de tout le matériel génétique au cours de la phase S, 
suivie de sa répartition précise entre les deux cellules filles au cours de la mitose. Au cours de 
la prophase des cellules eucaryotes, l’enveloppe nucléaire est désassemblée et les 
chromosomes se condensent, permettant ainsi l’accès aux microtubules constituant le fuseau 
mitotique. Les centrosomes dupliqués continuent à se séparer pour former un fuseau mitotique 
symétrique, ce qui permet sa fixation aux kinétochores (attachement kinétochore-microtubule 
(KT-MT)) sur tous les chromosomes durant la prométaphase. Ce n'est que lorsque tous les 
kinétochores sont correctement fixés aux microtubules et que tous les chromosomes sont 
alignés au niveau de la plaque métaphasique que les cellules peuvent séparer leurs 
chromosomes. Après la ségrégation des chromosomes au cours de l'anaphase, l'anneau 
d'actinomyosine est formé et se contracte pour permettre la formation du sillon de division et 
l'abscission pendant la cytokinèse lorsque deux cellules filles sont prêtes. L'action coordonnée 
des protéines kinases et des phosphatases conduit à une correcte progression mitotique dans 
l'espace et dans le temps15. 
PROJET 1 : IMPLICATION TRIM15 DANS LA PROGRESSION DU CYCLE 
CELLULAIRE ET LA MIGRATION 
Dans ce projet, j’ai étudié le rôle de l’E3-ubiquitine ligase, Trim15 qui n’était pas bien compris 
à l’époque. Je me suis concentrée sur la détermination des profils d'expression de Trim15 chez 
la souris adulte ainsi que sur l'étude de lignées cellulaires knock-out dans le but de caractériser 
son importance dans la régulation du cycle cellulaire. En travaillant sur ce projet, plusieurs 
publications sur Trim15 ont paru, couvrant partiellement le travail que j'ai effectué, ce qui m'a 
amené à changer de projet. Dans ma thèse, j'ai résumé tous les résultats obtenus sur Trim15 
dans le contexte des publications actuelles. 
PROJET 2 : UCHL3 CONTRÔLE LA SÉGRÉGATION DES CHROMOSES PENDANT 
LE MITOSE 
Mon projet principal de thèse était d’étudier le rôle de l'UCHL3 dans la mitose. Par conséquent, 
je vais me concentrer sur sa description. Dans ce projet, je me suis particulièrement intéressée 
à l'étude de la régulation de la protéine motrice moléculaire CENP-E et de la kinase Aurora B. 
Parmi de nombreux rôles mitotiques, Aurora B assure la correction des attachements aberrants 
des kinétochores aux microtubules (KT-MT) et son activité est également indispensable pour 
l'activité motrice de CENP-E. Lorsqu'elle est active, la protéine CENP-E transporte les 
chromosomes polaires de la périphérie de la cellule vers la plaque métaphasique, facilitant ainsi 
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l'alignement des chromosomes. Une mauvaise régulation de la complexe machinerie mitotique 
conduit souvent à une aneuploïdie et à une instabilité génomique, caractéristiques de la 
tumorigenèse. 
PRINCIPALES QUESTIONS: 
1.  Pouvons-nous identifier des acteurs mitotiques inconnus auparavant ? 
Nous avons effectué un criblage de siRNA et régulait négativement toutes les protéines de 
liaison à l'ubiquitine et les enzymes de dé-ubiquitination (~ 500 gènes) connues et présumées. 
L’enzyme de dé-ubiquitination, UCHL3 est sortie en haut de la liste. 
2.  Comment UCHL3 régule-t-il la progression de la mitose ? 
Dans mon projet de thèse, je me suis concentrée sur la détermination du rôle de UCHL3 dans 
la progression du cycle cellulaire. D'après le criblage de siRNA, nous savons que l'inactivation 
de UCHL3 entraîne une division cellulaire aberrante conduisant à un phénotype de noyaux 
cellulaires polylobés. Le but de ma thèse était de comprendre le mécanisme sous-jacent à ce 
processus. 
QU'EST-CE QUE UCHL3 ? 
UCHL3 est une DUB de la famille de protéines hydrolase C-terminale. Sa structure est 
hautement conservée parmi les espèces et il existe une forte homologie avec d'autres protéines 
de la même famille, UCHL1 et UCHL5. UCHL3 contient trois sites catalytiques (Cys 95 étant 
le principal) et plusieurs domaines de liaison à l’ubiquitine (Ub)16. Récemment, il a été rapporté 
que UCHL3 régule la réparation des dommages de l'ADN par recombinaison homologue17 et 
est également impliqué dans la réparation des ruptures chromosomiques induites par la 
topoisomérase18. Fait intéressant, les résultats à partir d'échantillons de patients atteints de 
tumeur indiquent que les taux d'expression de UCHL3 sont modifiés dans divers types de 
cancer, et en particulier dans le cancer du côlon. La participation de UCHL3 au cours de la 
mitose n'a pas été rapportée à ce jour. 
Au cours de mon doctorat, je me suis concentrée sur la caractérisation détaillée du mécanisme 
par lequel UCHL3 contrôle la ségrégation des chromosomes, y compris l'identification du 
substrat de UCHL3. Mes données démontrent que UCHL3 détermine le bon alignement des 
chromosomes au niveau de la plaque métaphasique et la ségrégation des chromosomes lors de 
la mitose dans les cellules cancéreuses humaines ainsi que dans les cellules primaires. 
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PRINCIPALES CONCLUSIONS 
En confirmant les résultats du criblage siRNA, j'ai pu démontrer que la régulation négative de 
UCHL3 conduit à de graves défauts de la mitose. 
Tout d'abord, j'ai utilisé un ensemble d'outils différents (inhibiteur de UCHL3, siRNA) pour 
démontrer que la régulation négative ou l'inhibition de UCHL3 entraine une augmentation du 
nombre de cellules avec des noyaux irréguliers. Les images ont été quantifiées avec Cell 
Profiler, en utilisant le facteur de forme comme critère de régularité du noyau. Les noyaux 
irréguliers résultent souvent de problèmes de ségrégation au cours de la mitose. Pour répondre 
à cette question, j'ai synchronisé les cellules en métaphase et observé l'alignement des 
chromosomes. L’appauvrissement en UCHL3 a entrainé de graves problèmes d’alignement. 
La surexpression de la protéine sauvage UCHL3 a rétabli le phénotype. Au contraire la 
surexpression du mutant avec les domaines catalytiques inactivés de UCHL3 (c / s) n’était pas 
suffisante pour rétablir ce phénotype. J’ai observé le même phénotype en utilisant l'inhibiteur 
de UCHL3 dans deux types de cellules différents : les cellules cancéreuses, HeLa et les 
fibroblastes primaires humains, IMR90. Il est important de noter que 90 minutes de traitement 
avec l'inhibiteur de UCHL3 suffisent pour promouvoir un nombre accru de chromosomes mal 
alignés, ce qui confirme le rôle de UCHL3 en particulier pendant la transition prométaphase-
métaphase. Des expériences de vidéo en direct par microscopie ont montré un nombre accru 
de chromosomes à la traine au cours de l'anaphase, ce qui a confirmé l'hypothèse selon laquelle 
UCHL3 est indispensable a une progression mitotique appropriée. Les résultats pris tous 
ensemble démontrent que UCHL3 contrôle l'alignement des chromosomes pendant la 
métaphase et leur séparation dans les deux cellules filles et tout ceci dépend de son activité 
catalytique. 
L’immunoprécipitation (IP) suivie par de la spectrométrie de masse a identifié Aurora B 
comme substrat potentiel de UCHL3.Jj’ai confirmé que UCHL3 interagissait avec Aurora B et 
était responsable de sa dé-ubiquitination. En utilisant la microscopie à super résolution, j'ai 
observé que UCHL3 contrôlait la localisation de CENP-E au cours de la métaphase, ce qui 
avait déjà été observé pour assurer un bon alignement des chromosomes19,20. En l'absence de 
UCHL3, j'ai observé une diminution des niveaux de CENP-E au niveau des kinétochores, ce 
qui entraîne des problèmes de ségrégation. Comme l'aneuploïdie et l'instabilité génomique qui 
en résulte sont caractéristiques de nombreux cancers, nos résultats suggèrent un rôle important 
de UCHL3 dans la carcinogenèse. 
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CONCLUSIONS ET PERSPECTIVES FUTURES 
Dans mon projet de thèse, j'ai décrit un nouveau rôle pour l’enzyme de dé-ubiquitination, 
UCHL3 au cours de la mitose. En combinant les approches biochimiques, et la microscopie 
(vidéo en direct et super résolution), j'ai réussi à démontrer que UCHL3 contrôle 
spécifiquement l'alignement des chromosomes lors de la transition prométaphase-métaphase et 
que son absence entraine de graves problèmes de ségrégation, notamment des chromosomes à 
la traine ayant pour conséquence la formation de noyaux irréguliers. Je suppose qu’UCHL3 
contrôle l’alignement des chromosomes en régulant l’activité d’Aurora B et le mouvement 
ultérieure des chromosomes à l’aide de CENP-E. Une régulation adéquate de la mitose est 
essentielle à la survie des cellules et une mitose aberrante conduit souvent à une aneuploïdie. 
Une compréhension approfondie des mécanismes contrôlant la correcte ségrégation des 
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PROJECTS OUTLOOK 
I have done my PhD in a study program ‘doctorat en co-tutelle’ between the University of 
Strasbourg, France and the Charles University in Prague, Czech Republic. I’ve spent part of 
my PhD study working at the Institute of Molecular Genetics, AS CR (IMG) in Prague under 
the supervision of Kallayanee Chawengsaksophak, PhD and Assoc. Prof. Radislav Sedláček, 
PhD and at the remaining time I was working at the Institute of Genetics and Molecular and 
Cellular Biology (IGBMC) in Strasbourg under the supervision of Izabela Sumara, PhD. 
During my PhD, I was interested in understanding the role of ubiquitin signaling in the 
regulation of cell cycle, in particular the specific functions of an E3-ubiquitin ligase Trim15 
and a deubiquitinating enzyme (DUB) UCHL3. During my PhD I was mainly using human 
cultured cells as a model, therefore many mechanisms explained in my thesis are taken from 
perspective of human cells.  
TRIM15 IMPLICATION IN THE CELL CYCLE PROGRESSION AND MIGRATION 
In this project I was studying the role of the E3-ubiquitin ligase Trim15, which at the time was 
not well understood. I focused on determining the expression profiles of Trim15 in adult mice 
as well as on studying knockout cell lines with the aim to characterize its importance for cell 
cycle regulation. I used mice as a model organism in combination with cultured human and 
mouse cells. While working on this project several publications about Trim15 appeared, which 
were partially covering the work I have done and it finally led me to change the project. In my 
thesis, I summarized the results that I obtained about Trim15 function and I discussed them in 
context of the recent publications.  
UCHL3 CONTROLS CHROMOSOME SEGREGATION DURING MITOSIS 
Studying the role of UCHL3 in mitosis was the main project during my PhD and therefore in 
my thesis I dedicated more space to its description. In this project I have been particularly 
interested in studying the regulation of Aurora B kinase and CENP-E molecular motor protein 
during mitosis. Among many mitotic roles, Aurora B is ensuring correction of aberrant 
kinetochore- microtubule (KT-MT) attachments and its activity is also indispensable for 
CENP-E motor activity. When active, CENP-E is transporting polar chromosomes from the 
periphery of the cell to the metaphase plate, thus helping the correct chromosome alignment. 
Misregulation of the mitotic machinery often leads to aneuploidy and genomic instability, 
hallmarks of tumorigenesis.  
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LIST OF ABBREVIATIONS 
AA Amino acid 
ADP Adenosine 5′-diphosphate 
APC/C Anaphase- promoting complex/ cyclosome 
APS Ammonium persulfate 
ATM Ataxia telangiectasia mutated 
ATP Adenosine-5'-triphosphate 
ATR Ataxia telangiectasia mutated and rad3-related 
Bp Base pair 
BSA Bovine serum albumin 
Bub1/3 Budding uninhibited by benzimidazoles- 1 
BubR1 Bub1- related protein-1 
CC Coiled-coil domain 
CCAN Constitutive centromere- associated network 
CDK Cyclin- dependent kinase 
CENP- Centromere protein- 
CEP55 Centrosome protein of 55 kDa 
CIN Chromosomal instability 
CKI CDK inhibitor 
CPC Chromosome passenger complex 
CRLs Cullin-RING ligases 
cDNA Complementary DNA 
CREST Calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and 
telangiectasia (CREST syndrome autoimmune antibody) 
DAPI 4′,6-Diamidino-2-phenylindole dihydrochloride 
DDR DNA damage response 
DNA Deoxyribonucleic acid 
DUB Deubiquitinating enzyme 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
FACS Fluorescence-activated cell sorting 
GFP Green fluorescent protein 
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H2A/ B Histone 2A/ B 
HASPIN Histone H3 associated protein kinase 
HECT Homology to E6AP C terminus 
HeLa K Human cervix carcinoma cells, K stands for Kyoto 
HIV-1 Human immunodeficiency virus 1 
IF  Immunofluorescence 
INCENP Inner centromere protein 
IP  Immunoprecipitation 
JAMM JAB1/ MPN/ MOV34 
K  Lysine 
K-fiber Kinetochore fiber 
KD Knockdown 
KIF Kinesin family 
KMN Kinetochore protein network 
KO Knockout 
KT Kinetochore 
KT- MT Kinetochore- microtubule 
Live SR Super resolution module 
LUBAC Linear ubiquitin chain assembly complex 
M1 Methionine 
MAD2 Mitotic arrest deficient-2 
MCAK Mitotic centromere-associated kinesin 
MDM2 Mouse double minute 2 homolog 
MEF Mouse embryonic fibroblasts 
MG132 Proteasome inhibitor 
MI Mitotic index 
MINDY Motif interacting with ubiquitin (MIU)- containing novel DUB 
mRNA Messenger ribonucleic acid 
MT Microtubule 
MTOC Microtubule organizing center 
Nedd8 Neural precursor cell expressed developmentally down-regulated 8 
NHEJ Non-homologous end joining 
OTU Ovarian tumor proteases 
PBS Phosphate buffered saline 
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Plk1 Polo- like kinase-1 
PP1/ 2A Protein phosphatase-1/ 2A 
PRC1 Protein regulator of cytokinesis-1 
pH3T3 Phospho histone 3 threonine 3 
qPCR Quantitative real-time polymerase chain reaction 
RBR Ring between Ring 
RING Really Interesting New Gene 
RNA Ribonucleic acid 
RT Room temperature 
RVD Repeat variable domain 
RZZ Rod-Zwilch-ZW10 
SAC Spindle assembly checkpoint 
SAGA Spt-Ada-Gcn5 acetyltransferase 
SCF Skip- Cullin- F-box 
siRNA Small interfering RNA 
shRNA Short hairpin RNA 
SKAP Small kinetochore-associated protein 
STLC S-trityl-L-cysteine (Eg5 kinesin inhibitor) 
SUMO Small ubiquitin modifier 
TALEN Transcription activator-like effector nuclease 
TBE Tris/ Borate/ EDTA 
TBS Tris-buffered saline 
TCID 4,5,6,7-tetrachlorodindan-1,3-dione (UCHL3 inhibitor) 
TEMED Tetramethylethylenediamine 
TRIM Tripartite motif 
UBASH3B Ubiquitin associated and SH3 domain containing B 
UCH ubiquitin C-terminal hydrolases 
UCHL3 Ubiquitin carboxyl-terminal esterase L3 (Ubiquitin Thiolesterase) 
USP Ubiquitin-specific proteases 








 -31-  
1 INTRODUCTION 
1.1   UBIQUITINATION 
1.1.1 Mechanism of ubiquitination 
Ubiquitin was first discovered by Gideon Goldstein in 1975 who described it as an ubiquitous 
small molecule that is highly conserved among different species, from yeast and plants to 
humans21. Since then, ubiquitin has been extensively studied and up to now, there are more 
than 60 000 publications about ubiquitin and recent study shows that 1.3 % of total cell 
proteome is modified by ubiquitin22, emphasizing its relevance for most of the biological 
processes. Ubiquitin is synthesized de novo from four different genes (UBB, UBC, UBA52 
and RPS27A), which are not functionally redundant as knocking out one of them results in 
severe phenotypes in mice23. Newly synthesized ubiquitin (ubiquitin precursor protein) is 
processed to monomers by deubiquitinating enzymes (DUBs)24. Free ubiquitin is covalently 
attached to different proteins by a complex cascade of reactions called ubiquitination.  
Ubiquitination is a reversible posttranslational modification mediated by three different 
enzymes: the E1 activating enzyme, which activates the ubiquitin by ATP-dependent 
adenylation and transfers the ubiquitin to the active site of the next complex, the E2 conjugating 
enzyme which assists the E3 ubiquitin ligase to transfer the ubiquitin to the substrate, most 
commonly onto a lysine amino-group in the target protein. Ubiquitination can be repeated to 
attach more than one ubiquitin to the same substrate or to already attached ubiquitin molecule 
and at the same time ubiquitin or ubiquitin chains can be cleaved off at any point by different 
DUBs (Figure 1). 
In humans, only two E1 enzymes have been described, UBE125 and UBA626,27 and around 40 
E2 enzymes28, which all bind E1 enzyme in addition to one or multiple of ~600 known E3 
ligases29. Based on their structural properties, E3 ubiquitin ligases are divided into three 
subfamilies: Really Interesting New Gene (RING) which can directly transfer ubiquitin from 
E2 enzyme to the substrate, Homology to E6AP C terminus (HECT) and Ring between Ring 
(RBR) which transfer ubiquitin in two steps, first to one of their domains and after to the 
substrate30. This multistep organization of ubiquitin transfer ensures high substrate specificity 
of the ubiquitination process. 
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1.1.2 Types of ubiquitin modifications 
Ubiquitin is a small 8.6 kDa protein, which is most commonly attached to a protein lysine 
residue (K), but other sites such as thiol groups of cysteine, hydroxyl group of serine and 
threonine residues or even the α-amino group of protein N-terminus have been also 
described31-34. The diversity of ubiquitin modifications lies in the different abilities of ubiquitin 
ligases to conjugate ubiquitin to the substrates which can result in mono-, multi-mono- and 
polyubiquitination. Mono-ubiquitination is the attachment of a single ubiquitin molecule to the 
substrate which can be further ubiquitinated to produce polyubiquitin chains. Any of the seven 
lysine residues (K6, K11, K27, K29, K33, K48, K63) or the N-terminal methionine (M1) of 
ubiquitin can be used for further ubiquitination forming polyubiquitin chains of different 
topologies. Typically, homotypic chains linked by one particular lysine residue are formed, 
heterotypic (mixed) chains linked by a combination of K sites35 and branched chains36 have 
Figure 1 Mechanism of ubiquitination 
There are three subsequent steps of ubiquitination which can be reverted by DUB mediated 
deubiquitination.  
Green circle – ubiquitin, E1 – activating enzyme, E2 – conjugating enzyme, E3 – ubiquitin ligase,  
DUB – deubiquitnating enzyme. Arrows indicate ubiquitin movement during each step. 
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been also observed. Additional regulation level of the complexity is given by post-translational 
modifications of ubiquitin itself by phosphorylation37,38, acetylation39, ADP-ribosylation40 or 
SUMOylation41. Mixed chains combined with ubiquitin-like modifiers (SUMO, Nedd8) also 
exist. This immense variety of ubiquitin modifications is referred to as ‘The ubiquitin code’ 
(Figure 2). Different chain topologies are specifically recognized by the effector proteins 
(ubiquitin receptors or ubiquitin-binding proteins), which can transfer modified substrates to 
the distinct cellular compartments or to the downstream signaling components, thereby 
determining substrates’ fate42,43.  
 
Figure 2 The ubiquitin code 
A schematic representation of possible ubiquitylation modifications occurring in cells. Each type of ubiquitylation 
is depicted by a different color: mono- and multi-ubiquitylation, polyubiquitylation linked through any of seven 
Lysine (K) residues or N-terminal Methionine (M1) as well as mixed and branched polyubiquitylation. Additional 
level of complexity is provided by posttranslational modifications on ubiquitin molecules (not depicted in the 
scheme). Based on the steric positioning of the used residues, the polyubiquitin chains may adopt distinct 
conformations (depicted in a schematic, inaccurate manner) ranging from more compact (K27, 29, 33, 48, 
branched, mixed) to more linear (K6, K11, K63 and M1) topologies. 
Source: Jerabkova, Sumara, DOI: 10.1016/j.semcdb.2018.12.007 
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1.2   BIOLOGICAL ROLES OF DIFFERENT UBIQUITIN  
 MODIFICATIONS 
Initially, it was thought that ubiquitination is solely a signal for protein degradation and that 
protein has to be modified by at least four K48-linked ubiquitin molecules in order to be 
recognized by the large protease 26S proteasome. The first evidence of the non-proteolytic 
ubiquitination came in the 90s, when the role of K63 linkage has been connected to the DNA 
repair process44. It is now well accepted that the proteasome-mediated proteolytic degradation 
is not the only possible outcomes and that ubiquitination can regulate many different molecular 
events including activation of enzymes, protein-protein interactions or subcellular localization. 
K48 linkage is the most studied modification mediating degradation of substrates by the 26S 
proteasome45 and it is largely involved in cell cycle progression46–48, development49, cell 
differentiation50 and DNA damage response51. K11 linked chains promote proteasomal 
degradation of Cyclin B which is key for proper mitotic progression52,53. Mass Spectrometry 
studies revealed the also K6, K27 and K29 linked chains can target proteins for degradation54. 
Interestingly, degradation signal is not restricted to polyubiquitin chains, since single ubiquitin 
is sufficient to degrade proteins involved in muscle differentiation55, and a multiple mono-
ubiquitination is necessary for the proteasomal processing of precursor protein to generate 
active transcription complex56 and it can serve as an alternative degradation signal driving 
mitotic progression57. Lysosomal K63 chain-mediated protein degradation has been implicated 
in the immune response58 and lipoprotein uptake59. K63-linked and phosphorylated K6-linked 
chains are important for mitochondrial quality control by promoting mitophagy60. 
Next to K48-, the K63-linked chains are the second most abundant polyubiquitin modifications 
in the cells54 and, except for few cases, they most commonly have non-degradative signaling 
roles in protein-protein interactions61,62, protein sorting and trafficking63,64, kinase and 
transcription factors activation65,66 and during DNA damage response67,68 often functioning as 
a scaffold to facilitate recruitment of other proteins 69. 
Mono-ubiquitination is a wide spread protein modification, as more than a half of all ubiquitin-
modified proteins are mono-ubiquitinated70. It is largely involved in protein localization71,72, 
protein-protein interaction73 and complex formation74, DNA damage response75 and in 
epigenetic pathways76.  
So far the only described E3-ligase complex able to synthesize M1-linked linear ubiquitin 
chains is the linear ubiquitin chain assembly complex (LUBAC)77 which has been shown to 
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regulate the immune and inflammatory responses by NFκB activation78,79 and it is involved in 
cell death80,81 and in the regulation of mitotic progression19. 
1.3 DEUBIQUITINATING ENZYMES 
The complexity of the ubiquitin code demands a highly sophisticated system to counteract it. 
DUBs are directly opposing the action of E3-ubiquitin ligases by catalyzing a proteolytic 
reaction that cleaves ubiquitin/s from the substrate proteins creating a counterbalance and a 
possibility to quickly correct the signal based on the current cellular conditions or 
environmental inputs.  
There are approximately 100 DUBs encoded by the human genome, which belong to two major 
groups, the thiol proteases with a cysteine residue in their catalytic site and the metalloproteases 
with coordinated zinc ion (Zn2+). The two groups can be further divided into six structurally 
and evolutionary distinct families82,83. There are five cysteine families, the ubiquitin-specific 
proteases (USP), the ubiquitin C-terminal hydrolases (UCH), the ovarian tumor proteases 
(OTU), the Josephin family, the newly discovered motif interacting with ubiquitin (MIU)- 
containing novel DUB (MINDY)84 family and one metalloprotease family JAB1/ MPN/ 
MOV34 (JAMM)83.  
DUBs interact with ubiquitin hydrophobic patches which ensures specificity to the ubiquitin 
over the ubiquitin-like modifications83, but some UCH, USP and JAMM family members are 
also able to cleave NEDD885–87.  
The most abundant cellular DUBs are part of the proteasome system (Rpn11, UCHL5, USP14), 
the DUBs involved in ubiquitin processing during de novo synthesis and during ubiquitin 
recycling (USP5, Otulin), the DUBs associated with the linear ubiquitin chain assembly 
complex (LUBAC) and the DUBs regulating the translation initiation machinery associated 
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1.3.1 The substrate recognition patterns and the 
catalytic activity 
The ability of DUBs to cleave ubiquitin depends on their binding properties. They can bind to 
the ubiquitinated protein or to the ubiquitin molecule with different levels of specificity. 
Depending on the DUB activity, single ubiquitin molecule or the whole ubiquitin chain can be 
cleaved off during one proteolytic reaction. DUBs from the USP family often recognize and 
bind the target protein88 and they cleave ubiquitin non-specifically, precisely modulating 
signaling pathways and cellular processes. 
Another abundant group consist of DUBs binding the ubiquitin chains. These DUBs have 
different levels of specificity. They can bind a single ubiquitin molecule and process the chain 
non-specifically (exo-cleavage activity) or they can bind two ubiquitin molecules and based on 
the chain geometry they distinguish among different linkages (endo-cleavage activity). The 
DUBs from the OTU family show high linkage specificity towards specific homotypic 
chains89–91. Members of the JAMM family are often K63-linkage specific92,93 and the DUBs 
from MINDY family are K48-linkage specific84,94. In contrast, members of the UCH family 
bind ubiquitin close to its C-terminal region with only a little contact to the ubiquitin molecule 
increasing the possibility to cleave different types of chains17,95.  
A single DUB can have different activities, for example USP21 has endo-cleavage activity 
towards K63-linked chains96, but due to steric properties it has exo-cleavage activity towards 
K6-linked chains and can process them only from the distal end97. Branched chains  or modified 
ubiquitin can reduce the binding affinity of certain DUBs98 and their activity is also regulated 
by a number of posttranslational modifications83. Some DUBs work as a part of bigger 
complexes, as in the 26S proteasome (RPN11, USP14, UCHL5) where substrate recognition is 
given by other members of the complex99,100. The different DUBs’ recognition patterns and 
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Figure 3 The DUB activity is based on their recognition pattern. 
Different recognition and binding properties of DUBs and their cleavage activity with examples. A single 
DUB can have more than one activity depending on the substrate. 
Blue crescent – ubiquitin binding site, light blue circle – DUB, notch shows the cleavage site, green circle – 
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1.4 UBIQUITIN SIGNALING IN CELL CYCLE REGULATION 
1.4.1 The cell cycle progression and its checkpoints 
Cell cycle is a complex set of events that precedes and follows the cell division and it is driven 
by CDK activity. Proper CDK activation depends on the ubiquitin-mediated oscillation in 
protein levels of cyclins and kinase inhibitors that dictate the progression through different 
phases. In the first growth phase (G1) cell increases its mass and synthesizes necessary proteins 
until it reaches a restriction point (in mammals, START in yeast), where it either commits to 
the next cell cycle or it stops dividing and enters quiescence (G0). Decision to enter the cell 
cycle is irreversible, it starts with duplication of the genetic material during DNA synthesis 
phase (S), followed by a second growth phase (G2) and by equal distribution of the duplicated 
chromosomes during mitosis (M) which is completed by the cell separation during cytokinesis. 
Uncontrolled cell division often gives rise to the malignant tumor growth and the cancer 
progression. In order to prevent malignancies, cell activates checkpoints to delay the cell cycle 
progression and to gain time for error correction. The G1/S, G2/M and M checkpoints can be 
recognized which are largely regulated by the balanced activity of ubiquitin ligases and 
deubiquitinating enzymes. 
In addition to the phase transition checkpoints, the DNA damage checkpoint controls the 
genome integrity and prevents proliferation of cells with damaged DNA by cell cycle arrest. 
DNA damage happens continuously as a result of environmental stress, therefore the cell needs 
a robust mechanism of DNA damage detection and DNA repair. In presence of DNA breaks 
or damage associated with replication, cell initiates a cascade of signaling events, the DNA 
damage response (DDR) mediated by ATM/ATR kinases, respectively101,102. The DDR 
includes a number of phosphorylation and ubiquitination events which result in reversible cell 
cycle arrest giving time for DNA repair. When the DNA damage checkpoint is activated it 
results in ATM dependent recruitment of repair factors, degradation of cyclins and stabilization 
of the tumor suppressor protein p53, further promoted by several DUBs (USP10103, USP11104, 
OTUD5105). The G1 DNA damage checkpoint can not only slow down the cell cycle 
progression, but it can also irreversibly stop the cell cycle if the DNA damage is not repaired, 
resulting in apoptosis or in cellular senescence. Components of the DNA damage checkpoint 
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1.5  MITOSIS 
Mitosis is the last phase of the cell cycle during which one cell is divided into two. Cell division 
poses a potential risk for the cell, because the genetic information needs to be divided between 
the two daughter cells. Errors in this process or damage to the genetic material are deleterious 
for the cell, resulting often in a cell death. A tight control of mitosis is necessary for the normal 
cell growth. Mitosis has fascinated scientists since the 19th century and it was named by W. 
Flemming who derived the name from Greek word for thread (mitos) and he was one of the 




The human cells, in contrast to some yeast, undergo an open mitosis, which means that the 
nuclear envelope is disassembled in the beginning of the process. The nuclear envelope 
dissolves in prophase when the chromosomes condense and microtubules start to form the 
mitotic spindle. It is followed by the centrosome separation, the attachment of spindle 
microtubules to the kinetochores (the protein structures assembled around the centromeric 
Figure 4 Different stages of mitosis 
Illustration of different phases of mitosis as seen by Walther Flemming using the newly discovered anilin dyes. 
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region of the two sister chromatids) and the formation of bipolar spindle during prometaphase, 
until all chromosomes are aligned in the equatorial zone of the cell in metaphase. The fidelity 
of chromosome attachment and alignment is controlled by the Spindle Assembly Checkpoint 
(SAC) also known as the mitotic checkpoint. Upon alignment of all chromosomes, the 
anaphase starts and the two sister chromatids of each chromosome are pulled apart and 
segregated to the opposite spindle poles. In telophase the chromosomes decondense, the 
nuclear envelope is reassembled and the ingressing cleavage furrow leads to the physical 
separation of cytoplasm giving rise to the two daughter cells in the last step of cell division 
called cytokinesis. 
1.5.1 Mitotic structures 
Mitosis is a very dynamic process and a lot of structural rearrangements need to be done. The 
whole cell changes its appearance for the duration of mitosis. In this following chapter I will 
describe the main structures typical for mitosis, their assembly, regulation and function.  
Mitotic chromosomes 
To ensure proper division of the replicated DNA mass, chromosomes need to change their 
structural properties from relaxed chromatin to a highly compacted state (condensed 
chromosomes). Mitotic chromosomes have the typical X shape as visible on the scanning 
electron microscope image107 (Figure 5A) and the simplified drawing (Figure 5 B) showing the 
two sister chromatids of each chromosome connected in their centromeric regions onto which 
the multi-subunit protein complexes called kinetochores are assembled. The first images of 
mitotic chromosomes by electron microscope were taken at the end of 70s, but it took 20 years, 
until discovery of a heteromeric complex Condensin, in Xenopus laevis egg extracts108 which 
shed a light on how the DNA is compacted. Several models were proposed since then, but the 
mechanism still remains unclear109. The condensation process starts in prophase and is 
triggered by CDK1 activity110. Vertebrates have two condensin complexes, first condensin II 
interacts with DNA in the nucleus, condensin I binds to DNA after nuclear envelope breakdown 
and they are distributed along the chromosome arms. Loop exclusion model111,112, proposes the 
existence of condensin generated DNA loops (Figure 5D) that are held together in a 
dynamically moving system resulting in tightly packed mass with very low structural 
reproducibility, suggesting a rather stochastic mechanism113. Condensins are necessary for 
structural integrity of chromosomes and for successful completion of mitosis114. In addition, 
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Topoisomerase II activity is needed for decatenation of entangled DNA as inhibition of its 
activity showed increased number of chromosome bridges in anaphase115. 
Cohesin complex is structurally very similar to condensin (Figure 5C), yet it has a distinct role. 
After DNA replication, cohesin holds two sister chromatids together along the whole 
chromosome arms. In prophase, Plk1 and Aurora B activity triggers cleavage-independent 
dissociation of cohesin from chromosome arms resulting116,117 in resolution of sister 
chromatids that are still held together by cohesin in the centromeric region. It is the cohesin 
cleavage by separase that triggers anaphase onset and allows for segregation of the sister 
chromatids to the two daughter cells. Proper timing of cohesin cleavage is a key for error-free 
chromosome segregation and is tightly controlled by the mitotic checkpoint118.  
 
  
Figure 5 Cromosome structure and condensation 
(A) Mitotic chromosome under scanning electron microscope, scale bar 1µm, zoom 0.5µm. PMID: 
7166573 (B) cartoon depicting different regions of chromosome (C) Color-coded structure of human 
cohesin and condensin with their subunits. DOI: 10.1038/nsmb.3507 (D) Loop organisation of DNA 
by Condensin I and Condensin II. DOI: 10.1126/science.aao6135 
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The centromere is essential for chromosome segregation since it is a building platform for the 
kinetochore complex, the place where spindle microtubules attach. Different organisms have 
centromeres of various sizes, from point centromere (very short region) in budding yeast to 
holocentromere in C. elegans (whole chromosome)119. Human cells possess regional 
centromere, a specific region of DNA with cohesion of sister chromatids that can be seen under 
a microscope as a thin part of the condensed chromosome (Figure 5A, B). It has high structural 
elasticity therefore it can bend without causing damage to the chromosomal DNA120. 
Centromere is a constitutive heterochromatin region defined by zones of short repetitive 
sequences (α-satellites) with a typical nucleosome composition containing histone H3 variant 
Centromere Protein-A (CENP-A).  
Kinetochore is the place where spindle microtubules attach to the chromosome and therefore 
it is crucial for proper chromosome segregation. It is not only a place of attachment, but also a 
residing site of many molecular motors that are the driving force for chromosome movement 
around the cell, important for chromosome alignment and their segregation during anaphase. 
Human kinetochores bind around 30 microtubules121 in contrast to 7 in mice and 1 in the 
budding yeast. Kinetochores are assembled de novo every cell division, from prophase to 
prometaphase, when spindle microtubules start to make first contacts with the chromosomes. 
CENP-A is indispensable for kinetochore assembly, since its deletion has a lethal phenotype 
in mice122. Based on the proximity to the centromere the inner and the outer kinetochore can 
be distinguished (Figure 6).  
In prophase, CENP-A directly binds and recruits CENP-C and CENP-N, creating a necessary 
structural base for kinetochore formation123. CENP-C links centromere with the kinetochore 
and recruits 14 different CENP- (-C, -H, -I, -K to -U) proteins forming the constitutive 
centromere-associated network (CCAN)124 and the inner kinetochore.  
The outer kinetochore is a multi-subunit complex interacting with microtubules and forming 
the stable attachments. It consists of three main complexes (KNL1, Mis12, Ndc80) which is 
often referred to as the kinetochore protein network (KMN)125. Ndc80 is a tetrameric complex 
that binds microtubules126 through its two N-terminal domains, also known as Hec1 subunits. 
Mis12 complex (MIS12, PMF1, Nsl1, Dsn1) connects the KMN to the inner kinetochore via 
CENP-C and CENP-T binding. KNL1 is the largest subunit and is mostly disorganized, serving 
as a scaffold for protein binding. Kinetochore recruits many different proteins regulating either 
microtubule attachment (MCAK, Kif2b, Astrin-SKAP complex), SAC response (Bub1, 
MAD1, MAD2) or chromosome movement (motor proteins dynein and CENP-E). 
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Dynein is targeted to kinetochores by the adaptor complex Rod-Zwilch-ZW10 (RZZ) and is 
responsible for chromosome movement towards the (-) microtubule end as well as for removal 
of mitotic checkpoint components, when the SAC response is being attenuated.  
CENP-E is a kinesin motor protein mediating microtubule (+) end movement of chromosomes 
and it is also known to help microtubule capture127 and it is involved in maintenance of stable 
microtubule attachment. CENP-E inhibition disrupts proper chromosome alignment at 
metaphase.  
MCAK belongs to the Kin I group of kinesins which is not primarily involved in movement 
along MTs, but it depolymerizes them. MCAK activity is important for correction of merotelic 
attachments and for chromosome congression128.  
 
 
Figure 6 Kinetochore structure 
A color-coded scheme depicting the individual protein complexes forming human 
kinetochore and their special position from centromere (left) towards the 
microtubule (right). Source: DOI: 10.1016/j.ceb.2019.03.016 
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Centrosomes 
Centrosomes are cellular organelles important for spindle formation and spindle geometry 
functioning as the microtubule organizing centers (MTOC). Mature centrosome consists of two 
centrioles that are surrounded by pericentriolar material (PCM) with high level of structural 
organization129. Each centriole is composed of nine microtubule triplets forming the typical 
barrel-like structure. PCM consists of different proteins which recruit γ-tubulin necessary for 
formation of new microtubule fibers (MT nucleation) emanating from the pole130. Centrosomes 
are replicated in a cell cycle dependent manner. In G1/S transition, centrioles are separated 
followed by duplication and elongation of the daughter centriole in S phase. Centrosome 
maturation is finished at the mitotic entry and the two centrosomes are separated and positioned 
in the cell by Eg5 (kinesin-5, KIF11) movement resulting in a bipolar spindle formation131.  
Mitotic spindle 
Microtubules are tubular structures composed of α- and β-tubulin heterodimers in a highly 
organized manner. Microtubule protofilaments (linear chains of tubulin) form a planar sheet 
that is closed by α, β subunit binding and forms a polarized tubule in which α-subunits mark 
the (-) end and β-subunits mark the (+) end. Microtubules are very dynamic structures, they are 
constantly growing and depolymerizing in and ATP dependent manner (Figure 7) which can 
happen on any of the MT ends. 
During prometaphase, mitotic spindle is formed by microtubules growing from the two 
centrosomes that are positioned at the opposite poles of the cell, forming a bipolar spindle.  
Different types of microtubules can be identified within the spindle (Figure 8A), such as non-
kinetochore microtubules which are not stably attached or the kinetochore fibers (K-fibers) 
which are stably binding to the kinetochores. K-fibers are bundles of parallel microtubules 
which are further stabilized by clathrin containing inter-microtubule bridges132,133 which are 
part of the mesh network (proteins connecting and stabilizing K-fibres)134. Nucleation of 
microtubules can be initiated from the spindle poles (most common) or from the kinetochores 
and they are incorporated in the spindle by sliding of antiparallel MTs135–137, but these events 
are rather rare in normal conditions. Spindle microtubules have stable orientation, their (-) ends 
are directed towards the poles and their (+) ends are facing the equator or cell cortex.  
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Inter-polar microtubules are important for stability of the spindle and for chromosome 
segregation. They emanate from spindle poles and grow towards the equatorial zone where 
they meet with microtubules from the opposite pole and form antiparallel microtubule bundles 
crosslinked with Protein regulator of cytokinesis-1 (PRC1) and other proteins, referred to as 
the ‘mesh network’. The antiparallel microtubules can grow and slide along each other 
resulting in spindle elongation which is important for segregation of sister chromatids during 
anaphase, but it also determines the spindle length in metaphase138. Sliding of anti-paralel 
microtubules is regulated by activity of (+) and (-) end directed motor proteins KLP61F and 
Ncd, respectively139,140. Recent studies propose an existence of bridging fibers connecting the 
K-fibers of both sister chromatids which helps to withstand the tension and contributes to the 
curved spindle shape141,142. 
The Kinetochore-microtubule (KT-MT) attachment is a stochastic process which happens in 
prometaphase and is prone to errors therefore a reliable correction mechanism is needed to 
Figure 7 Microtubule dynamics 
Left: mechanism of γ-tubulin mediated microtubule nucleation from centrosomes. 
Right: GTP dependent microtubule polymerization and depolymerisation dynamics. 
Green circle- γ-tubulin, blue circle- α-tubulin, violet circle- β-tubulin 
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achieve error-free chromosome segregation. The desired bipolar (amphitelic) attachments are 
formed when the kinetochores are attached to the microtubules emanating from the opposite 
poles, monotelic and syntelic attachments result from binding of one or both kinetochores to 
MTs from a single pole. Merotelic attachments are similar to bipolar attachment, but one 
kinetochore is attached to both spindle poles (Figure 8B). If these attachments persist until 
anaphase, the chromosomes are not segregated properly and result in lagging chromosomes. 
The merotelic attachments are the most frequent cause of aneuploidy (loss or gain of 
chromosome) in mammalian cells143 and greatly increase the chromosomal instability (CIN)144. 
 
  
Figure 8 Structure of mitotic spindle 
(A) Drawing showing the main components of mitotic spindle and the different types of microtubules forming 
mitotic spindle. (B) Types of kinetochore- microtubule attachments. 
MT – microtubule, K-fiber – kinetochore microtubules 
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1.5.2 Mitotic regulators 
Cell cycle regulation depends mainly on ubiquitination and phosphorylation events, which are 
frequently interconnected. In this chapter I want to provide an overview of the most important 
kinases and ubiquitin-related factors for mitotic progression. Their activity needs to be properly 
coordinated in time and space by restricting their localization to specific cell compartments or 
by recruitment of phosphatases or DUBs that oppose their role (Figure 9).  
Mitotic kinases 
Cdk1 (cdc2 in yeast) belongs to Ser/Thr protein kinase family and it is highly conserved among 
species. Protein levels of Cdk1are stable during the cell cycle and its activity is regulated by 
association with mitotic cyclins (cyclin A and B) that function as regulatory subunits. Cdk1 is 
an important regulator of mitotic progression, it is activated by cyclin B at the G2/M transition, 
its activity peaks in prometaphase and it is inactivated at anaphase onset by APC/C mediated 
cyclin B degradation. Cdk1 promotes mitotic entry and its activity is necessary for many 
structural changes typical for mitosis, such as nuclear envelope breakdown, centrosome 
separation, chromosome condensation, kinetochore assembly and cytoskeleton rearrangement, 
which are all necessary for spindle formation and separation of the two daughter cells. A high-
throughput search for Cdk1 substrates in mitosis identified more than 400 potential substrates 
including proteins associated with nuclear envelope (Lamin A/B/C, NUP133, RANBP2), 
centromere and kinetochore (INCENP, CENP-C, DSN1) and cytoskeleton (TPX2, KIF20A, 
KIF18B, MAP 4/7) further underlying Cdk1 importance145. Interestingly, Cdk1 also 
phosphorylates other mitotic kinases (Aurora B, Haspin) and phosphatases (PP1) to regulate 
their activity146.  
The family of Aurora Ser/ Thr protein kinases contain three members: Aurora A, Aurora B and 
Aurora C. They are structurally very simmilar, yet they have distinct functions. Aurora C 
expression is restricted to germ cells that undergo meiosis, therefore high Aurora C levels can 
be found in testis and oocytes147,148. In contrast, Aurora A and B are expressed ubiquitously 
and they are important regulators of mitosis.  
Together with Cdk1 and Plk1, Aurora A activity is necessary for the Cdk1 dependent mitotic 
entry and deletion of Aurora A results in G2 arrest. Aurora A localizes to the centrosomes and 
contributes to their maturation by recruitment of PCM components (centrosomin, γ-tubulin). 
In addition, Aurora A phosphorylates CDC25 phosphatase and the level of phosphorylation is 
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proportional to cyclin B translocation to the nucleus and to the subsequent activation of 
Cdk1149. This step is tightly controlled by the DNA damage checkpoint preventing premature 
onset of mitosis. Aurora A strenhtens cohesion of sister chromatids by phosphorylation of 
histone variant CENP-A (Ser7) which prevents the chromosomes from ‘cohesion fatigue‘ (loss 
of cohesion)150. Aurora A participates in spindle organization during prometaphase and is also 
necessary for the formation of the central spindle during anaphase where it promotes MT 
nucleation in the midzone151. Despite their different roles, Aurora A and Aurora B have some 
common substrates important for chromosome movement and microtubule stability and spindle 
dynamics including MCAK, KIF2b, KIF18 and CENP-E20,152,153.  
Aurora B is the catalytic subunit of the Chromosome passenger complex (CPC), consisting of 
inner centromere protein (INCENP), Survivin, Borealin (known as Dasra B) and Aurora B 
kinase154. The CPC has dynamic localization during mitosis and controls many important 
processes including chromosome condensation, SAC activation, correction of KT-MT 
attachments and cytokinesis155.  
In early mitosis, CPC is targeted to inner centromere by phosphorylation of two histones, H2A 
(Thr120), H3 (Thr3) by Bub1 and Haspin kinases which creates the docking sites for Borealin 
and Survivin subunits of CPC156. CPC binding to pH3T3 is further promoted by Aurora B 
activation of Haspin, generating a positive feedback loop stimulating CPC recruitment to the 
inner centromere157. Aurora B is activated by INCENP binding which triggers 
autophosphorylation at Thr232 residue resulting in full activation. In prophase, Aurora B 
contributes to chromosome condensation by promoting condensing I association with mitotic 
chromosomes158. Aurora B is the main kinase involved in the correction of erroneous KT-MT 
attachments (syntelic, merotelic)159. In prometaphase, Aurora B phosphorylates kinetochore 
proteins including Ndc80, KNL-1 and Mis12 resulting in decreased affinity of KMN towards 
microtubules leading to destabilization of KT-MT attachments. This mechanism increases the 
MT turnover at KTs and increases the chance that correct, amphitelic attachments will be 
made160,161. Aurora B activity negatively regulates Astrin-SKAP complex further weakening 
the KT-MT attachments during prometaphase. Another important substrate of Aurora B is 
MCAK (KIF2C) which has a MT- depolymerizing activity. Aurora B phosphorylation inhibits 
MCAK activity and retains it at the centromere. Upon dephosphorylation it is relocalized to 
KTs where it promotes MT disassembly and thus correction of improper attachments162. This 
probably serves as an additional mechanism to correct erroneous attachments even after Aurora 
B activity is attenuated. Aurora B is also an important mediator of the SAC response (see 
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chapter about SAC). Upon chromosome alignment, before the anaphase onset, ubiquitin ligase 
Cul3-mediated mono-ubiquitination triggers Aurora B relocalization to the microtubules by 
UBASH3B ubiquitin receptor and MKLP2 (kinesin-6) motor protein163. In telophase, Aurora 
B localizes to the midbody and contributes to timely regulation of abscission and cytokinesis 
in order to prevent cells from chromosome breakage by cytokinetic machinery164.  
Polo-like kinase 1 (Plk1) belongs to the family of Ser/Thr kinases and contains two polo-box 
domains that are important for regulating its activity and the dynamic subcellular localization. 
Plk1 activity is necessary for duration of the whole mitosis. It promotes mitotic entry and 
regulates centrosome dynamics, KT-MT attachments, SAC signaling and mitotic exit. In G2, 
Plk1 localizes to centrosomes and contributes to the centrosome maturation by phosphorylation 
of pericentrin, promoting the recruitment of γ-tubulin and Aurora A to centrosomes165. In 
addition, Plk1 contributes to centrosome separation by two distinct mechanisms: 
phosphorylation of Mst2-Nek2A166 kinase module and by phosphorylation of kinesin Eg5 
leading to centrosome positioning by a Cdk1-independent mechanism167. In prometaphase, 
Plk1 localizes to kinetochores and contributes to stability of KT-MT attachments by 
recruitment of the protein phosphatase 2A (PP2A) which opposes the role of Aurora B168,169. 
In metaphase, Plk1 is removed from kinetochores which contributes to SAC silencing170. In 
telophase and during cytokinesis, Plk1 localizes to the midbody and negatively regulates 
recruitment of the abscission factor CEP55 which complements the Aurora B mediated control 
of timely abscission and cytokinesis171. At mitotic exit, Plk1 is polyubiquitinated by APC/CCdh1 
and degraded by proteasome.  
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The mitotic ubiquitin- related factors 
The most studied E3 ligases regulating cell cycle progression are SCF and APC/C. They are 
both Cullin-RING ligases (CRLs) and they form multi-subunit complexes with different 
cofactors and adaptor proteins which further tune their substrate specificity (Figure 10). Mitotic 
entry is regulated by SCFβ-Tcrp complex which controls protein levels of negative regulators of 
CDK1 (Wee1, Emi1) and is counteracted by USP50 deubiquitinase172. CDK1 and Aurora A 
activity is necessary for the mitotic entry and is controlled by USP7 which indirectly promotes 
Aurora A degradation resulting in G2 arrest173. Error- free mitotic progression is under the 
control of the mitotic checkpoint (also called SAC), which prevents chromosome segregation 
prior their proper alignment at metaphase plate by inhibiting the APC/C ubiquitin ligase. 
USP44 further stabilizes the mitotic checkpoint complex and inhibits anaphase onset174 while 
USP16 promotes chromosome alignment by targeting Plk1 to kinetochores175. The USP39 and 
USP9X DUBs have been implicated in the control of proper chromosome alignment by 
regulating the transcription and localization of the key mitotic kinase Aurora B176,177. 
Figure 9 Overview of the main kinases and phosphatases regulating mitotic progression.  
Left to right: different phases of mitosis ordered chronologically together with important structural changes of the 
cell (a). (b) List of kinases important for regulation of mitosis and (c) the phosphatases counterbalancing kinase 
activity. Length of the purple rectangle corresponds to the time they are activated in mitosis.  
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Additionally, USP4 indirectly contributes to SAC activation by control of mRNA splicing of 
important SAC components178. Upon chromosome alignment, APC/Ccdc20 promotes 
proteasomal degradation of Cyclin B by K11-linked polyubiquitination179 and results in 
cytokinesis and mitotic exit. Several DUBs have been shown to control cytokinesis, CYLD 
which negatively regulates cytokinesis by increasing the stability of microtubules180 and USP8 
and AMSH promote the scission by deubiquitination of ESCRT machinery components at the 
central spindle and the midbody181. Mitotic exit is further promoted by APC/Ccdh1 mediated 
ubiquitination and degradation of mitotic cyclins (cyclin A, cyclin B) and mitotic kinases (Plk1, 
Aurora A, Aurora B)48,182. USP35 is so far the only DUB described to oppose the APC/Ccdh1 
by deubiquitinating and stabilizing Aurora B kinase183 (Figure 10).  
Until now, several DUBs have been identified to regulate mitotic progression as discussed in 
this chapter, but the list is by far incomplete and further studies are necessary to fully 
understand how DUBs are regulating mitotic progression.  
 
  
Figure 10 Regulation of mitosis by ubiquitin- related factors 
Orange rectangle – ubiquitin ligase, blue circle – DUB, green circle – positive cell cycle 
regulator, red circle – negative cell cycle regulator.  
Adapted from: DOI: 10.1146/annurev-biochem-060410-105307 
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1.5.3 Mechanism of the spindle attachment and the 
 chromosome congression 
To achieve proper chromosome alignment, kinetochores first need to be attached to the spindle 
microtubules and after, chromosomes need to be transported to the equatorial zone of the cell 
(chromosome congression) by combination of pushing and pulling forces of molecular motors 
and by polymerization and depolymerization of the spindle microtubules.  
KT-MT attachment is a stochastic process, described by the ‘search and capture’ model. Polar 
microtubules elongate and search for kinetochores, exploring the space as they grow. 
Interestingly, fission yeast use the microtubule pivoting around the polar body (human 
centrosome) to quickly capture kinetochores along the whole length of MT184. Mitotic spindle 
nucleates from centrosomes and many temporary and unstable attachments are made, before 
the bi-oriented state is achieved. In the beginning, kinetochores often bind to the side of 
microtubules (lateral attachments) and they are pulled towards the MT (+) end to form the 
stable end-on attachments in a conversion process185.  
It remained a big question in the field what is the mechanism of chromosome congression, 
which factors are the key players and how the pulling forces are generated. It is now clear that 
more than one mechanism contributes fast and efficient chromosome alignment.  
Different congression mechanisms apply depending on the position of chromosome in the cell 
and its attachment status. When the chromosome is captured by the spindle microtubule at the 
cell periphery, it is transported by a dynein mediated movement to the pole186, a microtubule 
dense region, where it has a higher chance to be bound by microtubules from the opposite pole 
(Figure 11A). Chromosomes with the monotelic attachment can be transported to the equatorial 
zone by a CENP-E dependent movement along an already established K-fiber (Figure 11B). 
Chromosomes with bipolar attachments need to be transported to the equatorial zone to 
complete their alignment (Figure 11C). This chromosome has more MTs attached from the 
near pole, but yet it is moving away from this pole. We can distinguish the leading kinetochore 
(closer to the equatorial zone) and the trailing kinetochore (facing the pole). The mechanism 
regulating this chromosome movement has long been discussed and it was proposed that the 
force is proportional to the length of the microtubule, resulting in a movement away from 
pole187. Both, plus and minus end directed motors are present at the kinetochore and their 
activity is regulated by phosphorylation, therefore chromosome can be moved in both 
directions, depending on the surrounding signals188. Laser ablation studies showed, that the 
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pulling force is generated only on the leading kinetochore ensuring movement to the center of 
the cell189 during which MTs at the leading KT are shortening and MTs at the trailing KT are 
growing. This is possible due to the ability of kinetochores to stay attached to microtubules 
even when they are polymerizing/ depolymerizing (Figure 11D) and results in chromosome 
alignment. In metaphase, all chromosomes are attached to the spindle, but despite its static look 
it is a highly dynamic structure. K-fibers are constantly growing from their (+) ends and they 
are shrinking at the poles from their (-) ends. This shrinkage happens at a higher pace than the 
growth, resulting in pulling forces towards the poles and it also causes a constant polar 
movement of tubulin subunits in the spindle, so called ‘poleward microtubule flux’190. 
Poleward flux has been observed by photoactivation and photobleaching experiments, where 
patches of tubulin were seen to move to the poles190,191 (Figure 11E). It serves as an additional 
mechanism for protein removal from kinetochores and it was shown to contribute to 
chromosome movement during anaphase192,193.  
 
Figure 11 Mechanisms of chromosome congression and properties of the bi-oriented spindle. 
(A-C) Different mechanisms of chromosome transport from the cell periphery to the equatorial zone. (D) The 
kinetochore- microtubule interface showing the mechanism by which kinetochores bind growing and shrinking 
microtubules. Adapted from: DOI: 10.1016/S0092-8674(03)00115-6 (E) The poleward flux established upon 
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1.5.4 Spindle assembly checkpoint (SAC) 
SAC senses the occupancy of kinetochores by microtubules and is regulated by activity of 
different kinases and phosphatases. When there are no MTs attached to KTs, the activity of 
mitotic kinases is dominant and the SAC response is high. Upon formation of bipolar 
attachment, the activity of mitotic phosphatases becomes dominant and SAC is silenced. 
Interestingly, the SAC response is potentiated by presence of unattached KTs and therefore it 
is not efficient in sensing merotelic attachments, because the kinetochores are bi-oriented and 
fully occupied by MTs143. Aurora B activity is necessary for correction of erroneous (merotelic, 
syntelic) attachments161. SAC prevents premature anaphase onset by inhibiting the activity of 
APC/C ligase, which ubiquitinates separase inhibitor securin and the CDK cofactor cyclin B 
and targets them for proteasomal degradation. Cohesin cleavage by separase triggers anaphase 
and subsequent drop in CDK activity results in mitotic exit. APC/C activity is dependent on 
the cdc20 cofactor, which is the target of the SAC generated mitotic complex (cdc20, MAD2, 
Bub3 and BubR1)194. Aurora B activity promotes localization of SAC components to the 
kinetochores195 by targeting Mps1 kinase to KTs and by potentiating its activity196. Mps1 
phosphorylation promotes recruitment of Bub1 kinase to KTs, amplifying the SAC response. 
Aurora B inhibition results in weak SAC signaling and premature mitotic exit197.  
SAC signal is generated at the kinetochore and it is diffused in the cell by cascade of events. 
First, unattached kinetochores recruit Mad1 which interacts with MAD2 dimer and is able to 
change the conformation of cytoplasmic ‘open’ MAD2 (o-MAD2) to ‘closed’ MAD2 
(c-MAD2) which has a high binding affinity to cdc20 cofactor, activator of APC/C ligase198. 
Complex of c-MAD2 and cdc20 can diffuse to cytoplasm and another MAD2 can be ‘activated’ 
leading to fast amplification of the signal (Figure 12A). The APC/C-cdc20-c-MAD2 complex 
is inactive and cells remain arrested in metaphase.  
After KT attachment and chromosome alignment, the SAC signaling needs to be silenced, 
which is achieved by combination of poleward microtubule flux and dynein dependent removal 
of SAC components from kinetochores199 in addition to high activity of PP1 phosphatase which 
opposes Aurora B and dephosphorylates its substrates200. Upon SAC silencing, Bub1 stays 
localized to kinetochores but MAD1 and MAD2 dissociate from KTs leading to physical 
separation of the kinase and its substrates, stopping further generation of SAC signal201. 
Interesting protein is p31Comet which is structurally very similar to MAD2. It binds to 
MAD1-MAD2 core complex at kinetochores and sterically blocks the site for O-MAD2 
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binding, which subsequently blocks O-MAD2 activation and stops generation of SAC 
response202. In addition, p31Comet binds to soluble MAD2 forming APC/C-cdc20-Mad2-
p31Comet complex, which can partially activate APC/C resulting in auto-ubiquitination and 
dissociation of MAD2 cdc20 complex, further contributing to the APC/C activation203 (Figure 
12B). Combination of these mechanisms leads to SAC silencing and timing of these events 
needs to be tightly controlled since it results in irreversible sister chromatid separation by 
cohesin cleavage and to the anaphase onset.  
Defects in SAC signaling or in the correction machinery result in segregation errors. The most 
frequent causes are weak SAC response (premature anaphase entry) and aberrant KT- MT 
attachments (merotely) which both lead to lagging chromosomes and aneuploidy. At certain 
rate, aneuploid cells are present in normal tissues204, but they are quickly eliminated. Lagging 
chromosomes can result in micronuclei or they can cause chromosomal damage by the 
cytokinetic machinery which is detrimental for the cell and induces a global stress and 
activation of the DNA damage response pathway which leads to cell cycle arrest, apoptosis or 
senescence205–207. In some cases, cells adapt and manage to tolerate aneuploidy either by 
inhibition of the DNA damage response pathway (p53 mutation) or by transcriptional 
adaptation (increased gene transcription, higher copy number) leading to upregulation of the 
compensatory mechanisms208,209. This constant adaptation of the cancer cells to tolerate 
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Figure 12 Spindle assembly checkpoint activation and deactivation 
(A) In presence of unattached kinetochores, MAD1 binds to kinetochores and catalyses conformational chance of 
o-MAD2 to c-MAD2 which forms complex with cdc20 and inhibits APC/C ligase activity. 
(B) Upon attachment of all kinetochores to microtubules the SAC is silenced, mitotic checkpoint components are 
removed from kinetochores and p31comet inhibits the conformational change of MAD2 stopping the SAC signal 
from propagation. Polyubiquitination of cdc20-MAD2 leads to dissociation of the mitotic checkpoint complex 
and to full activation of APC/C. 
Source: DOI: 10.1016/j.str.2008.10.002 
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AIMS OF THE STUDY 
Mitosis is one of the cell cycle phases and it is the step of physical cell division. During this 
process the duplicated genetic content is divided into two daughter cells and therefore it needs 
to be tightly regulated. Defects in the cell division are highly detrimental for the cell and for 
the whole organism and they often lead to cell death or to aneuploidy, a known driver of 
tumorigenesis.  
 
Main aim: The main aim of this project was to identify novel factors of the ubiquitin signaling 
that are important for regulation of the cell cycle progression and mitosis. 
 
Aim 1: Describe the function of ubiquitin ligase Trim15 and assess its ability to regulate the 
cell cycle progression. 
 
Aim 2: Characterize the deubiquitinase UCHL3 and confirm its involvement in the regulation 
of mitosis. 
 
Aim 3: Characterize the phenotype of UCHL3 downregulation and its relevance for the human 
primary cells. 
 
Aim 4 Investigate the mechanism by which UCHL3 regulates mitotic progression and identify 
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PROJECTS 
2 UCHL3 CONTROLS THE CHROMOSOME 
SEGREGATION DURING MITOSIS 
2.1  BACKGROUND 
UCHL3 is a deubiquitinating enzyme belonging to the family of ubiquitin C- terminal 
hydrolases and it catalyzes the removal of ubiquitin molecule from its substrates.  
UCH protein family consists of four members: UCHL1, UCHL3, UCHL5 and BAP1210 which 
have high structural similarity. UCHL3 is well conserved throughout the evolution. There is a  
high homology of UCHL3 proteins among species, from Arabidopsis and Drosophila to mouse 
and human211. UCHL3 is a small protein of 27 kDa encoded by a 9 exon gene of ~1000 bp 
which is located on the human chromosome 13. The mRNA of UCHL3 can be alternatively 
spliced producing three putative transcript variants. Until now, only the longest transcript has 
been well described to produce the UCHL3 protein of 230 amino acid (AA)212. UCHL3 protein 
has several ubiquitin binding domains and multiple catalytic sites among which the cysteine 
95 residue is the main one213,214 (Figure 13). The UCHL3 gene has about 50% homology to the 
UCHL1 gene, but despite their similar function in the ubiquitin cleavage, it was shown that 
they regulate distinct biological processes. Unlike UCHL3, UCHL1 possesses also ubiquitin 
ligase activity and its expression is restricted to the brain, testes and ovary while UCHL3 is 
expressed ubiquitously215. Interestingly, UCHL3 has a capacity to cleave the ubiquitin- like 
molecule Nedd886 which regulates the activity of Cullin ring ligases216. UCHL3 also has an 
established role in the processing of the ubiquitin precursor proteins during de novo ubiquitin 
synthesis24. Several in vitro studies described UCHL3 as a protease capable of hydrolyzing 
only small ubiquitin conjugates and peptides, due to the structural properties of UCHL3 
suggesting that bigger substrates would not fit into the catalytic site214,217–221. These findings 
have been recently challenged by the growing number of in vivo studies describing the role of 
UCHL3 in protein deubiquitination.  
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UCHL3 knockout mice are viable, but they show degeneration of skeletal muscles and retina222. 
Other studies with UCHL3 knockout mice show involvement of UCHL3 in spatial learning 
and working memory223 as well as in insulin signaling and obesity224,225. Recently a number of 
publications appeared describing the role of UCHL3 in DNA repair pathway by homologous 
recombination (HR)17 and non-homologous end-joining (NHEJ)226 as well as in the DNA repair 
of topoisomerase-induced breaks95. In addition, some studies described upregulation of 
UCHL3 in the invasive breast cancer, in cervical carcinoma and in the progression of prostate 
cancer metastasis227–229. Those studies collectively show involvement of UCHL3 in various 
biological processes by catalyzing the removal of different ubiquitin modifications from its 
substrates and thus opposing proteolytic as well as non-proteolytic ubiquitination.  
 
Figure 13 UCHL3 protein is highly conserved among species 
The sequence alignment of UCHL3 protein from different species: UCH-L3 (human), UCH-L1 (human), UBL-
DROME (D.melanogaster), SCHPO (Schizosaccharomyces pombe), YUH1 (S.cerevisiae). Yellow color: 
ubiquitin binding sites, red color: catalytic site, black asterisk: C95.  
Source: doi: 10.1093/emboj/16.13.3787 
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2.2 MATERIALS AND METHODS 
2.2.1 Reagents and antibodies 
TCID (4,5,6,7-tetrachlorodindan-1,3-dione) UCHL3 inhibitor (Ref. 27720-1), C9H2Cl4O2, 
CAS #: 30675-13-9, Tebu-Bio. UCHL3 inhibitor which was published previously to 
successfully inhibit the catalytic activity of UCHL3. TCID inhibits also UCHL1 (IC=75µM), 
I used TCID at 2µM working concentration to ensure specificity for UCHL3215,230,231. 
Monastrol (Ref. M8515) and 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) (Ref. 
D8417) were purchased from Sigma-Aldrich. S-Trityl-L-cysteine (STLC), (Ref. ALX-105-
011-M500) was purchased from Enzo Life Sciences and the proteasomal inhibitor MG132 was 
purchased from Tocris bioscience (No. 1748). Protease inhibitors (cOmplete EDTA-free 
Protease Inhibitor Cocktail) were purchased from Roche, 1 tablet was diluted to final volume 
10 ml lysis buffer. 
UCHL3 antibody was produced by IGBMC antibody facility using immunized rabbits and I 
purified the serum with SulfoLink resins according to the manufacturer’s protocol. The Astrin 
polyclonar rabbit antibody was a kind gift from Ulrike Gruneberg (Cancer Research UK). 
Following commercial antibodies were used: Mouse monoclonal BubR1 (BD Biosciences, 
612502 clone 9/BubR1), mouse monoclonal α-tubulin (Sigma Aldrich, T5168), human 
polyclonal CREST232 (Antibodies Incorporated, 15-234), rabbit polyclonal Aurora B (Abcam 
ab2254), mouse monoclonal UCHL3 (Sigma Aldrich, clone H7171), mouse monoclonal 
CENP-E (Thermo Scientific, MA1-5758), rabbit polyclonal GFP (Abcam, ab290) 
2.2.2 Plasmids 
All GFP plasmids used were cloned into pEGFP-N1 plasmid (Clontech) generating different 
expression vectors: pEGFP-N1, pEGFP-N1-UCHL3-WT, pEGFP-N1-UCHL3-C/S. For 
UCHL3 cloning the longest transcript variant (NCBI, variant2 NM_006002.4) was used to 
design specific primers for amplification of UCHL3 from human cDNA. To generate the 
catalytic dead mutant of UCHL3, cysteine 95 residue was mutated to serine by G > C base 
exchange in the cysteine codon (Appendix Table 8).  
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2.2.3 Cell culture 
Cell lines and medium 
All cell lines were purchased from ATCC and cultured at 37 °C in 5% CO2 humidified 
incubator, if not stated otherwise. I used several different cell lines of human origin and 
cultured them as listed below.  
HeLa Kyoto (HeLa K) human cervix carcinoma cells were cultured in high glucose DMEM-
GlutaMAX (4.5 g/L glucose) supplemented with 10% fetal calf serum (#9150), 1% penicillin 
and streptomycin. HeLa K cells stably expressing Tubulin-GFP-H2B-mCherry were purchased 
from Ellenberg laboratory and a standard medium for HeLa K cells was used to culture them.  
Human primary lung fibroblasts (IMR90) were cultured in EMEM containing non-essential 
AA, 2 mM L-glutamine, 1 mM sodium pyruvate, 1500 mg/L sodium bicarbonate, 10% fetal 
calf serum and gentamycin. Dld1-mCherry cell line was a kind gift from Don Cleveland and it 
was cultured in RPMI-1640 medium containing 2 mM L-glutamine, 10 mM HEPES, 1 mM 
sodium pyruvate, 4500 mg/L glucose, 1500 mg/L sodium bicarbonate, 10% fetal calf serum 
and gentamycin.  
Cell seeding 
I trypsinized cells and counted them in Neubauer chamber (5-10 squares) and calculated the 
concentration. For all immunofluorescence experiments I was seeding cells on 9-15 mm glass 
coverslips (Menzel-Glaser) in 24-well plates at a density 15 000 cells per well.  
Cell cycle synchronization 
1. STLC (prometaphase) 
I diluted STLC in DMSO to produce 50 mM stock and I treated cells for 16 hours with STLC 
containing medium at 5 µM working concentration. 
2. Monastrol (prometaphase) 
I used 100 mM stock of Monastrol in DMSO and I incubated cells for 16 hours in Monastrol 
containing medium at final concentration 100 µM.  
3. Monastrol washout (different mitotic phases) 
I incubated cells for 16 hours in Monastrol containing medium at final concentration 100 µM, 
washed them five times with warm medium and released them in fresh culture medium for 
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different time intervals, aproximately 30 minutes to reach metaphase and 45 minutes to reach 
anaphase. 
4. Monastrol release (metaphase) 
For all Monastrol release experiments, I used 100mM Monastrol stock in DMSO and 50 mM 
stock of proteasome inhibitor (MG132) in DMSO. For each experiment I diluted both drugs in 
culture medium and used them at following working concentrations: Monastrol 100 µM and 
MG132 50 µM and I used the same protocol for all cell types. I treated cells with 500 µl of 
Monastrol containing medium for 16 hours and after I washed them five times with 2 ml of 
warm medium and released them for 90 minutes to fresh medium containing proteasome 
inhibitor to arrest the cells in metaphase.  
2.2.4 Stable UCHL3-GFP cell lines 
Stable cell lines were generated in HeLa Kyoto cells by random integration of GFP-UCHL3 
plasmids (section Plasmids). Three lines were generated: GFP-HeLa expressing empty GFP 
plasmid as a control, GFP-WT-UCHL3 expressing wild-type sequence of UCHL3 and GFP-
C/S-UCHL3 expressing catalytic dead mutant of UCHL3. Expression levels of different 
proteins were estimated by western blot and for my experiments I chose the cell lines which 
were expressing near endogenous levels of those proteins.  
2.2.5 UCHL3 shRNA virus production and generation  
of the HeLa K and Dld1 cell lines 
For retroviral mediated silencing of genes induced by stable expression of short hairpin RNA 
(shRNA), four sequences targeting UCHL3 and one control sequence (targeting Firefly 
luciferase) was cloned into an LMP backbone233 (Appendix Table 1). This plasmid contains 
long terminal repeats and retroviral packaging signal necessary for the virus production and 
PKG promoter driven expression of a cassette coding for puromycin resistance and GFP. 
Furthermore, for improved production of the shRNA, it contains a cassette with U6 promoter 
driven expression of miR30 microRNA context into which the designed shRNA sequences are 
cloned. 
Retrovirus was produced by transiently transfecting the Phoenix packaging cell line (G. Nolan, 
Stanford University, Stanford, CA) with the prepared plasmids. Supernatant was collected, 
filtered to remove cellular debris, polybrene was added and the supernatant was used to infect 
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HeLa cells or Dld1 cells overnight. After 2 days, cells were selected using puromycin for 
48 hours. After the selection, the presence of replicatively competent retrovirus was excluded 
using qPCR. Knockdown of UCHL3 was validated using qPCR. 
2.2.6 UCHL3 silencing by siRNA 
Cells were transfected by Oligofectamine at the final concentration 30 nM of the siRNA. I used 
different siRNAs (sequences are listed in Appendix Table 2). Transfection reaction was based 
on the manufacturer’s instructions and I downscaled it to use of smaller volumes (Appendix 
Table 3). For rescue experiments with UCHL3 GFP plasmids, I used Lipofectamine 2000 
according to manufacturer’s instructions to transfect both, cDNA and siRNA at the same time.  
2.2.7 Immunoprecipitation 
For IP experiments, I used HeLa K cells stably expressing GFP-UCHL3 proteins. I prepared 
cell extracts from cells in 1ml of lysis buffer (10 mM Tris HCl pH 7.5, 150 mM NaCl, 0.5 mM 
EDTA, 0.5% NP-40, protease inhibitor cocktail) per four 10 cm dishes in each condition. To 
capture the proteins I used GFP-trap agarose beads (Chromotek) which I blocked overnight in 
3% BSA diluted in wash buffer (10 mM Tris HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 
protease inhibitor cocktail). After blocking beads, I washed them three times in lysis buffer and 
incubated them with 10 mg of cell extracts overnight, rotating at 4 degrees. Before elution, I 
washed the beads 5 times for 5 minutes with 1 ml washing buffer (centrifugation 500g, 2 
minutes) and after I boiled them in 2x Laemmli SDS sample buffer (BioRad) for 15 minutes 
and loaded the samples on SDS-PAGE followed by western blotting (WB).  
2.2.8 Western blot analysis 
To isolate proteins from the cells, I scraped them from the culture dish, pelleted them by 
centrifugation at 4⁰C and washed them twice with PBS. I lysed them using RIPA buffer (50 mM 
Tris-HCl pH7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA) supplemented with 1 mM 
NaF, 1 mM DTT and protease inhibitor cocktail Complete. I lysed the cells on ice by 
mechanical disruption with a needle (26G brown) 10 times up and down. After, I centrifuged 
the samples at 10 000g for 30 minutes at 4⁰C, transferred the supernatant to a clean tube and 
measured protein concentration using Bradford assay (Biorad) in 1 mL cuvettes. Samples were 
boiled 10 minutes in Leamli buffer with β-Mercaptoethanol (BioRad), resolved on 10% 
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polyacrylamide gels or pre-cast gradient gels (Thermo Scientific, NW04120BOX) and 
transferred to PVDF membrane (Millipore) using semi-dry transfer unit (Amersham). I used 
5% non-fat milk for blocking the membranes and for antibody dilution and TBS-T (25mM 
Tris-HCl, pH 7.5, 150mM NaCl, 0.05% Tween) for washing the membranes. 
2.2.9 RNA isolation and cDNA preparation 
To isolate RNA from cells I used the RNA isolation kit from Machery Nagel according to their 
protocol. I used at least 300 000 cells per one reaction. For cDNA preparation I used 
SuperScript II Kit from Invitrogen and 2500 ng of RNA per reaction with 10mM dNTPs mix 
from Sigma and Oligo_dT anchor (Appendix Table 4). 
2.2.10 Quantitative PCR analysis 
I used 20 ng of cDNA as a template, SybrGreen I master mix from Roche (04 887 352 001) 
and 1µM primers in final volume of 10 µl per reaction as listed in primer sequences (Appendix 
Table 4). I normalized the UCHL3 expression to a combination of three housekeeping genes 
(GAPDH, HPRT, PO) and I run them at 62⁰C annealing temperature. I used the software from 
Roche (LightCycler® 480 SW 1.5.1) to analyze my data. I determined the efficiency (E) for 
all primer pairs using large dilutions of template cDNA (50x – 3000x) and I calculated the 
relative expression using this formula: R = E^[CP sample – CP control]. If not calculated 
otherwise, I assumed that E= 2.  
2.2.11 Immunofluorescence 
Motor proteins 
 I removed medium and incubated cells in extraction buffer (PHEM, 1 mM PMSF, 1 mM ATP, 
0.5% Triton X-100) for 3 minutes at 37 ⁰C and after I fixed the cells in 4% PFA for 2 minutes 
at 37 ⁰C followed by two times 5 minutes incubation with 0,5% Triton in PBS at 37 ⁰C. Next, 
I blocked the cells in 3% BSA in PBS-T and I followed the normal protocol from this step 
onwards. PHEM buffer (pH 6.9, PIPES 45mM, HEPES 45mM, EGTA 10mM, MgCl2 5mM). 
Standard protocol 
I used this protocol for all my experiments if not stated otherwise. I washed the cells once in 
PBS and fixed them in 4% PFA for 17 minutes at room temperature, washed them three times 
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in PBS and permeabilized them in 0.5% NP-40 for five minutes. Next, I washed them three 
times in PBS-T and blocked them in 3% BSA in PBS-T for either 90 minutes at room 
temperature (RT) or at 4 degrees overnight. I diluted primary antibodies in the blocking buffer 
and incubated them for 2 hours at RT, I washed the cells 3 times five minutes in PBS-T and 
incubated them with secondary antibodies at 1:500 dilution for one hour at RT in the dark. 
I washed the cells 3 times 10 minutes with PBS-T and incubated them with DAPI diluted in 
PBS at final concentration 1 µg/ml for 10 minutes at RT. I washed them 2 times in PBS-T and 
mounted them on glass slides using Mowiol and dried them overnight at RT in dark. 
For all the samples I took high resolution images using Leica spinning disc confocal 
microscope at 100x magnification with Live SR module and I processed the pictures in Image J 
followed by the analysis in Cell Profiler as described later. 
2.2.12 Mitotic index quantification 
I used HeLa cells stably expressing the shRNA against either Luciferase (control) or UCHL3 
(sh2 UCHL3), I synchronized them by monastrol and after 16 hours of treatment I took 
photographs of living cells in multiple randomly chosen regions of the culture dish. I calculated 
the mitotic index (MI) for each condition as a ratio of the mitotic cells number divided by the 
total number of cells. I determined the mitotic cells by their characteristic round shape. 
2.2.13 Live video imaging 
To film the cells, I used glass bottom dish, 30 mm diameter with four compartments. I used 
two wells per each treatment/ cell line. For acquisition, I used Leica CSU-W1 spinning disc, 
63x objective, oil. Time frame 5 min, z step= 2µm. I placed the cells into a humid heated 
chamber with 5% CO2 and 80% humidity in the microscope and I rinsed the cells five times 
with warm medium to wash the monastrol out. I selected eight positions for each condition and 
I was acquiring pictures for four hours. After acquisition, I processed the files using ImageJ 
and I created maximum projections for all positions in all time points.  
2.2.14 Quantification: the percentage of cells with 
misaligned chromosomes 
To quantify cells with misaligned chromosomes I stained the cells with DAPI to visualize 
DNA. To eliminate biased counting, I always used a blinded approach and I revealed the 
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sample IDs only in the end of each experiment. I counted the cells directly at the microscope. 
I was counting the number of cells with aligned chromosomes and the number of cells with 
misaligned chromosomes and I calculated the percentage of each from the total number of cells 
counted. In each experiment I counted between 200-800 cells per condition depending on the 
seeding density.  
2.2.15 Cell Profiler data analysis 
To analyze the immunofluorescent images I used Cell Profiler 3.1.8 and I created different 
pipelines according to the question I was asking, which is described in detail in the following 
paragraphs. 
1. Irregular nuclei quantification 
In my experiments I was determining the shape of nuclei in different conditions and I wanted 
to find an unbiased way how to quantify this parameter. For this purpose, I decided to use the 
form factor as a criteria. In Cell Profiler, the form factor is calculated as 4*π*Area/Perimeter2, 
where area is the number of pixels in the region and perimeter is the total number of pixels 
around the boundary of each region in the image 234. Objects that are perfectly round have their 
form factor equal to 1. For each set of experiments, I identified the primary objects (nuclei) 
based on the DAPI channel, I measured the form factor for each nucleus in the given treatment 
group and I set a threshold to discriminate between regular and irregular nuclei. I considered 
all nuclei above the threshold as regular and all nuclei below it as irregular. I calculated the 
percentage of irregular nuclei per each condition. All nuclei were numbered to be able to trace 
back the form factor values to the individual nuclei. (For examples, see Appendix Figure 33) 
2. The relative intensity on kinetochores  
To quantify relative intensity of the proteins of interest (POI) on kinetochores I generated a 
pipeline that automatically recognizes single kinetochores based on the CREST 
immunofluorescence image. I used thresholding to make the image clearer for automated 
recognition, but this thresholding served only for recognition, all quantifications were made 
from the raw images (Appendix Figure 34A). The software recognized objects of different sizes 
and shapes (Appendix Figure 34B), but I estimated that all kinetochores are approximately of 
the same size and those differences are a result of focus plane position and the signal quality. 
To make the size of kinetochores uniform, I added a step in which the program drew circles 
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around the centers of the objects, which allowed for having all kinetochores of the same size 
(8 pixels in diameter) (Appendix Figure 34C). Next, the program measured intensity of the 
CREST signal and the intensity of POI (BubR1 or CENP-E) within the circle area. Following 
the measurements, the program exported several overlay images in a tiff format with numbered 
kinetochores so I was be able to track back the position of each kinetochore and its number 
(Appendix Figure 34E). In the end, the program exported all the intensity measurements to an 
Excel file which contained among other parameters the Mean Intensity value of each 
kinetochore region. After processing all the images in Cell Profiler, I went through the exported 
overlay images manually to check the quality of the recognition. In Excel I calculated the ratio 
of the POI intensity to the CREST intensity (POI/ CREST) and I normalized these results to 
the control (control = 1). All values are shown relative to the control, which allows for 
comparison of the results from different experiments.  
In case of the Astrin intensity quantification, I enlarged the circle determining the region of 
kinetochore in all the conditions to 16 pixels in diameter, because the CREST and Astrin 
signals do not have exact overlap (Appendix Figure 34D). After I calculated the Astrin to 
CREST ratio and normalized the relative intensity to the control as previously.  
For most of my experiments I was interested to know the intensity value relative to the 
kinetochore spatial position in the cell. To get this information, I went through the exported 
overlay images and I manually assigned the spatial attributes directly to the Excel file, based 
on the kinetochore numbering (A- aligned, M- misaligned).  
2.2.16 Statistics 
To statistically evaluate my data I used parametric t-test, One-Sample T-test for samples 
normalized to the control and Two-sample T-test for the rest of the conditions. I considered the 
values significantly different when P value was smaller than 0.05 and I assigned stars according 
to P values as follows: P<0.05 *, P<0.01 **, P<0.001 *** P< 0.0001 ****. In all graphs I show 
my results as Mean ± SEM (or SD) of minimum three independent experiments or more. 
Details for each result are listed in figure legends. 
2.2.17 High-throughput siRNA screen 
Description taken from Methods section of manuscript ‘Ubiquitin Receptor Protein UBASH3B 
Drives Aurora B Recruitment to Mitotic Microtubules’ published previously by the lab163. 
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siRNA-based libraries and visual high-content screening 
For the siRNA screens, custom-made libraries were purchased from Dharmacon. 20 nM of 
siRNA SMARTpools with 4 different siRNAs for each gene (siGENOME for the primary 
screen and ON-TARGETplus for the secondary screen) were transfected into HeLa cell lines 
(obtained from the German Cancer Research Centre DKFZ, Heidelberg, Germany) grown in 
Greiner µClear 96-well microplates using a high-throughput (HT) reverse chemical 
transfection with the INTERFERin delivery reagent (Polyplus-transfection SA, Illkirch 
France). The HT transfection protocol was optimized for reaching 90-95% transfection 
efficiency with minimal toxicity on a TECAN Freedom EVO liquid handling workstation. The 
screens were performed in technical triplicates. To limit biological variability, cell passage 
(n=3 after thawing), serum batch, transfection agent batch were strictly determined. Internal 
controls such as positive and negative siRNA controls (Table S1), transfection efficiency 
control (“PLK1” siRNA that leads to mitotic cell death), were added to each microplate to 
determine parameters for inter-plate and day-to-day variability. Three days post-transfection, 
the cells were fixed and subjected to immunofluorescence with anti-α-Tubulin antibody (Sigma 
T5169) allowing labeling of the cytoplasmic (“cell”) compartment. Secondary detection was 
performed with Alexa fluor-488-labeled secondary antibodies (Molecular Probes) and nuclei 
were stained with DAPI (labeling nucleus compartment “Nuclei”). High-throughput cell 
imaging was carried out with the INCELL1000 HCS epi-fluorescent microscope to collect an 
average of ~1,000 cells per microwell.  
Analysis of the high-content siRNA screening data  
Multi Target Analysis parameters measuring nuclei and cell morphology for the non-targeting, 
control siRNA and for the Aurora kinase B siRNA-treated cells were extracted using the Multi 
Target Analysis module of the INCELL1000. These parameters describe the DAPI nuclei stain 
and the cytoplasmic α-Tubulin stain of the two assay conditions. The Principle Component 
Analysis (PCA) was used to identify parameters that maximize the dynamic range between 
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2.3 RESULTS 
2.3.1 High-content siRNA screen identifies novel  
human DUBs required for faithful mitosis.  
In order to identify novel components of the ubiquitin system controlling mitotic division, we 
performed high-content visual siRNA screens in human cells. We were particularly interested 
in screening the ubiquitin factors from the family of deubiquitinating and ubiquitin binding 
proteins. The ubiquitin siRNA library targeting about 500 genes including about 100 known or 
predicted DUBs and other ubiquitin factors was used. To silence selected candidate genes a 
pool of four different siRNAs was used (Appendix Table 9).  
It was shown previously that defects in mitosis lead to formation of irregular nuclei in the 
daughter cells235,236. We took the nuclear shape as a readout for our screen and considered the 
top hits as potential mitotic regulators. Cells were fixed and automatically analyzed by multi-
parameter software for 40 different visual parameters including number of nuclei per single 
cell as well as shape of the nuclei (indicating possible defects in chromosome segregation), 
based on Principle Component Analysis (PCA). This novel approach allowed generating a hit-
list of the ubiquitination system-related genes that may play a role in the regulation of cell 
division. Importantly, all our positive controls, such as Aurora B and Cullin 3 which roles in 
mitosis are already well described, scored high on the list. Notably, the hit-list contained also 
other proteins with established roles in chromosome segregation and cytokinesis, including 
APC, CUL4B and others, suggesting the relevance of the selected approach. Interestingly, a 
number of putative candidates for novel regulators of chromosome segregation and cytokinesis 
were identified using this approach. Among them, the DUB, Ubiquitin carboxyl-terminal 
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2.3.2 UCHL3 is important for maintenance of a proper 
nuclear shape. 
To validate the results from the siRNA screen the silencing of UCHL3 was repeated using two 
single siRNAs from the pool. Additionally, we used siRNA to silence UCHL1, another member 
of the C-terminal hydrolase family to address the whether this is a common phenotype for all 
the members or whether it is specific to UCHL3. We observed that silencing of UCHL3 
resulted in an increase of irregular and polylobed nuclei, but despite the high homology of 
UCHL1 to UCHL3, the nuclear shape was not affected by UCHL1 silencing. This led us to a 
conclusion that only UCHL3 plays a role in irregular nuclei maintenance (Figure 14A). We 
confirmed the efficiency of single siRNAs in depleting the target gene by western blot analysis 
(Figure 14B). Quantification of cells with irregular nuclei revealed that about 45 % of UCHL3 
depleted cells display irregular nuclei compared to 18 % of control cells (Figure 14C).  
In the beginning of my project, I wanted to further confirm the results from the siRNA screen 
using a different set of tools to rule out a possibility of the off-target effect of the siRNAs used. 
I silenced UCHL3 in unsynchronized HeLa cells by treatment with a different siRNA targeting 
the 3’UTR region of the UCHL3 mRNA (UCHL3 3’UTR) for 48 hours. Additionally, I 
inhibited UCHL3 hydrolase activity with a commercially available inhibitor (TCID) for 24 
hours. As TCID has been shown to inhibit also UCHL1 at higher concentrations (IC=75µM), 
I used 2µM working concentration for the TCID inhibitor, to ensure specificity for 
UCHL3215,230. To quantify the effect of UCHL3 inhibition on the nuclear shape I took form 
factor as a criterion for regularity of the nucleus and I quantified it using Cell Profiler as 
described in the methods section. Both treatments (siRNA, TCID) lead to increased number of 
cells displaying irregular nuclei phenotype (Figure 15A, D). Upon treatment with 3’UTR 
siRNA I could see an increase in the irregular nuclei phenotype from 18 % in the control cells 
to 42 % in UCHL3 depleted cells (Figure 15B). The efficiency of the UCHL3 knockdown was 
confirmed by using western blot (Figure 15C). The effect of UCHL3 inhibitor was less 
pronounced, but I could still see an increased number of cells with irregular nuclei, from 19 % 
in the control cells to 29 % in TCID treated cells (Figure 15E).  
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Figure 14 Validation of the siRNA screen. 
(A) HeLa cells were transfected with control, UCHL1 and UCHL3 siRNA-1 and siRNA-2. After 
48 hours cells were fixed and stained for tubulin (red), DAPI (blue) and UCHL3 (green).  
(B) Western blot showing the efficiency of different siRNAs to downregulate UCHL3.  
(C) Quantification of A. Graph shows percentage of cells displaying irregular nuclei phenotype. 
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Figure 15 UCHL3 downregulation or inhibition leads to irregular nuclei phenotype. 
(A) Representative image of HeLa cells treated for 48 hours with UCHL3 3’UTR siRNA. (B) Quantification of 
irregular nuclei phenotype using Cell Profiler. Control siRNA 18.3 % ± SEM 3.3 % and 3’UTR siRNA 42.3 % ± 
SEM 4.3 % cells with irregular nuclei, P= 0.0043. Graph represents four experiments with total number of 
analysed cells 886 in control and 828 in siRNA treated cells. (C) Western blot confirmation of the UCHL3 
knockdown. (D) Representative image of HeLa cells treated for 24 hours with UCHL3 inhibitor (TCID). (E) 
Quantification of irregular nuclei phenotype using Cell Profiler. Control (DMSO) 19.5 % ± SEM 1.1 % and TCID  
28.6 % ± SEM 1.1 % cells with irregular nuclei, P= 0.0012. Graph represents four experiments with total number 
of analysed cells 2110 in control and 2230 in siRNA treated cells. Scale bar represents 10 µm. 
DMSO TCID 
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2.3.3 UCHL3 controls proper chromosome alignment  
during metaphase. 
Since irregular nuclei are often observed due to segregation problems during mitosis, I 
hypothesized that UCHL3 could be a factor controlling chromosome alignment and their 
segregation. To answer my question whether UCHL3 regulates the early steps of mitosis, I 
needed to have a closer look at the mitotic progression in UCHL3 depleted cells. For my 
experiments I used HeLa cells transfected with 3’UTR siRNA against UCHL3. I synchronized 
the cells using monastrol release protocol. Monastrol inhibits Eg5, a motor protein necessary 
for centrosome separation and spindle formation, thereby arresting cells in prometaphase. Cells 
were synchronized by 16 hours of monastrol treatment, followed by wash and release into a 
proteasome inhibitor for 90 minutes. Degradation of securin and cyclin B is the key step 
necessary for the onset of anaphase, therefore the cells stayed arrested in the metaphase upon 
the inhibition of proteasome. This protocol (Figure 16A) enabled me to observe the 
chromosome alignment process during the 90 minute time-window as cells align their 
chromosomes and proceed from prometaphase to metaphase. After 90 minutes, I fixed the cells 
and counted the percentage of cells with aligned or misaligned chromosomes (Figure 16B). In 
the control situation, majority of the cells had no defects, up to 75 % of the cells aligned their 
chromosomes properly with only 25 % of cells displaying misalignment phenotype. After 
knockdown of UCHL3 there was a strong increase in cells showing misaligned chromosomes, 
as 45 % of cells did not manage to form a proper metaphase plate (Figure 16C). In contrast, 
UCHL3 depletion did not affect the formation of the bipolar mitotic spindle (Figure 16B). To 
our knowledge, these results present a first evidence that UCHL3 can regulate mitotic 
progression in human cells. 
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Figure 16 UCHL3 controls chromosome alignment during metaphase plate formation. 
(A) Experimental setup: cells were transfected with control and 3’UTR UCHL3 siRNA 48 hours prior fixing.  
(B) Representative images of HeLa cells treated for 48 hours with UCHL3 3’UTR or control siRNA and 
synchronized to metaphase according to the protocol in A. Cells were fixed and stained, α-tubulin (green), DNA 
(blue). (C) Quantification of B. Percentage of cells having at least one misaligned chromosome were counted in 
both categories. Graph represents results from seven experiments with total number of analysed cells 2356 in 
control and 2801 in siRNA treated cells. Control siRNA 25.2 % ± SEM 3.7 % and 3’UTR siRNA 45.4 % ± SEM 
4.2 % cells with misaligned chromosomes, P= 0.0034. 
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2.3.4 UCHL3’s catalytic activity is necessary for proper 
chromosome alignment. 
To confirm that the observed phenotype is specific to downregulation of UCHL3 and to 
exclude a possible off-target effect of the siRNA, I performed rescue experiments with 
overexpression of UCHL3 cDNA from a plasmid. Additionally, I wanted to assess whether the 
UCHL3 catalytic activity is important for chromosome alignment. To this purpose I used two 
different N-terminal GFP-labelled UCHL3 protein expression constructs: ‘UCHL3-WT’, 
which contains a wild type cDNA sequence of UCHL3 and ‘UCHL3-C/S’ which has a 
mutation in the catalytic center of the protein (Cysteine 95 to Serine). This mutation renders 
the catalytic center inactive and abolishes the hydrolase activity of UCHL3. GFP expressing 
construct was used as a negative control. I transfected HeLa cells with 3’UTR siRNA together 
with GFP control or UCHL3-WT or UCHL3-C/S plasmid. I synchronized the cells to 
metaphase using monastrol release protocol (as shown in Figure 16A) and after fixing the cells 
I stained DNA with DAPI (Figure 17A). In parallel, I isolated proteins from a fraction of the 
cells for western blot analysis to confirm the expression levels of the introduced proteins. All 
ectopic proteins were expressed equally and on a level similar to the expression of the 
endogenous UCHL3 (Figure 17B). In each condition I counted the number of cells that had 
misaligned chromosomes. To avoid any bias, I quantified all my experiments in a blinded setup. 
In the cells transfected with empty-GFP plasmid, UCHL3 knockdown led again to increased 
number of cells showing misaligned chromosomes, this was rescued in cells expressing the 
GFP-UCHL3-WT protein. Interestingly, the expression of the catalytically dead mutant GFP-
UCHL3-C/S did not rescue the phenotype and cells showed higher number of alignment defects 
compared to their controls (Figure 17C). Interestingly, catalytically dead version GFP-UCHL3-
C/S did not affect chromosome alignment in WT cells, suggesting that this form cannot act as 
dominant negative mutant. From these experiments I conclude that UCHL3 specifically 
controls proper chromosome alignment at the metaphase plate and its catalytic activity is 
necessary for this process.  
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Figure 17 Catalytic activity of UCHL3 is important for proper chromosome alignment. 
HeLa cells were transfected with control and 3’UTR UCHL3 siRNA 48 hours prior fixing the cells and 
synchronized to metaphase according to the protocol in Figure 16A. (A) Representative images showing 
chromosome alignment in different conditions. Arrowheads point to misaligned chromosomes. Cells 
transfected with GFP plasmids are shown in green. (B) Western blot showing expression levels of different 
UCHL3 proteins, probed with UCHL3 antibody with Actin as a loading control.  (C) Quantification of A. 
Percentages of cells having at least one misaligned chromosome were counted in all categories (Appendix 
Table 5). Graph represents results from four individual experiments with average number of 2000 analysed 
cells per each condition. P values are P= 0.0242, P= 0.4306, P= 0.0366, respectively. 
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2.3.5 UCHL3 does not regulate Spindle assembly 
checkpoint (SAC) response in human cells. 
The observed phenotypes of UCHL3 downregulation, the formation of irregular nuclei and 
chromosomal misalignment in metaphase are indicative of defects in chromosome segregation. 
Segregation errors, such as lagging chromosomes are deleterious for the cell and as such can 
have fatal consequences, therefore the cell strictly controls the alignment status prior to 
anaphase onset. This raised the question whether the UCHL3-depleted cells can properly 
activate SAC. To answer this, I focused mainly on two parameters: the ability of cells to 
maintain mitotic arrest induced by drugs perturbing proper spindle assembly and second, the 
ability to recruit checkpoint components to the kinetochores.  
To address the first point, I treated cells with monastrol in which presence the bipolar spindle 
cannot be formed, resulting in increased number of attachment errors. This subsequently leads 
to a number of unattached or partially attached kinetochores, which activate the SAC and arrest 
the cells in prometaphase. To this purpose I used HeLa K cells where UCHL3 was silenced by 
stable expression of shRNAs (see Methods) and after 16 hours of monastrol synchronization 
I took photographs of living cells (Figure 18A) and I quantified the mitotic index (MI) for each 
condition. The average mitotic index was MI= 0.7 for both control and UCHL3 depleted cells 
showing no significant change between the two conditions (Figure 18B). Taken together, 
UCHL3 downregulation does not change the ability of cells to maintain the mitotic arrest.  
Next, I measured the kinetochore intensity of BubR1, which is a key component of the mitotic 
checkpoint and is recruited to unattached kinetochores during prometaphase. I quantified the 
fluorescent signal of BubR1 and CREST in HeLa cells transfected with either control or 
UCHL3 siRNA, after synchronization to prometaphase by monastrol. I did not see any 
difference in BubR1 recruitment to kinetochores in control and UCHL3 depleted cells (Figure 
18C, D), suggesting that UCHL3 is not directly involved in BubR1 recruitment to kinetochores. 
In conclusion, upon UCHL3 downregulation, the mitotic checkpoint is not affected during 
prometaphase, because cells are able to maintain mitotic arrest and to recruit mitotic checkpoint 
component BubR1 to kinetochores normally. These results indicate that UCHL3 is not involved 
in the spindle assembly checkpoint response. 
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Figure 18 UCHL3 does not regulate SAC response. 
(A) Representative phase contrast images of control (shLuc) and UCHL3 depleted cells (sh2 UCHL3).  
(B) Quantification of A, data from three different experiments, total number of cells counted: control n= 1384, 
sh2 UCHL3 n= 1288. Mitotic index, Mean ± SEM: control MI= 0.707 ± 0.018, sh UCHL3 MI= 0.718 ± 0.013, 
Statistical analysis by T-test, P= 0.6571. (C) HeLa K cells transfected with control or 3’UTR UCHL3 siRNA, 
scale bar= 2 µm. Left: IF images with antibodies against BubR1 (green) and CREST (red), co-stained with DAPI 
(blue). Right: Enlarged kinetochore regions showing co-localization of BubR1 (green) and kinetochore (red) 
signals. (D) Quantification of relative BubR1 intensity on kinetochores normalized to the control shown as Mean 
± SEM, data from three different experiments. Control = 1, n= 2740 kinetochores, UCHL3 siRNA 1.06 ± 0.18, 
n= 2831 kinetochores. Statistical analysis by One-sample T-test, P= 0.7765. 
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2.3.6 UCHL3 regulates the chromosome alignment 
during prometaphase to metaphase transition. 
To better understand the mechanism by which UCHL3 controls mitosis, it is important to 
understand the timing of these events. In my previous experiments, I was using siRNA for 
UCHL3 downregulation. This is a long treatment and cells undergo at least one division in the 
absence of UCHL3. Due to this fact, I could not exclude the possibility that UCHL3 acts during 
interphase and the resulting phenotype is just a consequence of earlier events. To rule out this 
scenario, I established a protocol where, instead of siRNA, I used TCID to inhibit UCHL3 for 
two different time-periods, and I employed the previously established protocol for monastrol 
release to assess the alignment of chromosomes at the metaphase plate. First, I added the 
UCHL3 inhibitor together with monastrol for 16 hours and subsequently after the washout for 
90 minutes. In the second condition, I added the UCHL3 inhibitor only after the washout and 
incubated cells for 90 minutes (Figure 19A). Using this approach, I could distinguish whether 
UCHL3 acts directly in prometaphase to metaphase or earlier in the cell cycle. To better 
visualize the positions of individual chromosomes, I performed the experiment in HeLa cells 
stably expressing GFP labelled CENP-A kinetochore protein and after fixing the cells, I stained 
DNA using DAPI (Figure 19B) and for each condition I counted the number of cells that had 
misaligned chromosomes. Data are presented as a fold increase relative to the control. In the 
first group, labelled ‘Long-term treatment’, I could observe 50% increase of cells that did not 
align their chromosomes properly, fold change from 1.0 to 1.5, which corresponds to 25 % and 
38 % cells with misalignments in DMSO and TCID treatment, respectively (Figure 19C). These 
results are very similar to the results obtained with UCHL3 siRNA where I also observed about 
50% increase in cells having misaligned chromosomes (fold change from 1.0 to 1.55). 
Interestingly, after the 90 minutes treatment with UCHL3 inhibitor, labelled ‘Short-term 
treatment’, I could observe about 40% increase of cells that did not align their chromosomes 
properly. Fold change from 1 to 1.39, representing an increase from 35 % to 47 % cells with 
alignment problems in control and UCHL3 inhibition, respectively (Figure 19D). Taken 
together, 90 minutes of UCHL3 inhibition is sufficient to induce the misaligned chromosomes 
phenotype and this short treatment has a similar effect as 17.5 hours treatment with UCHL3 
inhibitor or 48 hours of siRNA-mediated downregulation of UCHL3. This result confirms the 
initial hypothesis that UCHL3 regulates chromosome alignment during prometaphase to 
metaphase transition.  
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Figure 19 UCHL3 acts specifically during prometaphase to metaphase transition. 
All experiments were done using HeLa cells stably expressing GFP-CENP-A. (A) Experimental design for cell 
synchronization and UCHL3 inhibition. (B) Representative images showing chromosome alignment after 17.5 
hours of treatment with UCHL3 inhibitor. GFP-CENP-A (green), DNA stained with DAPI (blue). (C) 
Quantification of B – Long term treatment. The graph represents three different experiments and shows the fold 
increase of cells having misaligned chromosomes. Control (DMSO) 1.0, UCHL3 inhibition (TCID) 1.50 ± SEM 
0.06, P= 0.0157, total number of analyzed cells: 830 in control and 1090 upon UCHL3 inhibition. (D) 
Quantification of Short-term treatment. The graph represents five different experiments and shows the fold 
increase of cells having misaligned chromosomes. Control (DMSO) 1.0, UCHL3 inhibition (TCID) 1.39 ± SEM 
0.13, P= 0.0394, total number of analyzed cells: 1260 in control and 1541 upon UCHL3 inhibition.   
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2.3.7 UCHL3 is indispensable for the chromosome 
alignment in human primary cells. 
I wanted to investigate if the mechanism of UCHL3 action is also relevant for human primary 
cells. Until now, I was using HeLa cells for my experiments, which are of cancer origin and 
therefore I wanted to understand whether this is a unique feature of cancer cells or whether 
UCHL3 is also important for division of primary cells. To address this question, I selected 
IMR90 (human primary lung fibroblasts) as a new model to study the UCHL3 function. I used 
the standardized protocol for monastrol release (Figure 20A) and I treated the cells with 
UCHL3 inhibitor (TCID). After releasing cells from monastrol, I fixed them using PFA and 
stained with antibodies against CREST and tubulin and co-stained DNA with DAPI (Figure 
20B). In all conditions I quantified the number of cells displaying at least one misaligned 
chromosome and normalized the results to their respective controls. In the long-term treatment, 
I observed 34% increase in cells having alignment defects which corresponded to increase from 
42 % in the control to 54% in UCHL3 inhibited cells (Figure 20C). In the short-term treatment, 
after 90 minutes with UCHL3 inhibitor, I observed 43% increase in cells having misaligned 
chromosomes, which represents increase from 38 % in controls to 53 % in UCHL3 inhibited 
cells (Figure 20D).  
Thus, 90 min treatment with UCHL3 inhibitor is sufficient to induce the same phenotype as 
long-term treatment, confirming the hypothesis that UCHL3 activity is needed during the 
prometaphase to metaphase transition. Taken together, UCHL3 controls chromosome 
alignment not only in cancer cells, but also in human primary fibroblast, suggesting a 
fundamental role of UCHL3 in the control of chromosome segregation in human cells.  
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Figure 20 UCHL3 controls chromosome alignment in human primary fibroblasts, IMR90. 
All experiments were done using IMR90 cells. (A) Experimental design for cell synchronization and 
UCHL3 inhibition. (B) Representative images showing chromosome alignment after 17.5 hours of 
treatment with UCHL3 inhibitor. Cells were fixed and stained, α-tubulin (green), CREST (red), DNA 
stained with DAPI (blue). (C) Quantification of B – Long term treatment. The graph represents three 
different experiments and shows the fold increase of cells having misaligned chromosomes. Control 
(DMSO) 1.0, UCHL3 inhibition (TCID) 1.34 ± SEM 0.07, P= 0.0190, total number of analyzed cells: 
1378 in control and 1541 upon UCHL3 inhibition. (D) Quantification of Short-term treatment. The graph 
represents five different experiments and shows the fold increase of cells having misaligned chromosomes. 
Control (DMSO) 1.0, UCHL3 inhibition (TCID) 1.43 ± SEM 0.06, P= 0.0055, total number of analyzed 
cells: 951 in control and 994 upon UCHL3 inhibition.   
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2.3.8 UCHL3 protein is indispensable for proper 
chromosome segregation.  
In my previous experiments, I have confirmed that UCHL3 plays an important role in proper 
chromosome alignment at the metaphase plate. Next, I wanted to understand if this has a 
functional consequence and the alignment problems result in segregation errors later during the 
anaphase. To answer this question, I used live-video microscopy to be able to follow individual 
cells in time. First, I used HeLa cells stably expressing GFP-tubulin to visualize the spindle 
and mCherry-Histone H2B (mCherry-H2B) to follow the chromosomes. I used control and 
3’UTR UCHL3 siRNA for 48 hours to downregulate UCHL3 and I determined the efficiency 
of the knockdown by qPCR which showed that the levels of UCHL3 mRNA dropped to 20% 
upon siRNA treatment (Figure 21E).  
I synchronized the cells into prometaphase by adding monastrol for 16 hours and after the 
monastrol washout I acquired time-lapse images every five minutes for four hours. 
Representative time frames are shown in Figure 21A, where the presence of polar 
chromosomes can again be observed in the UCHL3 knockdown, similar to my previous results 
with siRNA and the UCHL3 inhibitor. In these live video experiments, I was quantifying two 
main parameters: presence of segregation errors and time the cells needed to transit from 
prometaphase to anaphase onset. In control situation, cells could divide normally, they aligned 
their chromosomes at the metaphase plate and segregated them equally to the two daughter 
cells. In the cells depleted of UCHL3, I could observe, in addition to the alignment defects, 
frequent segregation errors, mainly lagging chromosomes. Examples of segregation errors are 
shown in Figure 21B. I counted the total number of cells showing lagging chromosomes in 
both conditions and I could see a significant increase in cells with segregation errors upon 
UCHL3 downregulation, from 17 % in the control to 39 % in the knockdown (Figure 21C). 
These results further confirm that UCHL3 controls chromosome alignment during metaphase 
plate formation as well as their subsequent segregation to the two daughter cells.  
Next, I measured the time the cells needed to proceed from prometaphase (time of the release 
was set as time = 0) to anaphase. I did not observe any significant difference in the timing 
between the control and UCHL3 knockdown, but there was a non-significant tendency for 
UCHL3 depleted cells to take longer time to reach anaphase. Control cells needed on average 
64 minutes to reach anaphase compared to UCHL3 depleted cell which needed on average 70 
minutes (Figure 21D, Figure 22F). These results further confirmed my initial observation that 
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UCHL3 controls chromosome alignment. Furthermore, I was able to show that the alignment 
problems are followed by segregation errors in UCHL3 depleted cells and therefore UCHL3 is 
indispensable for proper chromosome segregation.  
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Figure 21 Live video experiments show that UCHL3 depletion leads to segregation errors. 
Live video experiment using HeLa K cells stably expressing Tubulin-GFP and H2B-mCherry synchronised to 
prometaphase by monastrol and released in fresh culture medium at t=0 of the acquisition. (A) Selected time-
frames of control and UCHL3 depleted cells showing merge of Tubulin (green) and DNA (red) signal and DNA 
single channel (grey). (B) Examples of segregation errors often observed upon UCHL3 KD. (C) Quantification of 
segregation errors shown as mean percentage of cells with errors ± SEM of four different experiments. Control 
17.07 % ±5.92 % n= 127 cells, UCHL3 KD 39.01 % ± 3.78 % n= 198 cells. Statistical analysis by Student’s t-
test, p= 0.0354. (D) Quantification of the average time the cells needed to proceed from prometaphase to anaphase 
shown as mean time ± SEM. Control 63.8 min ± 0.4 min, UCHL3 KD 70.4 min ± 7.0 min. Statistical analysis by 
Student’s t-test, P= 0.4450. (E) qPCR analysis of cells transfected with siRNA to estimate the knockdown 
efficiency. 
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In order to confirm the results obtained with HeLa cells in a different experimental model, I 
used the colorectal adenocarcinoma cells (Dld1) that stably express histone H2B-mCherry and 
control or UCHL3 shRNA (see Methods and Appendix Table 1). I verified the UCHL3 
knockdown using qPCR and I chose UCHL3 shRNA2 for my further studies (Figure 22E). The 
advantage of this approach is that the cells expressing the shRNA express GFP at the same 
time, so it is possible to distinguish the cells with the knockdown from the wild type ones.  
To synchronize the cells, I used the monastrol washout protocol and I was acquiring images 
every five minutes during four hours. Representative time frames are shown in Figure 22A, 
where we can see the polar misaligned chromosomes in UCHL3 depleted cells in prometaphase 
and the lagging chromosomes during anaphase. I quantified the same parameters as for HeLa 
cells: the number of segregation errors and the time that cells needed to go from prometaphase 
to anaphase. Interestingly, the results were very similar to the ones obtained with HeLa, I could 
observe increase in cells showing segregation errors upon knockdown of UCHL3 (Figure 22B). 
I quantified the number of cells displaying segregation errors and I could see a significant 
increase of lagging chromosomes from 26 % in controls to 51 % in UCHL3 depleted cells 
(Figure 22C). I also counted the time the cells needed to proceed from prometaphase to 
anaphase, but despite a strong tendency of the UCHL3 depleted cells to take longer time to 
reach anaphase (59 min in control vs. 69 minutes in UCHL3 knockdown), the difference of 
duration did not reach statistical significance (Figure 22D). When I plotted the values from all 
experimental replicates together, in both cell lines I could see a strong tendency for the UCHL3 
depleted cells to take longer time before reaching anaphase. In wild type situation the majority 
of cells divides within 75 minutes, therefore I set the threshold at 75 minutes and calculated 
the percentage of cells that did not manage to divide within this time period. In HeLa K as well 
as in Dld1 cells I could see a higher percentage of cells that did not divide within 75 minutes 
upon UCHL3 downregulation. In UCHL3 depleted HeLa cells 31 % cells did not divide before 
the 75 minutes compared to 21 % cells in control (Figure 22F) and in Dld1 cells 47 % of cells 
did not divide before 75 minutes compared to only 15 % of cells in the control (Figure 22G). 
Taken together, the results from the two different experimental approaches show that UCHL3 
controls chromosome alignment as well as chromosome segregation during mitosis and that 
UCHL3 downregulation does not lead to significant changes in the duration of mitosis. 
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Figure 22 UCHL3 controls chromosome segregation in human Dld1 cells.  
Live video experiment using Dld1 cells stably expressing H2B-mCherry and either control GFP-shRNA (shLuc) 
or UCHL3 GFP-shRNA (sh2). Cells were synchronised to prometaphase by Monastrol and released in fresh 
culture medium at t=0 of the acquisition. (A) Selected time-frames of Control and UCHL3 depleted cells. Frame 
t=0 shows DNA (red) and shRNA expression (green), following panels show DNA (grey). (B) Examples of 
segregation errors often observed upon UCHL3 downregulation. (C) Quantification of segregation errors shown 
as Mean percentage of cells with errors ± SEM of five different experiments. Control 26.1 % ± 3.2 % n= 125 
cells, UCHL3 KD 50.7 % ± 5.4 % n= 118 cells. Statistical analysis by T-Test, P= 0.0069. (D) Quantification of 
the average time the cells needed to proceed from prometaphase to anaphase shown as Mean time ± SEM. Control 
59.2 min ± 1.2 min, UCHL3 KD 68.7 min ± 4.5 min. Statistical analysis by T-Test, P= 0.1299. (E) qPCR analysis 
of cells transfected with shRNA to estimate the knockdown efficiency. Dld1 cells expressing sh2 UCHL3 were 
used for all live video experiments. (F-G) Summary of mitotic duration for individual cells from all experimental 
replicates. The percentage represents the number of cells that needed more than 75 minutes to reach anaphase. 
Comparison of two different cell lines, HeLa K (F) and Dld1 (G).  
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2.3.9 UCHL3 protein stabilizes KT-MT attachments by 
promoting the Astrin and CENP-E recruitment. 
Next, I analyzed the kinetochore- microtubule (KT-MT) attachments, because both, 
prematurely stabilized kinetochore attachments to spindle microtubules, or weak attachments 
were reported to lead to segregation problems. To address the stability of KT-MT attachment, 
I used Astrin recruitment as a readout, because Astrin is only recruited to the kinetochores with 
stably attached microtubules. I transfected HeLa cells with control and UCHL3 siRNA and 
synchronized them in metaphase, using monastrol release protocol. (Figure 23A, B). I used 
Cell Profiler to quantify the intensity of the kinetochore (CREST) and Astrin signal in the 
control and in the UCHL3 depleted cells. As UCHL3 downregulation leads to increased 
number of misaligned chromosomes, I wanted to distinguish the recruitment of kinetochore 
proteins between aligned and misaligned chromosomes. Therefore, I selected two categories in 
UCHL3 knockdown cells: Aligned (chromosomes in the metaphase plate) versus misaligned 
(polar chromosomes) and I categorized them manually, assigning the alignment status (A, M) 
to each measured intensity (Methods and Appendix Figure 34). Interestingly, UCHL3 
downregulation led to reduced recruitment of Astrin to the kinetochores of both, aligned and 
misaligned, chromosomes. In the absence of UCHL3, I observed 20% decrease in Astrin 
recruitment to the kinetochores of aligned chromosomes and even more dramatic decrease (up 
to 40%) of Astrin recruitment to the kinetochores of misaligned (polar) chromosomes (Figure 
23C). I co-stained the cells with antibody against α-tubulin to be able to observe the kinetochore 
attachments. Overall the tubulin signal looked different in UCHL3 depleted cells compared to 
control cells. I observed that microtubules were more frequently spanning the equatorial zone 
in UCHL3 depleted cells (Figure 24A), suggesting that microtubules grow longer and form 
bipolar end-on attachments less often. As these attachments are necessary for proper 
positioning of chromosomes and formation of the metaphase plate, this could result in the 
observed alignment errors. To estimate the kinetochore attachment status in more detail, I 
processed tubulin and CREST images using Imaris software, which let me to reconstruct the 
images in 3D. I observed increased number of lateral attachments in UCHL3 depleted cells and 
polar chromosomes were often completely unattached (Figure 24B). Interestingly, 
downregulation of UCHL3 resulted in elongated spindle (Figure 24C). I measured the inter-
polar distance in Image J and I observed that control spindle measured 6.5 µm on average and 
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the spindle of UCHL3 depleted cells was significantly longer and measured 8.3 µm on average 
(Figure 24D). 
These results suggest that UCHL3 is important for proper KT-MT attachment. Absence of 
UCHL3 results in weaker KT attachment to the spindle microtubules and also leads to 
increased number of lateral attachments and altered spindle morphology, which could explain 
the segregation defects.  
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Figure 23 UCHL3 promotes Astrin recruitment to the kinetochores. 
(A) Representative images of Tubulin, Astrin and CREST immunofluorescent staining. (B) Enlarged regions from 
A, showing Astrin (blue) localization to the kinetochores (red). (C) Quantification of A, relative Astrin intensity 
on kinetochores in four different experiments shown as Mean ± SD. Control = 1, n= 4017 kinetochores, UCHL3 
siRNA Aligned = 0.82 ± 0.06, n= 3962 kinetochores, UCHL3 siRNA Misaligned = 0.59 ± 0.07, n = 470 
kinetochores.  
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Figure 24 UCHL3 promotes formation of bipolar stable kinetochore- microtubule attachments. 
Spindle microtubules in HeLa K cells transfected with control or UCHL3 3’UTR siRNA and synchronised by 
monastrol release protocol. Scale bar = 2 µm. (A) Examples of Tubulin staining showing the density of spindle 
microtubules in the central equatorial zone (red circle). (B) Examples of kinetochore- microtubule attachments in 
control and UCHL3 knockdown. 1-2 End-on attachments, 3-6 lateral attachments, 7-8 unattached kinetochores. 
(C) Representative images showing Tubulin (green), CREST (red) and DAPI (grey) staining. (D) Measurement 
of spindle length in C, represented by Mean ± SEM of six different experiments, control: spindle length= 6.56 µm 
± 0.61 µm, UCHL3 siRNA: spindle length= 8.35 µm ± 0.25 µm. Statistical analysis by Student’s t-test, p=0.0451. 
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It has been previously shown that Astrin is important for CENP-E recruitment to the 
kinetochores, which helps to maintain the chromosomes aligned at the metaphase plate237. 
Therefore, I decided to look at CENP-E recruitment to kinetochores in presence and absence 
of UCHL3 using HeLa K cells and monastrol release protocol combined with IF protocol for 
motor protein staining (Figure 25A, B). I measured the intensities of CREST and CENP-E 
signals and I plotted them as relative intensity (ratio of CENP-E to CREST signal) normalized 
to the control. Upon UCHL3 knockdown I observed about 40 % decrease of CENP-E 
recruitment to the kinetochores of aligned chromosomes. This is in line with the previous 
experiments where I observed reduced Astrin recruitment to kinetochores upon UCHL3 
depletion which is necessary for the proper CENP-E recruitment to kinetochores. Surprisingly, 
I could observe more CENP-E present on the kinetochores of misaligned chromosomes and 
CENP-E signal was also enriched at the spindle. I quantified the relative kinetochore intensity 
of CENP-E on the polar chromosomes and I observed about 30% enrichment of CENP-E signal 
in the polar region compared to its intensity in control cells (difference not statistically 
significant, Figure 25C), which suggests that UCHL3 normally has an inhibitory action on 
CENP-E recruitment on the polar chromosomes. Next, I wanted to know whether CENP-E 
decrease on the aligned chromosomes correlates with reduced recruitment of Astrin to these 
structures. For this purpose, I co-stained HeLa cells with CENP-E and Astrin antibody together 
and measured signal intensities and I calculated their relative intensities to CREST. For each 
treatment condition I plotted the relative intensities on a dot plot. As expected, upon UCHL3 
knockdown, I observed less Astrin recruitment to the kinetochores, which was proportional to 
the CENP-E recruitment (Figure 25D). Those results suggest that UCHL3 regulates 
kinetochore microtubule attachment stability by promoting Astrin and subsequently also 
CENP-E recruitment to the kinetochores, which increases the stability of microtubule 
attachment and maintains proper chromosome alignment in metaphase plate.  
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Figure 25 UCHL3 is important for CENP-E recruitment to the metaphase kinetochores. 
(A) Representative images of CENP-E and CREST immunofluorescent staining. (B) Enlarged regions from A, 
showing CENP-E (green) localization to the kinetochores (red). (C) Quantification of A, relative CENP-E 
intensity on kinetochores in five different experiments shown as Mean ± SEM. Control = 1, n= 5846 kinetochores, 
UCHL3 siRNA Aligned = 0.61 ± 0.05, n= 5534 kinetochores, UCHL3 siRNA Misaligned = 1.29 ± 0.14, n = 855 
kinetochores. P values: Control to KD Aligned p= 0.0019, control to KD misaligned p= 0.1025, KD Aligned to 
KD misaligned p= 0.0018. (D) Dot plot showing proportional decrease of CENP-E and Astrin intensities upon 
UCHL3 siRNA. Control n= 1770 kinetochores, UCHL3 siRNA n= 1669 kinetochores. 
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2.3.10 UCHL3 interacts with the mitotic kinase 
Aurora B and deubiquitinates it. 
After establishing the UCHL3 function in mitosis, I aimed to understand what could be the 
potential substrate of UCHL3 that mediates its mitotic function. In order to answer this 
question, I followed two approaches, a candidate approach and an unbiased approach by Mass 
Spectrometric analysis.  
UCHL3 is a DUB and therefore it is possible that it regulates protein levels of key mitotic 
elements. Based on the observed phenotypes, there are several candidates that could be 
regulated by UCHL3 activity, such as Aurora B kinase, PP1γ phosphatase or CENP-E motor 
protein, which all contribute to proper chromosome alignment at the metaphase plate. To see 
if levels of these proteins in mitosis are affected by the presence or absence of UCHL3, we 
used HeLa cells with or without CRISPR-Cas9 generated UCHL3 deletion. We synchronized 
these cells by monastrol washout protocol, collected total protein at different time points (0, 
15, 30, 45 minutes) after the release and subjected them to western blot analysis (Figure 26A). 
We used Cyclin B as an internal control of the synchronization protocol, because it is degraded 
during anaphase by the proteasome. We did not observe any significant changes in protein 
levels of Aurora B, PP1γ and CENP-E, but we observed a strong degradation of Cyclin B at 
the last time-point, as expected. These results suggest that protein levels of neither of the 
candidates are regulated by UCHL3 mediated proteolytic degradation during the process of 
chromosome alignment and segregation. Interestingly, we observed a striking phenotype when 
we analyzed Aurora B signal on a full membrane. In time points 0 and 15 minutes after wash 
from monastrol, we observed a clear upshifted band at a size around 75 kDa and a smearing 
signal, characteristic for presence of ubiquitin conjugates, in cells deficient for UCHL3. Indeed, 
the size of Aurora B with four ubiquitin moieties is 74 kDa, which brought and interesting 
hypothesis that UCHL3 might specifically interact with Aurora B to deubiquitinate it.  
In parallel, to perform an unbiased search for UCHL3 substrates, we performed 
immunoprecipitation experiment with GFP tagged wild-type and catalytically dead UCHL3 
and Mass Spectrometry analysis. Interestingly, Aurora B was on the hit list among the 
identified candidate for UCHL3-interacting proteins, which encouraged us to further study the 
UCHL3-Aurora B relationship in greater detail. First, I wanted to validate the result from Mass 
Spectrometry and to confirm whether UCHL3 directly interacts with Aurora B. I performed 
immunoprecipitation experiments in the same setup as for the Mass Spectrometry analysis, but 
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instead of overexpressing protein by transient transfection, I used HeLa cell lines stably 
expressing either wild-type UCHL3 or catalytically dead mutant with GFP tags and 
synchronized them in prometaphase using STLC. Both proteins, UCHL3 WT and UCHL3 
mutant bound Aurora B (Figure 26B). I repeated the experiment three times, using different 
clones of UCHL3 WT and UCHL3 C/S stable cell lines and in all cases I saw an interaction of 
Aurora B with both UCHL3 forms which indicates that Aurora B could be a potential substrate 
of UCHL3 during prometaphase.  
Next, we aimed to understand if Aurora B is deubiquitinated by UCHL3, therefore we 
established IP under denaturing conditions to be able to observe only covalently bound 
ubiquitin conjugates. We used either control or UCHL3 knockout cell lines and we transfected 
them with GFP-Aurora B plasmid. After 24 hours we collected the proteins using GFP-trap 
beads and analyzed the samples by western blot (Figure 26C). To detect ubiquitinated 
Aurora B, we used FK2 ubiquitin antibody that specifically recognizes only conjugated 
ubiquitin and not the free ubiquitin. In line with previous WB experiments, we saw a stronger 
ubiquitin signal on Aurora B in the absence of UCHL3. Taken together, we hypothesize that 
UCHL3 interacts with Aurora B and deubiquitinates it during prometaphase to metaphase 
transition. Because the levels of Aurora B remained unchanged upon knockout of UCHL3, this 
ubiquitination appears to be a non-proteolytic type. In the next experiments, we would like to 
study, how this ubiquitination affects the Aurora B activity and localization. 
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Figure 26 UCHL3 interacts with Aurora B and deubiquitinates it. 
(A) Control and UCHL3 knockout (KO) HeLa K cells were synchronized by monastrol for 16 hours and after 
washout cells were released into fresh medium for 15, 30 or 45 minutes and analysed by western blot. (B) HeLa 
K cells stably expressing, GFP, GFP-UCHL3-WT or GFP-UCHL3-C/S were synchronized by STLC and after 16 
hours collected for IP with GFP-Trap beads. (C) IP under denaturing conditions. Control and UCHL3 KO cells 
were transfected by Aurora B-GFP plasmid, synchronized by monastrol and collected for IP with GFP-Trap beads. 
Membranes were probed with GFP and FK2 antibody against conjugated ubiquitin.  
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2.4 DISCUSSION 
During my PhD, I described a completely new role for the deubiquitinase UCHL3 protein 
during mitosis. Up to date only limited number of DUBs has been described to regulate mitosis 
including USP44, USP7 and USP39176,238,239. So far, UCHL3 has been mainly studied in the 
context of DNA repair signaling. Interestingly, other components of DNA repair pathway were 
implicated in mitosis, for example ATM is activated during mitosis, localizes to the 
centrosomes and controls integrity of the mitotic spindle240, BRCA1 controls centrosome 
duplication and prevents centrosome amplification, which is crucial for proper chromosome 
segregation241 and 53BP1 protein has been shown to localize to kinetochores242, and it is 
important for resolving the merotelic attachments in an Aurora B dependent manner243. 
Our interest in UCHL3 was triggered by results we obtained in a high-throughput screen, in 
which we were looking for novel regulators of mitosis. UCHL3 was the best candidate from 
tested DUBs and as the screen revealed, downregulation of UCHL3 leads to irregular nuclei 
phenotype. Interestingly, control of nuclear shape was specific to UCHL3, but not UCHL1 
another member from the UCH protein family (Figure 14). First, I confirmed that UCHL3 
controls nuclear morphology (Figure 15). Since irregular nuclei are a frequent consequence of 
segregation errors during mitosis I therefore designed several experiments to test the hypothesis 
that UCHL3 might be involved in the regulation of mitotic progression. Using different 
molecular and cellular tools, I could show that UCHL3 controls chromosome alignment and 
chromosome segregation during mitosis. I observed that chromosome alignment is regulated 
by UCHL3 during prometaphase and the rescue experiments confirmed that it is dependent on 
the catalytic activity of UCHL3 (Figure 17). Experiments with UCHL3 inhibitor showed that 
only a short inhibition of UCHL3 during prometaphase results in severe alignment problems 
further confirming UCHL3 direct involvement in this process (Figure 19D, Figure 20D). In 
addition, I confirmed these results by live video imaging experiments where I observed 
increased number of lagging chromosomes in the absence of UCHL3 (Figure 21, Figure 22). 
These results collectively suggest that UCHL3 is an important factor controlling chromosome 
segregation and thereby maintenance of genome integrity. Importantly, I observed the same 
phenotype in human primary fibroblasts where inhibition of UCHL3 caused misalignment 
defects (Figure 20). This result suggests that UCHL3 also controls proper division of human 
somatic cells and its role is not restricted to cancer cells. This is further supported by data 
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available in GEO database244 showing that human embryonic stem cells have higher levels of 
UCHL3 which drop upon cell differentiation. Furthermore, UCHL3 has been reported to 
regulate mammalian oocyte maturation during which UCHL3 colocalizes with the oocyte 
spindle and inhibition of UCHL3 leads to meiotic spindle defects231. Surprisingly, the UCHL3 
knockout mice are fertile and they develop without any obvious abnormalities245, suggesting 
an existence of a compensatory mechanism in the absence of UCHL3.  
2.4.1 How does UCHL3 regulate the chromosome 
congression? 
The most frequent phenotypes I observed include misaligned polar chromosomes in metaphase 
and lagging chromosomes during anaphase. The misalignment phenotype could result from the 
disruption of one or multiple mechanisms of chromosome positioning during mitosis for 
instance the transport of polar chromosomes to the equatorial zone. While the presence of 
lagging chromosomes could be a result of defects in the chromosomal attachment correction. 
Importantly, the UCHL3 catalytic activity is necessary for proper cell division suggesting that 
UCHL3 controls ubiquitination of one or more regulatory factors important for the 
chromosome alignment and/or segregation. In this chapter I would like to discuss the possible 
mechanisms by which UCHL3 could be involved in the regulation of chromosome congression 
and chromosome segregation. 
One of the important mechanisms contributing to chromosome alignment includes dynein 
mediated poleward movement of polar chromosomes which are later transported to the equator 
by combined activity of CENP-E and MCAK. CENP-E is a motor protein which helps 
chromosome alignment by promoting congression of polar chromosomes20,246,247 and it also 
actively helps to maintain alignment of already congressed chromosomes19,127,248,249. The 
MCAK protein does not move along MTs but it accumulates at the leading kinetochore and 
depolymerizes microtubules facilitating the chromosome congression128. MCAK, CENP-E and 
dynein downregulation lead to the congression defects observed as misaligned 
chromosomes128,185. In addition, MCAK downregulation causes accumulation of aberrant KT- 
MT attachments, syntelic and merotelic128 which creates a potentially dangerous situation for 
the cell since merotelic attachments are not recognized by the SAC.  
The alignment phenotype I observed in my experiments (Figure 16B) is very similar to CENP-
E depletion phenotype20,185. Despite the high similarity of UCHL3 depletion to the depletion 
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of CENP-E, UCHL3 removal has no impact on total CENP-E protein levels (Figure 26A). 
When I quantified the localization of CENP-E by measuring its intensity on kinetochores 
during metaphase, I saw a significant decrease of CENP-E localized to the KTs of aligned 
chromosomes, but not of the misaligned ones (Figure 25 A-C). Based on these results, I can 
conclude that UCHL3 is important for CENP-E recruitment to kinetochores, rather than for 
regulation of CENP-E protein levels directly. CENP-E is recruited to the KTs indirectly by 
Aurora B which first promotes BubR1 recruitment250 and this subsequently leads to CENP-E 
recruitment. In prometaphase, BubR1 is present at kinetochores in 1:1 ratio to CENP-E251 under 
normal circumstances. After chromosome bi-orientation, BubR1 dissociates from 
kinetochores, but CENP-E stays attached to KNL119 and further maintains the KT-MT 
attachment252. In my experiments, I did not address the CENP-E recruitment to kinetochores 
in prometaphase, but I studied the recruitment of BubR1. My results demonstrate that upon 
UCHL3 knockdown, BubR1 recruitment to KTs is not affected during prometaphase (Figure 
18C, D), yet I still observe decreased CENP-E levels in metaphase. There are three possible 
explanations for these observations. First, CENP-E is recruited to KTs normally during 
prometaphase, but upon MTs attachment it is not maintained at metaphase kinetochores and 
prematurely dissociates. Second possibility is that the CENP-E recruitment is also dependent 
on UCHL3 downstream of BubR1 loading onto the kinetochore. Third option could be a 
presence of an alternative mechanism for CENP-E KT recruitment, which is abolished by 
UCHL3 depletion. To prove or disprove one of the three possibilities, CENP-E localization 
during prometaphase needs to be addressed. 
Additionally, it would be interesting to understand why CENP-E is depleted only from the KTs 
of aligned chromosomes, but not from the misaligned ones. Upon UCHL3 knockdown, CENP-
E is more associated with the spindle, especially in the polar region (Figure 25A) and it is 
possible that this signal contributes to the increase in CENP-E kinetochore intensity. 
Nevertheless, CENP-E retention in the polar region could be an important indicator of impaired 
CENP-E movement. Interestingly, CENP-E movement towards equator is promoted by Aurora 
A and Aurora B phosphorylation20. 
In addition to CENP-E depletion at metaphase kinetochores, I also observed significant 
decrease in the levels of Astrin complex at kinetochores (Figure 23). Astrin is recruited in Plk1- 
Cdk1 dependent manner to kinetochores upon chromosome bi-orientation253 and it is 
negatively regulated by Aurora B activity254. Interestingly, Astrin localization to kinetochores 
is important for recruitment of other kinetochore components such as CENP-E237 which is in 
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line with my previous observations. Upon knockdown of UCHL3, I observed decreased 
recruitment of Astrin during metaphase which was proportional to the recruitment of CENP-E 
to the kinetochores (Figure 25D). From these observations I conclude that loss of CENP-E in 
the absence of UCHL3 is due to impaired Astrin recruitment. This phenotype could further 
contribute to the enrichment of misaligned chromosomes upon UCHL3 depletion since Astrin 
is necessary for chromosome congression and alignment maintenance252,255 by forming a MT 
interacting platform together with Ndc80 complex253. 
2.4.2 UCHL3, spindle morphology and the KT- MT 
attachment status 
UCHL3 depletion has also an effect on the spindle morphology. I observed more frequently 
the MTs that are spanning the equatorial region (Figure 24A) and that the metaphase spindle 
was elongated (Figure 24C). The appearance of microtubules spanning the equator could be 
due to aberrant bundling of spindle microtubules making the interpolar microtubules more 
visible or alternatively by increased bundling of the bridging fibers. This could be due to more 
PRC1 binding, making the fibers thicker and therefore more visible256.  
Spindle size is tightly controlled in cells and many experiments point to a precise scaling 
between the cell size and the spindle size suggesting that spindle size is evolutionary a well 
conserved feature257. Microtubule plus tips proteins are often connected with the regulation of 
spindle microtubules growth. For example, KIF4A has been implicated in the regulation of 
microtubule length in Aurora B-dependent manner during anaphase258. It is possible that 
KIF4A could regulate spindle microtubules in the same manner also during prometaphase and 
therefore it could contribute to the elongated spindle phenotype. As discussed earlier, PRC1 
stabilizes microtubules256 which could have an impact on the dynamics of microtubule 
polymerization and depolymerization, leading to the spindle elongation. It has also been shown 
that (+) end directed kinesin motor KLP61F bundles microtubules and determines the spindle 
length by promoting the sliding of the anti-parallel microtubules resulting in the spindle 
spacing139. Alternatively, the process of the microtubule nucleation and growth could be 
affected leading to the aberrant polymerization and elongation of spindle microtubules. MT 
nucleation from chromosomes occurs during mitosis and it is one of the determining factors 
for the spindle length, despite the fact that it is not essential in the presence of a functional 
spindle. MT nucleation is regulated by TPX2 which is a microtubule-associated protein 
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important for Aurora A activation. TPX2 mutants have short spindles, but they maintain their 
bipolar orientation259. It has been proposed by Young et al. that spindle size is important for 
proper chromosome segregation260 and it is therefore probable that the aberrant spindle 
morphology contributes to the increased number of segregation errors in UCHL3 depleted 
cells.  
In addition, I observed that UCHL3 depleted cells display lateral attachments more frequently 
(Figure 24B) which led me to the conclusion that UCHL3 regulates the end-on conversion 
process which is either delayed or inhibited in absence of UCHL3. Lateral to end-on conversion 
is a multistep process which requires CENP-E to tether microtubules to kinetochores and 
depolymerizing motor MCAK to release the laterally attached microtubules261. During early 
mitosis, also Aurora B has been reported to localize to the kinetochores, promoting end-on 
conversion process, which is counteracted by PP2A-B56 phosphatase262. It was shown that 
CENP-E, MCAK or Astrin deletion lead to increased number of laterally attached kinetochores 
resulting in congression defects and segregation errors128,246,255 further underlying their 
importance for the conversion process. I have observed that UCHL3 knockdown led to 
depletion of both, Astrin and CENP-E from the kinetochores, which could lead to the 
impairment of the end-on conversion process and thus explain the higher abundancy of lateral 
attachments in UCHL3 depleted cells. I did not assess the MCAK protein levels and its 
localization during metaphase. These experiments would provide additional information about 
the mechanism by which UCHL3 regulates chromosome alignment. Taken my results together, 
UCHL3 is indispensable for proper Astrin and CENP-E recruitment to kinetochores as well as 
for proper lateral to end-on conversion process which is necessary for chromosome congression 
and error-free segregation of chromosomes during anaphase.   
2.4.3 Regulation of the SAC response by UCHL3  
As mentioned above, knockdown of UCHL3 results in polar chromosomes with only partially 
attached or completely unattached kinetochores. This state should generate a strong SAC 
response leading to the mitotic arrest. Intriguingly, my live video experiments did not confirm 
this hypothesis, because I did not observe a significant change in time the cells needed to 
proceed from prometaphase to anaphase (Figure 21D, Figure 22D), yet I have observed 
significant increase of lagging chromosomes in UCHL3 depleted cells (Figure 21C, Figure 
22C). I performed the live video experiments in two different cell lines to gain more insight 
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and I also used different tools to achieve UCHL3 downregulation to avoid potential off-target 
effects. Nevertheless, I did not observe a mitotic arrest in any of my conditions. However, when 
I plotted values from all experimental replicates together, I could see a strong tendency for the 
UCHL3 depleted cells to take longer time before reaching anaphase (Figure 22F, G). It is 
puzzling why UCHL3 depleted cells do not manage to potentiate the SAC response enough to 
cause the mitotic arrest in presence of polar chromosomes and why they undergo a rather small 
delay and later enter anaphase regardless of the presence of the misaligned chromosomes.  
The lagging chromosomes are often the result of the alignment and attachment problems in 
metaphase. In some cases, the erroneous attachments are not sensed by the SAC machinery, as 
it was demonstrated for the merotelic attachments128,143,263,264, where all kinetochores are 
occupied by MT and under sufficient tension. Furthermore, the misalingment and attachment 
errors could be disregarded in the cases of the weakened SAC response265,266 or in the case of 
impaired amplification or diffusion of the SAC signal267–269. Dysfunctional SAC response 
prevents the cell from resolving all the problems in time and therefore it leads to the appearance 
of lagging chromosomes in anaphase. 
Weak SAC response means that the SAC components are not recruited to the kinetochores in 
the proper amount and therefore even in the presence of unattached chromosomes the SAC is 
satisfied and cells enter anaphase prematurely, resulting in the segregation errors. My data 
showed, that there is no difference in the recruitment of BubR1 to the kinetochores during 
prometaphase, meaning that the initial SAC response is triggered equally in the control and 
UCHL3-depleted cells. These experiments suggest that UCHL3 is not implicated in the 
generation of the checkpoint complex during prometaphase.  
Aurora B kinase activity is necessary for the maintenance of the SAC response and it was 
shown that inactivation of Aurora B results in fast exit from mitosis and decrease in the mitotic 
index. In my experiments, UCHL3 depletion did not affect the mitotic index upon 
synchronization in mitosis (Figure 18A, B) therefore I conclude that Aurora B activity 
necessary for the SAC activation and maintenance during prometaphase is not controlled by 
UCHL3 confirming the initial hypothesis that the early steps of SAC response are not affected. 
Taken all experiments together, the SAC response is triggered normally during prometaphase, 
but it is not maintained long enough, or it is not propagated properly in the cell to prevent the 
anaphase onset. This finding is very surprising, because it is well established, that a single 
unattached kinetochore is enough to delay the anaphase onset270,271. The signal generated by a 
single kinetochore is amplified and stops the cell from dividing. Experiments in fused cells 
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where two spindles are present in one cell showed that the signal was propagated only to the 
spindle with unattached kinetochore, but it was not propagated to the second one. These 
experiments suggest that the diffusion of the signal has only a certain reach and it is limited to 
the vicinity of the spindle containing the unattached kinetochore. It was also observed that 
when mature spindle entered anaphase, the second spindle would enter anaphase shortly after, 
regardless of the attachment status, suggesting existence of ‘wait’ and ‘start’ signals that are 
diffused in the cell and that the start signal is able to override the stop signal generated by 
unattached kinetochores272.  
Chan et al. did a large study with use of computational modeling where they were investigating 
the relationship between the spindle size and the ability to silence SAC. They showed that the 
longer spindles had troubles to spread the SAC signal from chromosomes close to the poles, 
because the distance was too long and the signal was diluted before it reached the kinetochores 
at the equator257. I have observed elongated spindles upon UCHL3 knockdown and I did not 
observe a significant delay in mitotic onset upon UCHL3 depletion even in presence of 
misaligned, polar chromosomes. One possibility is that the elongated spindle could prevent 
sufficient diffusion of the SAC signal and therefore the polar chromosomes would not cause a 
significant mitotic delay.  
Another possibility is that the pathway removing SAC components from the kinetochores is 
over-activated and SAC is prematurely silenced even in presence of unattached kinetochores. 
The SAC proteins are transported away from kinetochores by dynein motor 273 therefore an 
excessive dynein recruitment to kinetochores upon UCHL3 depletion could explain the 
phenotype. Another important antagonist of checkpoint response is p31Comet and its 
overexpression has been shown to result in the checkpoint override and mitotic exit274,275. To 
fully conclude whether it is a diffusion problem or premature disassembly of the checkpoint 
complex, localization studies of BubR1 and MAD2 to kinetochores of metaphase 
chromosomes should be performed. 
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2.4.4 Molecular mechanism for the mitotic role  
of the UCHL3 enzyme. 
To shed some light on the molecular mechanism by which UCHL3 regulates chromosome 
congression, I aimed at identification of the substrates of UCHL3 DUB in mitosis. The mass 
Spectrometry analysis of UCHL3 interacting proteins identified several interesting candidate 
substrates including Aurora B, PP1α, PP1γ phosphatases and MCAK. In the following 
experiments, I confirmed the interaction of UCHL3 with Aurora B in whole cell lysates (Figure 
26B) and therefore I focused on investigating whether Aurora B could be a substrate of UCHL3 
in mitosis. Experiments with UCHL3 knockout cell lines showed that the absence of UCHL3 
leads to the accumulation of upshifted bands recognized by Aurora B antibody, which are of 
an exact size of the ubiquitin tetramer (Figure 26A). This observation further confirmed a 
hypothesis that UCHL3 deubiquitinates Aurora B during mitosis. In addition, under denaturing 
conditions, we observed an increased ubiquitin signal on Aurora B in the absence of UCHL3 
(Figure 26C).  
Aurora B is a major mitotic kinase regulating many key events leading to proper mitotic 
progression and accurate chromosome segregation. In early mitosis, Aurora B localizes to the 
kinetochores with laterally attached microtubules and it promotes the end-on conversion 
process262. In metaphase, Aurora B is enriched at the merotelic attachment sites and is 
indispensable for correction of aberrant KT-MT attachments159–161,276. Interestingly, Aurora B 
negatively regulates MCAK activity276 which provides another layer of merotelic attachment 
correction. After establishment of attachments to all kinetochores, Aurora B does not reach its 
substrates leading to MCAK activation. Afterwards, MCAK is relocalized to KTs where it 
promotes MT disassembly and thus correction of merotelic attachments162. Additionally, 
Aurora B also regulates CENP-E motor activity20,277.  
Taken my results together, I propose a model in which UCHL3 controls chromosome 
alignment by regulation of Aurora B kinase (Figure 27). My results demonstrate that Aurora B 
is polyubiquitinated in mitosis and this ubiquitinated form accumulates in the absence of 
UCHL3. Hwever, this ubiquitination does not target Aurora B for degradation by the 26S 
proteasome, because the total Aurora B protein levels are not changed upon UCHL3 depletion 
(Figure 26A). I have addressed the activity of Aurora B by monitoring the T232 phosporylation 
which is a marker of Aurora B activity, as well as phosphorylation status of Hec1, the Aurora 
B substrate. In none of these experiments I observed any changes in phosphorylation levels, 
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suggesting that the UCHL3-mediated deubiquitination does not affect Aurora B kinase activity 
directly (data not shown). I hypothesize that in the absence of UCHL3, Aurora B is 
polyubiquitinated and this aberrant modification blocks the interaction of Aurora B with its 
substrates and therefore results in a phenotype similar to its inhibition. This situation would 
affect only several Aurora B substrates and not all of them, because UCHL3 downregulation 
does not fully mimic Aurora B inhibition. For example, I did not observe fast mitotic exit upon 
UCHL3 depletion which is one of the consequences of Aurora B inhibition159 (Figure 18A). 
Rather than inhibition of Aurora B kinase activity, I presume that this aberrant ubiquitination 
regulates Aurora B localization and interaction capacity with its substrates. This could be 
caused by a steric hindrance of the ubiquitin groups or by mislocalization. Indeed, further 
studies will be necessary to determine the interaction status of Aurora B during mitosis in the 
absence of UCHL3 and also to investigate its localization. Additionally, it would be interesting 
to identify the upstream E3 ligase and the type of ubiquitin-linkage that is present in this 
ubiquitin modification.  
In summary, during my PhD I described the role of UCHL3 in mitosis and I discovered that 
UCHL3 is critical for proper chromosome segregation. Its absence leads to chromosome 
alignment problems and subsequently could lead to aneuploidy caused by increased number of 
segregation errors (lagging chromosomes). Therefore, UCHL3 controls the genome integrity 
of the cell. The role of aneuploidy in cancer has been studied and it is clear that most solid 
tumor cells are aneuploid278 and various cancer cell lines show chromosomal instability. 
UCHL3 has been found to be overexpressed in several cancers including breast cancer, 
colorectal cancer and liver cancer227,279,280. It is probably the ability of UCHL3 to control 
genome integrity that makes it beneficial for cancer cells to survive their high rate of 
aneuploidy. It would be worth investigating whether targeting UCHL3 could improve cancer 
therapies. A few studies appeared already, supporting the idea to use UCHL3 inhibitors in 
combination with other commonly used chemotherapeutics17,281. Future studies will be 
necessary to investigate the significance of this approach in a greater detail.  
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Figure 27 Proposed model 
Suggested mechanism by which UCHL3 controls chromosome segregation. UCHL3 interacts 
with Aurora B in prometaphase and deubiquitinates it. This deubiquitination is necessary for 
proper Aurora B function in chromosome congression by promoting CENP-E movement, in 
lateral to end-on conversion process and in correction of merotelic attachments. Downregulation 
of UCHL3 results in chromosome congression and segregation defects.  
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3 TRIM15 IMPLICATION IN THE CELL 
CYCLE PROGRESSION AND MIGRATION 
 
3.1 BACKGROUND 
The tripartite motif (TRIM) proteins constitute a large subfamily of RING E3 ubiquitin ligases. 
More than 70 TRIM genes have been identified in human so far282. All TRIM proteins contain 
the tripartite motif usually comprised of a RING domain followed by one or two B-box motifs 
and a coiled-coil region at the N-terminus and a variable domain at the C-terminus282. Another 
common feature of TRIM proteins is their ability to form oligomers which is often essential 
for their biological activity283,284. They regulate many cellular activities, including the innate 
immune response and the antiviral response of a cell285. However, TRIM proteins also play 
important roles in cell proliferation286,287, DNA repair288, pluripotency289 and apoptosis290. This 
broad involvement in diverse cellular processes is underscored by the association of many 
TRIM genes with various pathologies, such as viral infections291,292, cardiovascular diseases293, 
neuropsychiatric disorders294, genetic diseases295 and cancer either as oncogenes296 or tumor 
supressors297. 
3.1.1 Evolution of the TRIM subfamily 
The tripartite motif, which is the main characterizing module that defines the TRIM family of 
proteins, appeared for the first time in metazoans298. The other eukaryotes do possess the 
individual TRIM subdomains, but only in different arrangements. In metazoans, the order and 
even the spacing between the subdomains is highly conserved, which indicates that this 
structure is a functional module299. 
TRIM genes can be classified into two groups a) highly conserved TRIM genes often also 
present in invertebrates b) evolutionary younger group present only in vertebrates with poor 
sequence and functional conservation298. The first group contains a small set of C-terminal 
domains which have been maintained with little changes throughout the evolution. In 
vertebrates and particularly in mammals the variety of TRIM genes radically increased, 
indicating the evolutionary success of this domain arrangement299. A number of these “young” 
genes are species specific and they are often implicated in the response to viral and microbial 
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infections. Furthermore, these dynamic genes are poised to be involved in providing novel 
functions which will be required in the course of evolution298. 
3.1.2 Structural determinants of the TRIM proteins 
function 
TRIM proteins are determined by their N-terminal tripartite motif and also possess highly 
variable C-terminal domain consisting of various subdomains300. In most TRIM proteins the 
tripartite motif begins with an N-terminal RING domain, which confers E3 ligase catalytic 
activity to this protein family. Following the RING domain, one or two B-box domains are 
positioned. Similarly to the RING domain, these domains coordinate two zinc ions to maintain 
their structure, however they do not possess the E3 ligase activity301. Despite some mutations 
in these domains are associated with disease phenotypes, not much is currently known about 
their exact role in the full length TRIM proteins295. The subsequent coiled-coil domain (CC) is 
necessary for the homodimerization of TRIM proteins and often also for their higher order 
oligomerization, which is in many cases strongly affecting their activity302. 
The C-terminal part of TRIM proteins contains a variety of domains and is considered to 
mediate the recognition and specificity towards their target. The family can be classified into 
11 subgroups based on the C-terminal domain structure303. The most abundant subgroup 
contains the PRY-SPRY domain, which often mediates protein-protein interactions, 
particularly in the context of immune signaling304. TRIM15 also belongs to this subgroup. 
Other domains present in some TRIM proteins are PHD/Bromo domain, NHL domains, TRAF 
domain and others. 
As mentioned previously, a crucial determinant of the activity of several TRIM proteins is their 
oligomerization. The most striking example is the interaction and organization of TRIM5 and 
related proteins. TRIM5 was shown to homodimerize through its CC domain and 
subsequently form higher order complexes via the RING and B-box2 domains. This greatly 
increases the avidity of the complex towards the capsid proteins of HIV-1 and allows it to act 
as a restriction factor305. It is interesting to consider, that TRIM protein transcripts are often 
extensively alternatively spliced producing proteins differing at their C-termini306. Such 
presence of different isoforms might constitute a regulatory activity. Adding further 
complexity, interactions between different TIRM proteins modulating the activity of the 
resulting complex were also reported297. 
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3.1.3 TRIM proteins in the regulation of biological 
processes 
As the TRIM proteins are one of the largest subfamilies of E3 ubiquitin ligases, it is maybe not 
surprising that they are regulating a wide variety of cellular processes282. 
Several specific substrates of TRIM E3 ligases were identified so far and many TRIM proteins 
preferentially bind to specific E2 enzymes282,307. E3 ligase activity of TRIM proteins is often 
associated with the regulation of immune responses. Besides the aforementioned role of 
TRIM5 in HIV-1 restriction, TRIM21 acts as a cytosolic receptor of IgG-bound pathogen, 
triggering cellular response upon binding308. Furthermore, more than a half of the TRIM 
proteins were shown to enhance innate immune response of cells and specific TRIM proteins 
were show to regulate the NFκB signaling285,309. 
However, the effects of TRIM proteins reach far beyond innate immunity. One of the first 
discovered TRIM proteins, TRIM19 also known as promyelocytic leukemia gene (PML) is 
necessary to transfer of small ubiquitin modifier (SUMO) onto its substrates310. This process 
is crucial for the formation of PML-nuclear bodies, important regulating centers of 
transcription. Another example is TRIM29 which can regulate the localization and activation 
of tumor protein 53 (p53) and prevent apoptosis of the cell311. DNA repair of double-stranded 
DNA breaks is another cellular process where a TRIM protein was shown to have a role. 
TRIM29, a histone binding protein, interacts with the chromatin around the break and acts as 
a scaffold, facilitating recruitment of the repair machinery288. 
Importantly, a number of TRIM proteins are involved in the control of cell cycle and in the 
regulation of mitosis312. TRIMs involved in interphase often facilitate progression through the 
cycle and their silencing in proliferating cells usually results in more cells dwelling in G1/G0 
and less cells in S/G2 at any given time. Among the identified cell cycle pathways regulated 
by TRIMs, the most important are p53 and Janus kinase (JAK)/signal transducer and activator 
of transcription (STAT) pathways313,314, but other like WNT/-catenin and AKT pathways 
were also reported315,316. Furthermore, multiple TRIMs were shown to regulate the assembly 
and function of the mitotic spindle and thereby to affect cell division312. In particular, TRIMs 
can affect centrosome duplication and spindle pole assembly, kinetochore protein degradation, 
kinetochore-microtubule attachment and midbody formation. 
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3.1.4 Involvement of TRIM family proteins in human 
pathology 
TRIM proteins have been shown and suggested to contribute to a wide variety of diseases in 
human. In response to viral infection TRIM25 leads to K-63 polyubiquitin chains formation on 
the viral RNA sensor protein Retinoic acid inducible gene I (RIG-I)317. This modification of 
RIG-I allows it to exert its downstream effects, namely activation of interferon (INF) 
production by the cell. Interestingly, Influenza A virus is capable to evade this INF mediated 
response thanks to the ability of its viral proteins to interact with TRIM25 and interfere with 
RIG-I polyubiquitylation318. Also, several TRIM proteins restrict HIV-1 at different stages of 
the infection cycle. As previously mentioned, TRIM5 interacts with the viral capsid affecting 
reverse transcription292,319. Additionally, TRIM22 inhibits long terminal repeat promoter 
driven transcription and TRIM28 inhibits viral integration into the genome320,321. 
Genome wide association studies uncovered connection of DNA polymorphisms of many 
TRIM proteins with neurological and psychiatric disorders, such as multiple sclerosis, 
Alzheimer’s disease and attention deficit hyperactivity disorder322. Furthermore, multiple 
hereditary diseases such as Optiz syndrome, Limb-girdle muscular dystrophies and Bardet-
Biedl syndrome are attributed to mutations in genes encoding TRIM proteins295,323. Many 
TRIMs regulating the cell cycle are involved in a wide variety of different cancer types, where 
they can strongly affect the progression of the disease in different ways312. 
TRIM proteins, such as TRIM28, TRIM14 and TRIM52 are upregulated in cancer cells and 
due to their positive effect on cell cycle progression, they act like oncogenes316,324,325. They do 
so by affecting the main cancer related signaling pathways, such as AKT and WNT and p53. 
In the opposite way, TRIM proteins also act as tumor suppressors often lost in cancer cells, 
whose restoration limits cancer progression and invasiveness. Specifically, TRIM8 has been 
shown to stabilize p53 and its absence in renal cell carcinoma leads to chemoresistance despite 
the presence of wild-type p53. Reactivation of TRIM8 in these cells re-establishes 
chemosensitivity mediated by p53326. 
TRIM proteins can also modulate cancer progression by regulating its metastatic potential. The 
ability of a particular cancer to metastasize is greatly influenced by the tendency of cancer cells 
to undergo epithelial to mesenchymal transition (EMT)327. TRIM14 associates with worse 
prognosis in patients with glioblastoma due to its ability to stabilize the transcription factor 
zinc finger E-box binding homeobox 2 (ZEB2) which facilitates the EMT of glioma cells328. 
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Importantly, the regulation of cell adhesion and cell migration is an important determinant of 
the ability of a cancer to metastasize329. Accordingly, several TRIMs affecting cell adhesion 
were identified to play a role in cancer. In gastric cancer, TRIM25 expression acts as a marker 
of poor prognosis. Knockdown by RNA interference in patient cancer cells did not affect 
proliferation, but reduced cell migration and invasion characteristics330. Conversely, ectopic 
expression of TRIM25 promoted migration and invasion via activation of tumor growth factor 
 (TGF-) signaling. Similarly, in colorectal cancer (CRC), TRIM14 knockdown reduced 
migration and adhesion of cancer cell lines, and its overexpression had the opposite effect331. 
In this context, the effect was shown to be mediated by sphingosine kinase 1 and STAT3 
pathways. Only in a few cases has the effect of individual TRIM proteins on cancer progression 
been clearly linked to their E3 ubiquitin ligase activity. In prostate cancer, the TRIM25 
polyubiquitylates ETS related gene (ERG) transcription factor, an oncogene driving many 
prostate cancers332. In a similar manner, TRIM31 promotes K48-linked polyubiquitylation and 
subsequent degradation of tuberous sclerosis complex (TSC) 1 and TSC2, the important 
suppressors of the mTORC pathway333. This in turn leads to overactivation of this oncogenic 
pathway. In gliomas, E3 ligase activity of TRIM45 mediates a tumor suppressor effect334. This 
is due to its ability to polyubiquitylate the p53 protein forming a K63-linked chain, and thereby 
inhibiting the availability of the residues for K48-linked polyubiquitylation which mediates 
p53 degradation. 
3.1.5 TRIM15 background 
TRIM15 is one of the less explored members of the TRIM family. An early GWA study 
uncovered a strong association of a single nucleotide polymorphism (SNP) in TRIM15 with 
the development of Alzheimer’s disease335. Our interest in understanding the function of 
TRIM15 was inspired by the fact that it is a putative E3 ubiquitin ligase and by the reported 
ability of TRIM15 to activate mitogenic signaling336. Therefore, we set out to investigate 
whether there is a role of TRIM15 in cell cycle regulation and whether it acts via ubiquitin 
mediated signaling. 
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3.1.6 Recent publications about TRIM15 
Within a few months after I started to work on the TRIM15 project, the first of the three 
publications describing the function of TRIM15 was published, indicating the role of TRIM15 
in focal adhesion maintenance337. This was later followed by two publications focusing on the 
role of TRIM15 in gastric and colon cancer338,339. This combined with a lack of evidence for 
the role of TRIM15 in regulation of the cell cycle led to our decision to discontinue the work 
on this project. The findings of these papers will be compared with my results in the discussion 
section. 
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3.2 METHODS 
3.2.1 Plasmids 
For my experiments I used Myc-FLAG, GFP and RFP expression vectors with human or mouse 
Trim15 cDNA. I purchased the full coding sequence of the human and mouse TRIM15 gene 
fused to a sequence of AA constituting the Myc-tag and DDK-tag (FLAG) at the C-terminus, 
TRIM15-Myc-FLAG (pCMV6 Entry Vector, Origine, human: RC207716, mouse: 
MR203968). I subcloned the coding sequence into different expression vectors: pCMV-AN-
RFP (Origene PS100033) generating TRIM15 N-terminally fused with a red fluorescent 
protein (N-RFP-TRIM15) and pCMV-AC-GFP (Origene PS100010) generating Trim15 
C-terminally fused with a green fluorescent protein (C-TRIM15-GFP). 
3.2.2 TALEN mutagenesis 
1. Design of TALEN pairs  
I designed TALEN pairs for both human and mouse TRIM15 gene. To identify optimal DNA 
sequences targetable by TALENs, I used the TALEN Targeter tool designed by the Cornell 
University340 (TAL Effector Nucleotide Targeter 2.0) which selected the best target site and 
designed the TALE subdomain arrangement according to DNA sequence. TALENs consist of 
repeat variable residue (RVD) domains, specific to different nucleotides (NN – G, NI – A, HD 
– C, NG – T).  
2. Golden Gate cloning 
To clone the individual TALEN plasmids, I used the Golden Gate cloning approach which 
allows to generate one plasmid from up to 10 source plasmids in a single step. TALENs are 
usually 15-20 RVDs long, therefore a two-step cloning is necessary. In the first step, I 
assembled arrays of 10 RVDs and 6-9 RVDs in two separate plasmids and in the second step I 
assembled them together to obtain a single TALEN targeting 16-20 AA long DNA sequence. 
TALENs are cloned into a backbone vector containing the C-terminal FokI domain necessary 
for DNA cleavage. The detailed mechanism of the Golden Gate cloning is visualized in 
Figure1D of the results section.  
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3. TALENs activity reporter system 
Reporter plasmids were generated earlier in the laboratory of R. Sedlacek by P. Kasparek and 
R. Haneckova. This system consists of a plasmid containing the target DNA sequence which 
is cleaved by the TALEN pair. Neighboring on the 5’ side is a fragment of a coding sequence 
of a selection marker (mRFP, blasticidine resistance gene) with a premature stop codon not 
allowing the production of the full protein. On the 3’ side there is a full coding sequence of the 
same marker with the ATG translation start site removed. After cleavage the homologous 
recombination DNA repair machinery recombines the homologous sequences surrounding the 
cleavage site, leading to expression of the selection marker (graphical representation is shown 
in Figure 2A). I used three different reporter plasmids: pAR-RFP producing RFP signal, pAR-
GFP-RFP producing RFP signal upon cleavage with basal GFP expression as a control of 
transfection efficiency and pAR-BSD reporter generating resistance to blasticidine antibiotic. 
3.2.3 Genotyping by DNA-PAGE gels 
To avoid large amount of sequencing I preselected my clones by DNA-PAGE genotyping 
which is sensitive enough to reveal a presence of point mutation in the genomic DNA. First, I 
isolated genomic DNA from my clones and then I amplified ~600bp regions around the sites 
of expected deletions using 83_hT15F, 84_hT15R and 85_mT15F, 86_T15R primer pairs. I 
also amplified the WT region and mixed the DNA from the clones with the WT PCR product. 
I heated the samples at 95⁰C to fully denaturate the DNA and I let the DNA slowly reanneal. 
In the WT cells this generates only one product of double stranded DNA made of two fully 
complementary DNA sequences visible on the gel as one band. If mutations in the target 
sequence are present, both the WT and the mutated sequences are present and their annealing 
leads to all combinations of WT and mutated DNA strands with mismatched regions dependent 
on the specific mutations. Such regions are unable to properly reanneal and their presence slows 
the movement of the dsDNA through the gel, resulting in the appearance of multiple bands.  
I run 10 µl of DNA sample in Tris-borate-EDTA (TBE) 5% Polyacrylamide gel (V= 7.5 ml: 
750 µl 10x TBE buffer, 1.2 ml 30% Acrylamide, 5.6 ml water, 70 µl 10% APS, 4µl TEMED) 
at 100 V for 60 minutes and stained the gels for 30 min in TBE buffer containing a drop of 
Ethidium bromide (EtBr) before imaging. 
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3.2.4 TOPO cloning and sequencing 
To sequence both alleles of mutant cell lines, I used TOPO cloning. First I amplified the target 
region by Phusion polymerase and I added A-tail to the PCR product by adding Taq polymerse 
(40 µl reaction= 8l PCR product, 1µl 10mM dATP, 5µl 10x PCR buffer (15mM Mg2+), 0.2µl 
Taq polymerase) for 20 min at 72⁰C. I transformed DH5α competent cells and performed blue- 
white selection using IPTG (0.1M) and X-gal (20 mg/ml) and I sent 5 clones per each mutant 
cell line for sequencing (SEQme, Sanger sequencing). 
3.2.5 Cell culture 
All cell lines were purchased from ATCC and cultured at 37 °C in 5% CO2 humidified 
incubator, if not stated otherwise. I used several different cell lines of human and mouse origin 
and cultured them according to the cell culture protocol given by ATCC webpage341.  
Human cell lines: BJ, CaCo2, HCT116, HEK293T, HepG2, Huh7, Jurkat, MCF7, Mo57J, 
Mo57K, THP-1, U2OS and mouse cell lines: Neuro2A, NIH3T3, NMuMG, Raw267.3. 
For all immunofluorescence experiments I was seeding cells on 12 mm glass coverslips 
(Menzel-Glaser) in 24-well plates at a density 15 000 cells per well. 
3.2.6 Generation of Trim15 knockout cell lines 
To generate TRIM15 knockout cell lines, I used human U2OS cells and mouse NMuMG cells 
which I transfected with the plasmids for TALEN pair expression together with the activity 
reporter plasmid producing GFP selection marker. I cultured the cells in 6 cm dish and 
transfected them with 2 µg of TAL1, 2 µg of TAL2 and 1 µg of reporter plasmid using 
Lipofectamine2000 reagent according to manufacturer’s protocol. After 24 hours, I sorted them 
using FACS and I collected RFP negative cells (control) and RFP positive cells (Trim15 KO) 
into 96 well plates, 1 cell per well. I cultured them until they grew in 10 cm dish, I froze 1 half 
of the dish and I isolated genomic DNA from the other half (Quiagen, DNA isolation Kit), I 
genotyped the clones using DNA page gels, TOPO cloning and sequencing as described above. 
I selected the clones having biallelic mutations. 
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3.2.7 Mice 
1. Trim15 knockout mice 
To generate a mouse model of TRIM15 loss we used an EUCOMM generated embryo 
harboring the “knockout first” allele of TRIM15 using selection driven recombination of the 
target site in mouse embryonic stem (ES) cells. A lacZ trapping cassette and a floxed promoter-
driven neomycin selection cassette was inserted into the intron of TRIM15. Recombination of 
tm1a with Flp recombinase generates a conditional allele (tm1c), which posesses gene activity. 
Recombination of the tm1a allele with Cre recombinase deletes the neomycin selection cassette 
and a floxed exon of the tm1a allele to generate a lacZ– tagged, Trim15 knockout allele (tm1b).  
Cre recombination of the tm1c allele deletes the floxed exon and generates a frameshift 
mutation (tm1d) (Figure 2F). The tm1a embryos were obtained from the EMMA repository 
and implanted in pseudo-pregnant female mice. The tm1a line was established and mouse 
embryonic fibroblasts were isolated from WT and homozygous embryos at E8.5. The presence 
of a WT allele was verified using a PCR with primers surrounding the construct insertion site 
and the tm1a allele was detected with a primer set recognizing region flanking the LacZ 
sequence. All mice were crossed into Bl/6J background.  
2. Colorectal carcinoma model  
We used the ApccKO/cKO mice that harbor two loxP sites surrounding APC, the commonly 
mutated gene in human colorectal carcinoma. We crossed the mice with Villin gene promoter 
driven expression of Cre recombinase coupled to estrogen receptor (Villin-CreER) which 
allowed the recombination to be activated selectively in the colon epithelium by administration 
of tamoxifen (Sigma Aldrich, 100 µl of 100 mg/ml stock). We sacrificed the mice four days 
after tamoxifen-induced recombination.  
3.2.8 Isolation of MEFs 
I isolated the mouse embryonic fibroblasts (MEF) from E8.5 embryos. I washed them in PBS 
and removed the organs, mainly liver to prevent contamination of the culture. I homogenized 
the tissue using small scissors. I plated the cells on gelatine coated 10 cm dishes. After 24 hours 
I changed medium to eliminate the debris.  
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3.2.9 RNA isolation and cDNA preparation 
To isolate RNA from mouse tissue samples I used Trizol reagent and for isolation of RNA 
from cultured cells I used RNA Isolation Kit (RNeasy Mini Kit – QIAGEN) according to 
manufacturer’s instructions. All RNA samples were DNAse I treated. For reverse transcription 
I always used 2 µg of RNA and M-MLV Reverse Transcriptase from Sigma Aldrich.  
3.2.10 Quantitative PCR analysis 
I used 20 ng of cDNA as a template, SybrGreen master mix from Sigma Aldrich (S4438) and 
1 µM primers in final volume of 10µl per reaction as listed in primer sequences (Appendix 
Table 7). I normalized the TRIM15 expression to a combination of three housekeeping genes 
(β-actin, Hprt, Gapdh for mouse and GAPDH, HPRT and Glucose-6-phosphate isomerase 
(GPI) for human) and I run them at 62⁰C annealing temperature. I used the software from Roche 
(LightCycler® 480 SW 1.5.1) to analyze my data.  
3.2.11 Proliferation assays 
ATP: I used the ATP Cell Viability Luciferase Assay Kit from Millipore containing D-
Luciferin, (CS224519), Firefly Luciferase (CS224520, ATP Assay Buffer (CS224521) and 
ATP 2 µM (CS224522). To detect my signal I used chemiluminiscence method in 384 well 
plate and measured cell density in different time points.  
Alamar Blue: As a second method, I did Alamar blue assay using a reagent from Thermo 
Fisher (DAL1025). First I estimated the optimal cell seeding density and after I measured 
Absorbance at 600 nm from which I calculated the cell number in different conditions during 
the course of 24 or 40 hours.  
FACS: As a third method to estimate the cell growth I used FACS to measure DNA content in 
the cells. I used Propidium Iodide (PI) stain from Thermo Fisher (P1304MP), I fixed the cells 
5 minutes in ice cold ethanol, resuspended them in 100 µl of PBS and stained with 3 µM PI in 
a staining buffer (100 mM Tris, pH 7.4, 150 mM NaCl) for 30 minutes in the dark. I analysed 
the results using FlowJo program.  
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3.2.12 Migration assays 
I seeded the cells in 12-well plates 24 hours prior the experiment. I performed a scratch using 
200 µl pipette tip and I washed the well once with warm medium to remove floating cells. I 
placed my plate to a heated chamber 37⁰C with 5% CO2 and I started acquisition for 12 - 24 
hours using TIRF microscope. I analysed the data and measured all parameters in ImageJ 
software. 
3.2.13 Immunofluorescence 
I fixed the cells in 4% PFA for 20 minutes at room temperature, washed them 3x in PBS and 
permeabilized in 0.5% NP-40 for 5 min followed by wash, 3x in PBS-T and blocking in 3% 
BSA in PBS-T for 1 hour at room temperature (RT). I diluted primary antibodies in blocking 
buffer and incubated them overnight at 4⁰C, I washed the cells 3x, 5 min in PBS-T and 
incubated them with secondary antibodies at 1:500 dilution for one hour at RT in dark followed 
by 3x 10 min wash in PBS-T and staining with 1 µg/ml DAPI in PBS for 10 min at RT and 
wash 2x in PBS-T. I mounted them on glass slides using Mowiol and dried them overnight at 
RT in dark. I used rabbit polyclonal Trim15 antibody (Proteintech, 13623-1-AP) at 1: 500 
dilution. 
3.2.14 Statistics 
To statistically evaluate my data I used parametric Student’s t-test for all experiments. I 
considered the values significantly different when P value was smaller than 0.05 and I assigned 
stars according to P values as follows: P<0.05 *, P<0.01 **, P<0.001 *** P< 0.0001 ****. In 
all graphs I show my results as Mean ± SD of minimum three independent experiments. I used 
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3.3 RESULTS 
3.3.1 Design and generation of molecular-biology tools 
to study TRIM15 function 
To characterize the function of TRIM15 I decided to prepare several tools to study the effects 
of TRIM15 in cells and in the whole organism. 
First, to be able to determine the localization of TRIM15 in the living cell, I generated 
mammalian DNA constructs expressing TRIM15 fused with fluorescent proteins. To get a vast 
image of TRIM15 localization, I cloned the human as well as mouse TRIM15 coding sequence 
into different vectors with C- or N- terminal GFP and RFP tags as it is described in methods 
section and illustrated in the plasmid maps of TRIM15-Myc-FLAG, N-RFP-Trim15 and C-
TRIM15-GFP vectors (Figure 28A). 
To study the effect of TRIM15 loss on the function of the cell I decided to knock out the 
TRIM15 gene in mouse and human cell lines. To achieve TRIM15 deletion, I decided to 
perform gene editing of the chosen cell lines using transcription activator-like effector (TALE) 
nucleases. TALE nucleases (TALENs) are a highly specific genome editing tool, whose 
precision is achieved by generating of a pair of DNA-binding proteins interacting with a 
specific DNA sequence. To cleave DNA at a specific site, two TALE proteins need to bind 
DNA sequences surrounding the cleavage site allowing the C-terminal FokI endonuclease 
domains to dimerize. The resulting double stranded DNA break is then repaired by the cellular 
DNA-repair machinery. Most frequently the cell uses non-homologous end joining (NHEJ) 
DNA repair which is an error- prone repair generating deletions, insertions or mutations around 
the cleavage site often leading to a frameshift of the open reading frame. 
To knock out the TRIM15 gene in the target cells, I designed two pairs of TALENs, one set 
targeting the human and the other set targeting the mouse Trim15 gene. In both cases, the 
cleavage site was positioned downstream but in close proximity of the translation start site 
codon (ATG) (Figure 28B). I used a software designed by Cornell University to identify the 
best regions for TALEN mutagenesis (Figure 28C) and I used the Golden Gate cloning 
approach to create TALEN pairs in two step process (Methods and Figure 28D). To verify the 
success of the cloning, the final constructs were digested with KpnI restriction enzyme. This 
cloning approach leads to the presence of a KpnI target sequence in the HD domains which are 
not on the 1st or 10th position in the first assembly step as well as in the backbone sequence 
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(Figure 28C). The resulting pattern of bands allows the assessment of the correct order of the 
subdomain assembly (Figure 28E). I managed to clone all the necessary plasmids for targeting 
of human Trim15 by a single TALEN pair as well as for targeting the mouse Trim15 by a 
second TALEN pair.  
3.3.2 Generation of cell and animal models to study the 
TRIM15 function 
Mutant cell lines 
In order to address the function of TRIM15 in cells I decided to knock out the TRIM15 gene 
by TALENs that I generated previously. For my experiments I chose two cell lines in which I 
deleted the TRIM15 gene: U2OS (human) and NMuMG (mouse) cell line. To improve the 
efficiency of generating TRIM15 knockout cells, I used the TALENs activity reporter system. 
It is a unique tool that allows to test the activity of TALEN pairs. If the TALEN pair is active, 
it cleaves the reporter vector and by homologous recombination the cell gains new selection 
markers (GFP, RFP signal or resistance to antibiotics) (Figure 29A). This allows enrichment 
of cells where TALEN mediated cleavage occurred, either by flow cytometry (Fluorescence-
activated cell sorting (FACS)) or antibiotics selection. 
I used the TALENs activity reporter system with RFP expression marker and I sorted the RFP 
positive cells by FACS, to isolate individual clones of U2OS and NMuMG cells where the 
DNA was successfully cleaved by TALENs (Figure 29B). I tested the individual clones for 
presence of mutations in the genomic sequence of TRIM15 by the DNA PAGE genotyping. 
(Figure 29C). Based on these results, I selected clones for further validation by sequencing 
with use of the TOPO cloning which allowed me to distinguish mutations in individual alleles 
of the gene. For my future experiments, I selected the clones where both alleles were 
successfully mutated. 
In NMuMG clone no. 2, each allele had a different mutation, either a deletion of 2 base pairs 
(bp) at the cleavage site or a larger deletion of 14bp centered on the cleavage site. Both of these 
deletions lead to a frameshift of the open reading frame and a predicted appearance of an early 
stop codon, which should lead to the loss of the protein (Figure 29D). I validated Trim15 
deletion on the mRNA level using RT-PCR (Figure 29E) as well as on the protein level using 
western blot (Figure 29F). In U2OS clone no. 1, each allele also had a different mutation. In 
the first case deletion of 83bp and in the second a deletion of 52bp occurred. As the cleavage 
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site was targeted to the ATG start site, the deletions led to loss of a part of 5’UTR, translation 
initiation site and several AA codons, potentially ablating the protein production (Figure 29D). 
Mouse model 
To generate a mouse model of TRIM15 loss we used a EUCOMM generated embryo harboring 
the “knockout first” allele of TRIM15 (tm1a). These embryos were generated using selection 
driven recombination of the target site in mouse embryonic stem (ES) cells. The tm1a embryos 
were obtained from the EMMA repository and implanted in pseudo-pregnant female mice. The 
tm1a line was established in the transgenic unit (IMG, Prague). The tm1a line can be crossed 
with Flippase or Cre mouse lines driven by different promoter producing various genotypes. 
The tm1c is a conditional allele possessing WT Trim15 function, which can further serve to 
generate tissue specific Trim15 deletions, tm1b is a knockout allele harboring LacZ gene which 
can be used to monitor Trim15 expression during development or in adult mice (Figure 29G).  
For my experiments I was using the tm1b Trim15 knockout animals. I always confirmed that 
the mice which I have selected had the desired genotype. I used site specific primers to 
distinguish between the WT and the tm1b (knockout) allele (Figure 29H). 
3.3.3 Expression pattern and subcellular localization of 
TRIM15 protein 
Due to the unknown function of TRIM15 at that time, I decided to assess the distribution of the 
protein within the cell to help identify cellular processes it could be involved in. To this purpose 
I first decided to use the fluorescently labelled protein expression vectors. I co-transfected 
U2OS cells using polyethyleneimine (PEI) transfection reagent, with two plasmids containing 
the human TRIM15 coding sequence (N-RFP-TRIM15 and C-TRIM15-GPF). After fixation 
and mounting I visualized the fluorescent signal using confocal microscopy. Surprisingly, the 
distribution patterns of the two different fusion proteins were not overlapping (Figure 30A).  
N-RFP-TRIM15 seemed to have mainly cytoplasmic localization, while the C-TRIM15-GFP 
localized to distinct foci within the cell. To help to resolve this conflicting result, I took 
advantage of a newly appeared commercial antibody recognizing the endogenous human 
TRIM15 protein. The immunostaining revealed accumulation of endogenous TRIM15 in 
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To further characterize TRIM15, I analyzed its expression in 21 different mouse tissues as well 
as in multiple mouse and human cell lines using qPCR. Interestingly, the intestinal tissues had 
high levels of TRIM15 expression, in comparison to other organs (Figure 30C). Notable 
expression could be observed also in kidney, stomach and mammary gland tissues. However, 
screening human and mouse cell lines did not reveal similar pattern based on their tissue of 
origin. In human cell lines, the highest expression was detected in hepatocellular carcinoma 
cell line HepG2. Higher expression was also present in colorectal adenocarcinoma cell line 
CaCO2, but also in cell lines derived from osteosarcoma (U2OS), T lymphoma (Jurkat) and 
another hepatocellular carcinoma cell line (Huh7). Another hepatocellular carcinoma derived 
cell line Hct116 did not show high expression of TRIM15. In mouse cell lines, the highest 
expression was observed in a cell line derived from neuroblastoma (Neuro2A) (Figure 30D). 
Despite this variability, both human and mouse cell lines show higher expression of TRIM15 
when compared to the primary (BJ) or non-transformed (NIH3T3) cells. This indicates, that 
increased levels of TRIM15 could be advantageous for growth of some cancer cells and 
therefore actively upregulated in the malignant cells. 
To test this hypothesis, we chose to measure the expression level of TRIM15 in a mouse model 
of inducible colorectal carcinoma (CRC). For this experiment, I used mouse model for CRC 
expressing a tamoxifen inducible transgene for APC deletion selectively in the colon 
epithelium driven by Villin Cre promoter342. Additionally, I assessed the TRIM15 expression 
in another colorectal carcinoma model, the azoxymethane (AOM) induced colon 
carcinogenesis in C57BL6J wild-type mice343. In both models, induction of the carcinogenic 
process led to increased expression of TRIM15 (Figure 30E). This was more pronounced in 
the conditionally ablated APC mice, in comparison to the random mutagenesis/ inflammation 
driven CRC model. Furthermore, analysis of RNA expression data from The Cancer Genome 
Atlas (TCGA) revealed that TRIM15 is often increasingly expressed in CRC samples (Figure 
30F). This indicates, that TRIM15 upregulation may be particularly involved in colorectal 
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3.3.4 Effects of TRIM15 on cell proliferation 
To investigate our original assumption, that TRIM15 is likely involved in cell cycle regulation, 
I decided to assess its effect on cell proliferation. For this purpose, I used mouse embryonic 
fibroblasts isolated from the Trim15-/- animals (tm1b allele). To reliably measure cell growth, 
I took advantage of a high-throughput assay measuring the cellular ATP level by ATP 
dependent, luciferase mediated bioluminescence. As ATP levels in cells are tightly regulated, 
increase in cell number is directly proportional to the increase of total ATP-luciferase signal. 
Similar increase in ATP signal after three days of culture could be seen in both, WT and 
Trim15-/- MEFs indicating, that loss of Trim15 does not affect cellular proliferation (Figure 
31A). This was further confirmed by a time-course measurement of cell viability using the 
Alamar blue assay. Following the cells over 40 hours revealed no difference between the WT 
and Trim15-/- (Figure 31B). 
Another approach to assess the effect of TRIM15 on cell cycle regulation I used, was flow-
cytometric cell cycle phase analysis by measurement of the DNA content. Similarly, as in the 
previous assay, the distribution of cells in different phases of cell cycle was not different 
between WT and Trim15-/- MEFs (Figure 31C). Also, in NMuMG, the ablation of Trim15 did 
not lead to noticeable changes in cell cycle phase distribution (Figure 31D). 
Lastly, I measured the effect of TRIM15 overexpression on cell proliferation in U2OS cells 
using Alamar blue assay. For this purpose, I transiently transfected the cells with available 
human TRIM15 expression constructs and measured the amount of cells after 24 hours. In line 
with previous results, overexpression of TRIM15 did not lead to changes in proliferation 
(Figure 31E). 
3.3.5 TRIM15 regulates cell migration 
As the next step, we decided to investigate the effect of TRIM15 on cell motility. This was 
triggered by the publication of a study by Uchil et.al. which shows that TRIM15 is often 
localized to focal adhesions and it affects the focal adhesion turnover344. To measure the 
capacity of cells to migrate in presence or absence of TRIM15, I performed a scratch assay. 
First, I used MEFs from WT and Trim15-/- mice and I observed reduced invasion of the 
Trim15-/- cells (Figure 32A). After 12 hours the WT cells were able to cover the wound area 
almost completely, whereas the KO cells were covering only around 80%. Similar result could 
be observed in the NMuMG Trim15-/- cells, although the difference seemed more pronounced 
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(Figure 32B). After 12 hours, the WT cells covered the area completely, but the KO cells 
reached only about 60%. Surprisingly, no difference of cell movement was observed in the 
U2OS cells (Figure 32C). 
We hypothesized, that the observed migratory effect could be due to an effect of TRIM15 on 
epithelial to mesenchymal transition. Despite the lack of effect on cell cycle, such a role could 
have an important effect on cancer progression or metastasis and based on the animal and 
human expression data, we decided to investigate the role of TRIM15 in colorectal cancer. 
Unfortunately, shortly after that, Ok-Hee et al. published their work which describes the role 
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Figure 28 Generating molecular tools for TRIM15 functional analysis. 
(A) Using restriction endonucleases, the coding sequences of human and mouse Trim15 were subcloned into 
vectors, creating TRIM15 fused with fluorescent protein at the C- or N- terminus. (B) TALEN pairs targeting 
human and mouse TRIM15 genomic sequences close to the transcription start site were designed using TALEN 
Targeter tool. (C) TALE subdomains arrangement of the designed TALENs was prepared for cloning. Red 
arrowheads indicate Kpn2I restriction site presence, used for cloning validation. (D) Golden Gate cloning of 
TALENs consisting of two assembly steps of TALE subdomains. In the first step two plasmids are assembled, 
one containing the first 10 subdomains and the second one with the remaining subdomains. In the next step the 
two parts are cloned into the full TALEN plasmid. (E) Restriction analysis of the final TALEN constructs. The 
position of Kpn2I sites predicts the expected band sizes after digestion. 
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Figure 29 TRIM15 knockout in cells and in the mouse 
(A-D) TRIM15 knockout was generated using TALENs in different cell lines. (A) To increase the likelihood of 
isolating cellular clones with mutations of interest, TALEN activity reporter plasmid containing the target 
sequence were used. Successful plasmid cleavage and subsequent recombination leads to expression of either 
mRFP or blasticidine resistance. (B) FACS sorting of individual cells positive for the TALEN activity reporter. 
(C) PCR and DNA PAGE analysis of the isolated clones. Reannealing of the PCR amplified genomic target 
sequence with WT sequence leads to multiple bands in clones with mutation. (D) Results of sequencing of the 
TOPO cloned PCR amplified genomic target region. Red letters indicate binding of individual TALENs, dashes 
indicate deletion of a base. (E) RT-PCR with Trim15 and Gapdh primers confirming absence ofTrim15 mRNA. 
(F) Western blot showing absence of Trim15 protein in NMuMG cells upon TALEN mutagenesis. (G) Design of 
the allele of TRIM15-/- mice obtained from EMMA repository. In the tm1a allele the expression of TRIM15 is 
stopped and LacZ expression can be detected instead. (H) PCR genotyping of the WT and the TRIM15-/- mice. 
NMuMG   U2OS 
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Figure 30 Localization and expression of Trim15 in human and mouse samples 
(A-B) Localization of TRIM15 in human U2OS cell line. (A) Overexpression of differently labelled TRIM15 
plasmids, N- RFP-TRIM15 and C-TRIM15-GFP. (B) Immunofluorescence staining of the endogenous TRIM15 
(green) co-stained with actin marker Phalloidin (red). (C) Trim15 expression in different mouse organs isolated from 
adult Bl/6J mice. Normalized to β-actin, Hprt and Gapdh. (D) Trim15 expression in selected human (left) and mouse 
(right) cell lines and normalized to the mean of three housekeeping genes. (E) Trim15 expression in two different 
models of colorectal cancer. From the left: Rows 1, 2 represent data from APCcKO/cKO mice, without tamoxifen 
and four days after tamoxifen administration. Rows 3, 4 represent data from azoxymethane (AOM) induced cancer 
in Bl/6 adult mice. Bars show Trim15 expression in vehicle and AOM treated mice. (F) TRIM15 expression profile 
in human samples of cancer tissue from different origins. Data are available in the protein atlas online database. 
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Figure 31 The role of Trim15 in proliferation 
(A) Trim15+/+ and Trim15-/- MEFs were used to measure the ATP content in two time points. First, 16 hours after 
seeding (D0) and second after 3 days in culture (D3). Graph represents data from D3 normalized to D0. (B) 
Trim15+/+ and Trim15-/- MEFs were seeded in 96 well plate and their proliferation rate was measure by Alamar 
Blue dye in the time course of 40 hours. (C) Analysis of cell cycle distribution by FACS in Trim15+/+ and 
Trim15-/- MEFs by PI staining. (D) FACS analysis of cell cycle distribution in TALEN generated WT and Trim15 
KO NMuMG cell lines. (E) Study of the effect of TRIM15 overexpression in human U2OS cells by Alamar Blue 
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Figure 32 Implication of Trim15 in cell migration 
Migration experiments with different cell lines. All experiments were done in the same setup. Migration ability 
of different cell types was analysed by the scratch assay. Cells were filmed and the distance migrated was 
measured in ImageJ. The graph represents the total distance migrated during 12 hours by individual cells. (A) 
Migration of Trim15+/+ and Trim15-/- MEFs. (B) Migration of TALEN generated Trim15 WT and Trim15 KO 
NMuMG cells. (C) Migration of TALEN generated Trim15 WT and Trim15 KO U2OS cells. 
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3.4 DISCUSSION 
In this project I was focusing on the characterization of TRIM15 and its roles in cells and 
animals, with a special emphasis on the cell cycle. To this purpose I generated multiple cellular 
models and acquired a mouse model of a TRIM15 knockout. Unfortunately, in publishing of 
the results on TRIM15 function I was preceded by two other research groups. The findings 
they reported greatly overlapped with our findings and this led to a decision to stop this project. 
As the first aspect of TRIM15 function I investigated its localization within the cell. Using 
protein expression constructs of TRIM15 fused with fluorescent proteins I was able to assess 
the localization of TRIM15 using confocal imaging. This led to a discrepant result, between 
the N-terminally and the C-terminally labelled TRIM15 proteins (Figure 30A). This 
contradiction was resolved by the appearance of a commercial antibody against endogenous 
human TRIM15. Stainings with this antibody revealed a similar pattern of localization as 
shown by the C-terminal labelled TRIM15, in multiple foci within the cells (Figure 30B). The 
mislocalization of the N-terminally labelled TRIM15 is likely due to the conserved structure 
of the TRIM domain which resides in the N-terminal part of the protein. Several subdomains 
of TRIM are important for mediating oligomerization or interaction with other proteins. 
Furthermore, their spatial arrangement in the protein forms a relatively rigid structure and 
therefore an addition of a bulky fluorescent protein could either block access to or destabilize 
the organization of these domains. In contrast, the C-terminal domain is much less conserved 
in the TRIM family of proteins and is often of modular character indicating that it could be 
capable of tolerating the addition of GFP more easily. This localization of TRIM15 was also 
reported in the other two publications. Both identified TRIM15 as a component of focal 
adhesions displaying similar speckled localization. Furthermore, they both report that deletion 
of the B-box domain leads to loss of this pattern and shows TRIM15 diffused in 
cytoplasm345,346. 
I also assessed the expression of TRIM15 in different human and mouse cell lines and in several 
mouse organs. From all the different tissues, TRIM15 showed a clear high expression in the 
intestines (Figure 30C). This is supported by the data from The Human Protein Atlas, where 
RNA sequencing shows strong expression only in the intestines (data not shown). Ok-Hee et 
al. performed TRIM15 mRNA expression analysis by qPCR in human tissues. In contrast to 
the Human Protein Atlas and to our data obtained from mice, the highest expression was 
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detected in the kidney. This was then followed by medium expression in the colon and a modest 
expression was detected in the small intestine346. Such difference could be potentially explained 
by the different normalization method used, as 18S ribosomal RNA expression has been 
reported to be variable in different tissues347 The tissue specific pattern was not maintained in 
human and mouse cell lines in respect to their tissue of origin. 
The abundant expression of TRIM15 in colon led me to investigate whether its expression 
levels are affected by malignant transformation. In a genetic model of CRC by a knock-out of 
APC in colon epithelia I observed an increased expression of TRIM15 in the malignant tissue. 
Similar trend could be observed in another CRC model induced by treatment with 
azoxymethane, however to a lesser extent and not reaching statistical significance (Figure 30E). 
Interestingly, Ok-Hee et al. reported reduced TRIM15 mRNA expression in matched human 
normal and CRC samples and suggested that TRIM15 could be acting as a tumor suppressor. 
In line with this conclusion, they showed, that overexpression reduces the anchorage 
independent growth of cancer cells and also slightly reduces tumor growth in a xenograft model 
of human CRC346. This difference could potentially be explained by our experimental setup. 
We isolated RNA from the whole small intestine of mice 4 days after induction of the APC 
knockout. At this time point, there is substantial hyperplasia of intestinal crypts, but no 
recognizable adenomas can yet be detected348. It could be that further transcriptional changes 
such as reduction in TRIM15 levels are required before a proper adenoma can be formed. 
Supporting data were reported by Chen et al. who showed an association of lower TRIM15 
expression in the tumors with reduced survival in gastric carcinoma patients349. This suggests 
that TRIM15 indeed may act as a tumor suppressor and that reduction of its expression allows 
the malignant cells to propagate more rapidly. 
One way by which TRIM15 could affect cancer patient outcome and tumor growth is via an 
action on the cell cycle regulation. This was also suggested by the results reported by Uchil et 
al. where TRIM15 overexpression lead to the activation of the AP-1 pathway. Out of these 
reasons I performed proliferation assays and cell cycle phases distribution analysis in various 
cells missing or overexpressing TRIM15. Neither the absence nor the overexpression affected 
the proliferation in a noticeable way and cells lacking TRIM15 had their cell cycle phase 
duration unaffected (Figure 31). Recently, Chen et al. reported the same finding349. The MTT 
proliferation assay on gastric carcinoma cells with a siRNA mediated TRIM15 knockdown, or 
with transient TRIM15 overexpression revealed no effects on the proliferation. 
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Other important cellular processes which can affect the outcomes of cancer are cell migration 
and invasion. Both cell behaviors depend on reorganization of the cytoskeleton and on the cell-
to-cell and cell-to- extracellular matrix (ECM) adhesion. Increase in adhesion and the 
subsequent reduction in cell migration reduces cancer metastasis350, but many cell adhesion 
molecules have independent tumor suppressing characteristics351. This is likely due to their 
ability to affect the cellular signaling pathways and impair tumor growth for example by 
strengthening the contact inhibition. I investigated the role of TRIM15 deletion in cell 
migration by using a scratch (wound closure) assay. Interestingly, TALEN mediated deletion 
of Trim15 in NMuMG cells as well as absence of Trim15 in MEF cells isolated from Trim15 
KO animals led to reduced speed of the wound closure in these cells (Figure 32 A-C). 
Surprisingly, no such effect could be observed in U2OS cells where TRIM15 was knocked out. 
This leads to a question whether TRIM15 was completely deleted in the genome. Sequencing 
of the TRIM15-/- U2OS cells clearly shows that the cells contain one allele with an 83bp and 
one with 52bp deletion, both removing the ATG translation start site and a bit of the 
surrounding sequence (Figure 29D). However, this deletion is about 120bp downstream from 
the transcription start site, which means that TRIM15 mRNA could still be produced. Also, 
recent improvements in the annotation of the human transcriptome indicate, that there could be 
another transcript variant of TRIM15, which is lacking the RING domain, but this is not 
supported by strong experimental evidence. Another possibility is that a different ATG site 
which lies in frame with the original ORF and its surrounding bases resemble a transcriptional 
start site and could originate the transcription of a truncated form of TRIM15. Using a 
transcription start site prediction tool I identified another ATG with favorable consensus 150bp 
downstream of the original ATG. Similarly, as in the previous case, this protein does not 
contain its RING domain, but it could potentially still replace the full length TRIM15 in its 
function in cell migration, since the RING domain has been shown not to be essential to 
regulate migration345. Another important factor to take into account is the karyotype of selected 
cell lines. Unlike NMuMG which are mostly diploid352, the U2OS cells have large 
chromosomal rearrangements with altered chromosome counts353 and therefore it is possible 
that the U2OS clone no. 1 had more than two copies of Trim15 gene which was not detected 
among the five sequenced colonies.  
The first publication exploring the role of TRIM15 in adhesion and migration was the report 
of Uchil et.al. He shows that TRIM15 localizes to the focal adhesions and this is mediated by 
its direct interaction with scaffold protein paxillin. When TRIM15 was knocked down using 
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RNA interference in HeLa cells the cell migration in a scratch assay was reduced, which is in 
full accordance with my results. Additionally, he reports that TRIM15 is involved in focal 
adhesion turnover where it mediates the disassembly of the FA complex. The knockdown of 
TRIM15 therefore leads to FA which are stable for extended periods of time and this prevents 
the cells from invading the empty surface. 
On the other hand, the publications of Ok-Hee et al.346 and Chen et al.349 report seemingly 
opposite observations. In both cases they measured cell migration in a trans-well invasion 
assay, where a knockdown of TRIM15 led to an increased migration of colon and gastric cancer 
cells, respectively. Furthermore, overexpression of TRIM15 in this setup caused migration 
impairment. However, the readouts from the scratch assay and the trans-well invasion assay 
are not completely equivalent. The first one models wound closure and it is strongly dependent 
on cellular migratory behavior and proliferation, while the second one is a model for 
extracellular matrix invasion and therefore it also reflects the ability of the cell to interact with 
the ECM. Also, the fact that different cells were used in these reports could also influence the 
outcome of the change in the levels of TRIM15. 
In summary, my data indicate that TRIM15 is a protein involved in cell-to-ECM adhesion. Its 
localization pattern resembling focal adhesion distribution and the reduced speed of wound 
closure in a scratch assay suggests that it has an important influence on cell migration. In 
contrast, I was not able to confirm our expected role of TRIM15 in cell cycle regulation. My 
and publicly available data indicate, that TRIM15 could play a role in the cells of the intestine 
and even that its regulation could be important in colorectal cancer. In particular, the 
association of low TRIM15 expression in tumor tissue with reduced survival rates makes it 
potentially a useful prognostic marker in CRC. However, the observed tumor suppressive 
effects and its role in cell invasion make it an interesting gene for research as a potential 
therapeutic target.  
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4 CONCLUSIONS 
During my PhD study I was interested in studying the role of ubiquitin signaling in cell cycle 
regulation.  I started my PhD while studying a ubiquitin ligase, Trim15 which at that time was 
a relatively unknown protein. Expression profiling showed higher expression of Trim15 in the 
intestine and further studies using different cancer models revealed increased expression of 
Trim15 especially in the colorectal carcinoma model. Based on those results, I focused on 
determining the role of Trim15 in the control of cell proliferation. Trim15 deletion or 
overexpression did not have any effect on cell number or the distribution of cell cycle phases, 
therefore I concluded that Trim15 does not regulate cell proliferation. Next to cell proliferation, 
cell invasiveness is a very important parameter of cancer cells therefore I decided to address 
the role of Trim15 in cell migration. From my experiments with various knockout cells I 
concluded that Trim15 promotes cell migration and therefore it could promote cancer 
invasiveness and metastasis formation.  Unfortunately, during the course of my PhD several 
studies were published associating Trim15 with colorectal cancer and cell migration. This led 
me to the decision to stop working on the project and shift my attention to the second project 
which was focused on the deubiquitinating enzyme UCHL3. We identified UCHL3 in a high-
throughput siRNA screen which aimed at finding new regulators of mitosis from the ubiquitin- 
proteasome network. During my PhD I investigated the function of UCHL3 and how it is 
implicated in cell division. Based on my results I conclude that UCHL3 controls chromosome 
alignment and chromosome segregation in human cells by controlling the proper kinetochore- 
microtubule attachments. My results show that UCHL3 is necessary for recruitment of key 
kinetochore components (CENP-E, Astrin) that are necessary for formation of stable 
microtubule attachments. UCHL3 downregulation results in congression defects which I 
observed in human cancer cells as well as in human primary cells.  Based on proteomics data, 
I identified Aurora B kinase as a potential substrate of UCHL3 during mitosis and I confirmed 
the interaction between Aurora B and UCHL3 in human cells. The role of Aurora B in mitosis 
has been well described and misregulation of Aurora B function leads to mitotic defects. From 
my experiments I conclude that UCHL3 interacts with Aurora B and deubiquitinates it. The 
ubiquitination is not targeting Aurora B for proteasomal degradation, since deletion of UCHL3 
does not affect Aurora B levels and the ubiquitination has merely a signaling role. My findings 
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are exciting because UCHL3 has not been associated with mitosis up to date and therefore they 
provide novel insights into the control of mitosis. The implication of ubiquitin ligases in mitosis 
has been studied extensively, but not many deubiquitinating enzymes have been described to 
regulate mitosis so far. My study brings important findings about regulation of chromosome 
segregation by ubiquitin signaling and its role in the maintenance of genome integrity. Indeed, 
UCHL3 is an interesting protein because understanding its mechanism of action could also be 
relevant for the study of cancer development and cancer progression. As my results collectively 
point to, UCHL3 is crucial for preventing segregation errors therefore it protects the cell from 
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APPENDIX 
Table 1 Sequences of shRNAs used for generation of stable cell lines by retroviral infection 
Name  Sequence 5’ → 3’  
Control  
(Firefly Luciferase) 
shLuc TAATCAGAGACTTCAGGCGG  
UCHL3 silencing 
sh1 TCAGGGACAAGATGTTACATCA  
sh2 ATAGAAGTTTGCAAGAAGTTTA  
sh3 CACCAACCAGTTTCTTAAACAA  
sh4 GACCCTGATGAACTAAGATTTA  
 
Table 2 sequences of siRNAs used for UCHL3 knockdown 
Name Sequence 
UCHL3 siRNA-05 CAG CAU AGC UUG UCA AUA A 
UCHL3 siRNA-06 GCA AUU CGU UGA UGU AUA U 
UCHL3 siRNA-07 GAA CAA UUG GAC UGA UUC A 
UCHL3 siRNA-08 GGG CAU CUC UAU GAA UUA G 
UCHL3 3’UTR siRNA CUG CCA UAC ACU AAC UCA A 
siRNA 05-08 belongs to UCHL3 On-TARGET smartpool, Dharmacon (L-006059-00-0005), 
UCHL3 3’UTR was ordered from Microsynth. 
 
Table 3 Optimized protocol for siRNA transfection using Oligofectamine in different dish sizes.  
 10 cm 
dish 
6 cm dish 12 well 24 well Incubati
on [min] 
 
Oligofectamine [µl] 30 10 2.4 1.2 
 5‘ 
 
Opti MEM [µl] 70 40 48 24  
      20‘ 
siRNA 40uM [µl] 9 3 0.75 0.4 
 5‘ 
 
Opti MEM [µl] 400 200 100 50  
       
Add Opti MEM 500 250     
       
Medium/ plate [ml] 4 2 0.6 0.3   
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Table 4 List of all primers used for qPCR determining UCHL3 expression 
Name Sequence 
Oligo_dT AATGCCAGCTCCGCGGCCGCGTTTTTTTTTTTT 
h_UCHL3_ F GCCTGTGGAACAATTGGACT 















Figure 33 Cell Profiler analysis of nuclear shape. 
(A) Original image in DAPI channel. (B) Mask for individual nuclei automatically recognised by the software. 
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Figure 34 Example of a Cell Profiler pipeline for quantification of Astrin intensity on kinetochores. 
(A-E) Control, (A’-E’) UCHL3 downregulation. (A) Example of CREST intensity image used for B kinetochore 
recognition in (B). (C) Primary objects identified by the software. (D) Enlarged circular area of the kinetochores 
used for Astrin measurement. (E) Examples of exported images showing kinetochore position and their numbering 
which were used to distinguish aligned and misaligned chromosomes.  
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Table 5 Detailed summary of rescue experiments presenting percentage of cells having misaligned 
chromosomes for all categories in four different experiments. 
 
Sample NT GFP 3' GFP NT WT 3' WT NT C/S 3' C/S 
Mean % of cells -Average of 4 experiments     
Average 37.3 46.2 37.5 40.9 39.0 46.7 
SD 4.9 3.3 5.3 5.9 5.4 1.8 
SEM 2.5 1.7 2.6 3.0 2.7 0.9 
% of cells - individual experiments    
Exp I 34.2 44.4 33.1 38.2 34.1 45.8 
Exp II 33.6 44.7 33.5 35.7 35.3 45.1 
Exp III 37.2 44.6 39.2 40.2 40.8 46.6 
Exp IV 44.3 51.2 44.2 49.3 45.9 49.3 
Number of cells counted per condition per experiment  
Exp I 38 304 323 319 299 301 
Exp II 156 269 97 107 196 163 
Exp III 645 850 545 614 686 601 
Exp IV 831 1209 978 1048 1085 1084 
Total # 1670 2632 1943 2088 2266 2149 
 
 
Table 6 Genotyping primers for Trim15 mutant cell lines and for Trim15 KO mice 
Name Sequence 5‘ -> 3‘ 
Mutant cell lines 
83_hT15F CCTGGAATTTGGACCCACT 
84_hT15R CGTGCTCCTCGCAGTAAGTT  
85_mT15F ACCTCGCTGAGCTGACATTC 
 86_mT15R TAACCGACTCCTGAGACGAT 
 
 
Mice Trim15tm1b (EUCOMM) Hmgu for PCR genotyping 
 
LacZ-F ACGGTTTCCATATGGGGATT  
Trim15-R GCTTTGAGGGTCAAAAGCAC  
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Table 7 Primer sequences for qPCR analysis of Trim15 expression 
Name Sequence 5‘ -> 3‘ 
Primers for human genes 
1_h TRIM15 F 

















Primers for mouse genes 




















Table 8 UCHL3 sequence used for cloning of WT and catalytically dead (C > S) mutant 
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  Catalog # Gene Symbol GENE ID Catalog # Gene Symbol GENE ID Catalog # Gene Symbol GENE ID Catalog # Gene Symbol GENE ID
Control genes M-028950-01 ANKIB1 54467 M-025327-01 KIAA0363 23148 M-006079-02 USP48 84196
M-006823-01 INCENP 3619 M-003603-00 PARK2 5071 M-008541-01 RABGEF1 27342 M-006099-02 USP9X 8239
M-003326-08 AURKB 9212 M-010993-01 AIRE 326 M-013680-01 NXF1 10482 M-006100-02 USP9Y 8287
M-003290-01 PLK1 5347 M-018070-00 FLJ32440 286053 M-010445-01 NXF2 56001 M-006085-01 USP37 57695
M-004101-02 BUB1B 701 M-003279-04 MDM2 4193 M-013801-01 SMARCAD1 56916 M-031837-01 USP50 373509
M-010224-02 CUL3 8452 M-006536-03 MDM4 4194 M-016930-01 TOLLIP 54472 M-021192-00 USP52 9924
Targeted genes M-006597-01 BRAP 8315 M-017578-00 TTRAP 51567 M-006087-01 USP39 10713
M-015375-01 ATG3 64422 M-038171-01 LOC648245 648245 M-017222-00 NSFL1C 55968 M-006489-00 ASPSCR1 79058
M-020623-01 UFC1 51506 M-022683-00 WDR59 79726 M-023533-01 KIAA0794 26043 M-025945-01 LOC137886 137886
M-003215-02 CCNF 899 M-003004-02 CBLB 868 M-006401-02 APPBP1 8883 M-018376-01 MGC46534 127002
M-014930-01 FBXL10 84678 M-006522-01 AMFR 267 M-020112-01 ATG7 10533 M-023237-01 DKFZP761G2113 56970
M-012881-00 GGA3 23163 M-006977-01 UHRF1 29128 M-006406-00 MOCS3 27304 M-015442-02 DKFZP547N043 83932
M-012066-00 TOM1 10043 M-007117-01 UHRF2 115426 M-013382-01 UBB 7314 M-018651-02 FLJ31031 199990
M-003911-01 TOM1L1 10040 M-021044-01 C1orf164 55182 M-019408-01 UBC 7316 M-024738-01 LOC153918 153918
M-018810-01 TOM1L2 146691 M-004591-00 RAD18 56852 M-010212-02 ATG12 9140 M-021000-00 CGI-62 51101
M-005314-02 EIF2AK4 440275 M-007098-00 ZNRF1 84937 M-013149-01 FAU 2197 M-007038-00 KIAA1536 57658
M-020439-01 IMPACT 55364 M-007165-00 ZNRF2 223082 M-019650-01 POLI 11201 M-010637-01 NDP52 10241
M-020946-01 RWDD1 51389 M-006949-01 UBOX5 22888 M-008234-01 REV1L 51455 M-004012-02 EEA1 8411
M-015117-01 RWDD2 112611 M-020569-01 C20ORF43 51507 M-004668-02 PRPF19 27339 M-003767-02 IKBKG 8517
M-013856-00 C21ORF6 10069 M-021181-01 FLJ20323 54468 M-007201-02 STUB1 10273 M-020327-01 KIAA1018 22909
M-016719-01 RWDD3 25950 M-015603-01 DHX57 90957 M-007200-00 UBE4A 9354 M-016269-02 OPTN 10133
M-016803-01 MGC10198 201965 M-004779-03 KIAA0999 23387 M-007202-02 UBE4B 10277 M-015381-01 PCF11 51585
M-016816-00 FLJ32642 137492 M-004632-00 LATS1 9113 M-007203-01 WDSUB1 151525 M-006454-01 POLH 5429
M-007193-01 HACE1 57531 M-003865-02 LATS2 26524 M-004609-01 CYLD 1540 M-021038-00 POLK 51426
M-007185-01 HUWE1 10075 M-004259-03 MARK1 4139 M-027332-03 DUB3 377630 M-005255-02 TANK 10010
M-017674-01 JOSD1 9929 M-003517-03 MARK3 4140 M-008570-00 TEX27 60685 M-016892-01 TAX1BP1 8887
M-015500-01 SBBI54 126119 M-005345-02 MARK4 57787 M-009701-01 ZNF216 7763 M-020406-01 PROSAPIP2 9755
M-012013-01 MJD 4287 M-019752-00 RHBDD3 25807 M-006061-02 USP1 7398 M-014328-00 TNIP2 79155
M-024927-01 ATXN3L 92552 M-003959-05 SNF1LK 150094 M-006062-02 USP10 9100 M-010072-02 WRNIP1 56897
M-005798-02 CXORF53 79184 M-003517-03 MARK3 4140 M-006063-01 USP11 8237 M-005067-01 XPA 7507
M-018630-01 FLJ14981 84954 M-005345-02 MARK4 57787 M-027148-00 USP12 219333 M-014036-01 ZFYVE20 64145
M-005905-02 MYSM1 114803 M-019752-00 RHBDD3 25807 M-006066-01 USP15 9958 M-005791-00 BAP1 8314
M-012252-02 PRPF8 10594 M-003959-05 SNF1LK 150094 M-004236-03 USP18 11274 M-004309-00 UCHL1 7345
M-012202-01 STAMBP 10617 M-004778-03 SIK2 23235 M-006068-02 USP19 10869 M-006059-02 UCHL3 7347
M-005783-02 STAMBPL1 57559 M-004322-05 SNRK 54861 M-006069-03 USP2 9099 M-006060-03 UCHL5 51377
M-005814-01 COPS5 10987 M-008533-01 KIAA1959 84959 M-006071-00 USP21 27005 M-008768-03 AKTIP 64400
M-006024-00 PSMD14 10213 M-014655-00 TDRD3 81550 M-006073-02 USP24 23358 M-003549-01 TSG101 7251
M-019535-02 EIF3S5 8665 M-003102-04 TNK2 10188 M-006075-01 USP26 83844 M-010064-03 UBE2V1 7335
M-003883-01 EIF3S3 8667 M-019399-00 KIAA1582 57690 M-031532-01 USP27X 389856 M-008823-00 UBE2V2 7336
M-017017-00 COPS6 10980 M-017914-00 PHGDHL1 337867 M-006077-01 USP29 57663 M-008494-02 UEVLD 55293
M-009621-01 PSMD7 5713 M-017474-00 UBAP1 51271 M-021294-03 USP30 84749 M-027120-00 ANKRD13 88455
M-004771-01 MAP3K7IP2 23118 M-013168-00 UBAP2 55833 M-022513-02 USP31 57478 M-018787-01 FLJ25555 124930
M-015572-01 TAB3 257397 M-021220-01 NICE-4 9898 M-006082-01 USP34 9736 M-026603-01 LOC338692 338692
M-020939-02 NEIL3 55247 M-008616-00 UBASH3A 53347 M-006083-02 USP35 57558 M-017685-01 DNAJB2 3300
M-005283-00 NUP153 9972 M-021567-01 VPS13D 55187 M-006084-02 USP36 57602 M-004724-00 EPN1 29924
M-004746-02 RANBP2 5903 M-006095-02 USP5 8078 M-006086-01 USP38 84640 M-004725-01 EPN2 22905
M-009065-00 RBM10 8241 M-010522-01 M17S2 4077 M-004974-01 USP4 7375 M-021006-01 EPN3 55040
M-020032-01 RBM6 10180 M-010230-00 SQSTM1 8878 M-006088-01 USP40 55230 M-004005-01 EPS15 2060
M-015936-01 RYBP 23429 M-019158-01 NYREN18 51667 M-031434-01 USP41 373856 M-004006-00 EPS15L1 58513
M-018575-02 SHARPIN 81858 M-005231-00 RAD23A 5886 M-006089-01 USP42 84132 M-016835-00 HGS 9146
M-006037-00 SOLH 6650 M-011759-01 RAD23B 5887 M-023019-03 USP43 124739 M-011423-00 STAM 8027
M-009265-01 YAF2 10138 M-020776-01 UBADC1 10422 M-006092-03 USP46 64854 M-017361-01 STAM2 10254
M-010158-00 ZNF265 9406 M-015044-00 BMSC-UBP 84993 M-006093-01 USP47 55031 M-016586-01 LOC130617 130617
M-010025-01 ZRANB3 84083 M-012942-01 UBQLN1 29979 M-027186-01 USP53 54532 M-011365-01 PSMD4 5710
M-020796-01 NPL4 55666 M-013566-00 UBQLN2 29978 M-016853-01 USP54 159195 M-006995-03 RAP80 51720
M-021061-01 OTUB1 55611 M-013398-00 UBQLN3 50613 M-006096-03 USP6 9098 M-006357-00 SENP1 29843
M-010983-01 OTUB2 78990 M-021178-00 C1ORF6 56893 M-006097-01 USP7 7874 M-006033-01 SENP2 59343
M-026487-01 OTUD1 220213 M-009106-01 FAF1 11124 M-005203-01 USP8 9101 M-006034-01 SENP3 26168
M-009927-00 OTUD4 54726 M-008652-00 LOC51035 51035 M-017741-00 C13ORF22 10208 M-005946-01 SENP5 205564
M-013823-00 OTUD5 55593 M-010649-01 ETEA 23197 M-006067-01 USP16 10600 M-006044-01 SENP6 26054
M-032033-00 HSHIN6 139562 M-016458-00 ASC1P100 84164 M-006070-02 USP20 10868 M-006035-01 SENP7 57337
M-008553-01 OTUD6B 51633 M-012410-01 AUP1 550 M-006072-01 USP22 23326 M-004071-00 SENP8 123228
M-016115-01 PARP11 57097 M-031847-00 CUEDC1 404093 M-006078-02 USP3 9960 M-029321-01 LOC392188 392188
M-009270-01 ZRANB1 54764 M-019139-01 DCUN1D1 54165 M-006081-00 USP33 23032 M-009477-01 ZFAND6 54469
M-019137-01 VCPIP1 80124 M-020261-01 DCUN1D2 55208 M-006091-01 USP44 84101 M-036937-00 LOC645402 645402
M-027369-00 YOD1 55432 M-031988-00 DMRT3 58524 M-010054-01 USP45 85015 M-183279-00 LOC645836 645836
M-003499-00 HDAC6 10013 M-026122-00 DMRTA1 63951 M-005945-01 USP49 25862 M-028352-02 DUB1A 402164
M-003966-05 MAP2K5 5607 M-021793-01 DMRTA2 63950 M-032247-01 USP51 158880 M-014021-01 RBAF600 23352
M-003582-04 MAP3K2 10746 M-015987-01 LOC124402 124402 M-006064-00 USP13 8975 M-017918-01 UFD1L 7353
M-006932-02 C20ORF18 10616 M-018939-00 MGC29814 283991 M-006074-02 USP25 29761 M-008727-01 VCP 7415
M-021419-01 RNF31 55072 M-016841-00 HYPK 25764 M-006076-01 USP28 57646 M-004701-02 C13ORF9 51028
M-019984-00 ARIH1 25820 M-019063-01 N4BP2 55728 M-006065-02 USP14 9097
M-020104-01 ARIH2 10425 M-027161-02 NACA 4666 M-006080-03 USP32 84669
Table 9 List of candidate genes in the High-throughput siRNA screen with gene ID and Dharmacon 
reference number for siRNA SMARTpool. 
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